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Abstract 
Skeletal muscle phenotype, size and fimction respond to exercise, disease and ageing. 
The aim of this thesis was to investigate the signal transduction pathways responsible 
for selected skeletal muscle phenotype and size changes. Myostatin, recently 
identified as a negative regulator of muscle mass was exposed at 10 ng ml 4 to C2C12 
cells, and using cDNA genome-wide profiling, was shown to act as a transcriptional 
suppressor. Furthermore, in these cells myostatin significantly (n8, p<0.05) reduced 
phosphorylation of components in the P1-3K pathway: PKB Ser473 -30 %, mTOR 
Ser2448 -50 %, p70 S6K Thr389 -60 %, whereas 4E-BP1 Thr37/46 remained 
unaffected. These data provide insights in to the mechanisms by which myostatin 
controls muscle mass, through negatively affecting transcription and translation. 
Differences in the concentrations of signalling proteins often alter cellular function 
and phenotype, as is evident from numerous heterozygous knock-out models. Whilst 
the levels of metabolic enzymes differ between fibre types, and are regulable by 
exercise, it is not known if this is also true of signal transduction proteins. Therefore, 
it was hypothesised that the relative levels of signalling proteins implicated in the 
adaptation to exercise in both fast rat extensor digitorum longus (EDL; 3% type I 
fibres) and slow Soleus (84% type I fibres) would be systematically different. 
Secondly, it was hypothesised that following 6 weeks of chronic electrical stimulation 
(CMNS) where the EDL undergoes a fast-to-slow transformation, the relative 
signalling protein concentrations between control EDL/stimulated EDL would mirror 
the differences shown in control EDL/Soleus. Finally, that CMNS would induce 
chronic signalling to produce, and maintain a slower phenotype. Western blots 
revealed that the concentrations of some proteins such as Calcineurin (2.6-fold) and 
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p38 MAPK (1.36-fold) were higher in EDL, whilst others such as PGC-la (1.4-fold); 
and NFiB (3-fold) (all n=4, pc0.05) were higher in Soleus. CMNS of EDL also led to 
changes in protein levels between control EDL/stimulated EDL: AMPK which is 
higher in Soleus was actually 1.4-fold lower following stimulation of EDL, whereas 
other proteins such as PGC-la moved in the direction of that of Soleus. CMNS was 
also able to induce chronic phosphorylation of proteins involved in fibre type and 
mitochondrial biogenesis, such as AMPK 4 fold, and p38 -4.5-fold. These data 
show that signal transduction protein concentrations vary between fast and slow 
muscles, presumably reflecting differences at a fibre level. Furthermore, signalling 
proteins are regulated by CMNS of EDL, but do not always change in the direction of 
slow Soleus. Chronic phosphorylation of many signalling proteins can explain the 
characteristic phenotypic change in response to CMNS. 
Resistance training stimulates adaptive protein synthesis and hypertrophy whereas 
endurance training induces a partial fast-to-slow fibre phenotype transformation. To 
simulate these conditions, isolated rat muscles were stimulated at 25 °C with either 
high frequency (HFS; 6 x 10 repetitions, 3 s-bursts at 100 Hz to mimic resistance 
training) or low frequency (LFS; 3 h at 10 Hz to mimic endurance training). HFS 
significantly increased myofibrillar and sarcoplasmic protein synthesis 3 h after 
stimulation 5.3 and 2.7-fold, respectively (n=6, p<0.05). LFS had no significant effect 
on protein synthesis 3 h after stimulation, but increased UCP3 mRNA 11.7-fold, 
whereas HFS had no significant effect on UCP3 mRNA (n6, pcO.OS). Only LFS 
increased AMPK phosphorylation significantly at ThrI 72 by 2-fold and increased 
POC- 1 a protein to 1.3-fold of control. LFS had no effect on PICB phosphorylation but 
reduced TSC2 phosphorylation at Thr1462 and deactivated translational regulators. In 
contrast, HFS acutely increased phosphorylation of PKB at Ser473 5.3-fold and the 
11 
phosphorylation of TSC2, mTOR, GSK-3j3 at PKB-sensitive sites. HFS also caused a 
prolonged activation of the translational regulators p70 56k, 4E-BPI, eIF2B, and 
eEF2 (all n=8, p<0.05). This behaviour has been termed the AMPK-PICB switch, and 
is hypothesised to mediate specific adaptations to endurance and resistance training, 
respectively. 
Ageing is associated with a loss of muscle mass tenned sarcopenia. Essential amino 
acids (EAA) are potent stimulators of muscle protein synthesis (MPS), and therefore 
defects in EAA-induced anabolism might affect ability to maintain muscle mass in 
ageing and disease. MPS and signalling responses to EAA-stimulation of 20 fasted 
young versus 24 elderly subjects (age 28 ± 6 and 70 ± 6; BMI 24 ± 3, 25 ± 4 kg.m 2 
respectively; means ± SD) and 8 fasted elderly versus 8 elderly with type II DM (age 
66 ± 3 and 70 ± 6; BMI: 25 ± 4 vs. 32 ± 2 kg.m 2, respectively means ± SD) were 
measured using gas combustion mass spectrometry and Western blotting methods. 
Basal MPS rates were indistinguishable, but the elderly displayed a reduced anabolic 
responsiveness of MPS to EAA, possibly due to decreased intramuscular 
phosphorylation after EAA, of amino acid sensing/signalling proteins mTOR, p70 S6 
kinase, 4E-BPI and eIF2Bs by —50 %. This was further exacerbated in elderly with 
type II DM whom exhibited reduced Ser2448 phosphorylation of mTOR by —50 %, 
reflecting decreased downstream signalling. Associated with the anabolic deficits 
were — 4-fold increases in NFiB protein, the inflammation-associated transcription 
factor, as well as —50 % and —20 % decreases in protein expression of p70  S6K of 
healthy elderly and elderly with type II DM, respectively. These results suggest that 
the elderly are unable to mount a full anabolic response to EAA and that this blunting 
is further pronounced in type II DM. 
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Chapter 1 
General Introduction 
1.1 Characteristics of skeletal muscle 
1.1.1 Skeletal muscle plasticity 
Skeletal muscle constitutes 75-80 % of total lean body mass, accounts for —50 % of 
body weight and is the largest component of the metabolically active cell mass of the 
body (Heymsfield ci aL, 1995). Functionally, its purpose is to contract in order to 
move limbs and maintain posture. Skeletal muscle is a unique multi-nucleated tissue 
that shows remarkable plasticity and both mass and phenotype varies between 
individuals, and throughout life. Muscle also responds to disease, nutrition and 
physical activity (Fluck & Hoppeler, 2003). To illustrate this, elderly with advanced 
sarcopenia and cancer patients with severe wasting are examples of skeletal muscle 
atrophy (Glass, 2003) whereas the hypertrophy elicited through resistance exercise 
shows how much muscle mass can be gained through training (Evans, I 995a) (figure 
l.Ia). In addition, any form of physical training may influence the expression of 
myosin heavy chain isoforms (Harber ci at, 2002) and endurance training and chronic 
low frequency electrical stimulation produces highly oxidative muscles (figure 1.1 b). 
(a) 
	
(b) 
Figure I.I. Images depicting the robust plasticity of skeletal muscle. (a) Example of 
muscle atrophy and hypertrophy in humans; (b) visual phenotypie transformation in 
rat tibialis anterior (paler to redder and weight loss) in response to 6 weeks of chronic 
stimulation. These changes are all reversible when the causative stimulus is removed. 
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1.1.2 Skeletal muscle structure 
Both ends of most striated muscles articulate the skeleton and are thus called skeletal 
muscles. They are attached to the bones by tendons which have some elasticity 
provided by proteins of the extracellular matrix that surround them (Takala & 
Virtanen 2000). The extracellular matrix forms a complex dynamic architecture and is 
composed of glycoproteins, collagen, and proteoglycans. Collagen is the most 
abundant protein, and as muscle, is regulable by physical activity (Takala & Virtanen 
2000). Proteoglycans have been suggested to play an important functional role in 
tissue differentiation. Proteoglycans affect the myogenic process by regulating 
collagen fibrillogenesis, modulating cell growth and controlling the response to 
growth factors. The extracellular matrix communicates information back to the cell 
through integrin receptors. Integrins are heterodimeric transmembrane glycoproteins 
that contain extracellular, transmembrane, and cytoplasmic domains (Velleman 1999). 
The anatomy of skeletal muscles starting from the outside of the muscle and working 
inwards is as follows: the outermost layer that surrounds the entire muscle is called 
the epimysium. Connective tissue called the perimysium surrounds individual bundles 
of muscle fibres. These individual bundles of muscle fibres are called fascicules. Each 
muscle fibre within the fasciculus is surrounded by connective tissue called the 
endomysium. Each individual muscle fibre is a thin, elongated cylinder that generally 
extends the length of the muscle, thus making them potentially very large cells. The 
cell membrane surrounding the muscle cell is called the sarcolemma. Beneath the 
sarcolemma lies the sarcoplasm, which contains the cellular proteins, organdies, and 
myofibrils. Myofibrils are the numerous thread-like structures that contain the 
contractile proteins (Powers & Fiowley 1998) (figure 1.2). 
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Figure 1.2. Diagram showing the structure of muscle. Tendons and bones support the 
muscle ends, which articulate them. The extracellular matrix surrounds the muscle 
cell. The epimysium surrounds the whole muscle, whilst the perimysium surrounds 
bundles of fibres. The endomysium surrounds individual fibres, as does the plasma 
membrane, the sarcolemma. The myofibrils contain the contractile proteins. Diagram 
taken from Powers & Howley (1998). 
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1.1.3 Skeletal muscle ultra-structure 
In general, myofibrils are composed of two major types of protein filaments. Thick 
filaments composed of the protein myosin, and thin filaments composed primarily of 
actin (figure 1 .3c). The arrangement of these two protein filaments gives skeletal 
muscle its striated appearance. Located on the actin filament are two additional 
proteins, troponin and tropomyosin (Powers & Howley 1998). These proteins play an 
important role in the regulation of the contractile process. Sarcomeres are separated 
from each other by a thin sheet of structural proteins called the Z-line which 
delineates the sarcomere (figure 1.3a). Myosin filaments are located primarily in the 
dark portion of the sarcomere which is called the A-band, whilst actin filaments occur 
principally in the light region of the sarcomere termed the I-band. In the centre of the 
sarcomere there is a portion of the myosin filament with no overlap of actin, this is 
termed the H-zone. The M-band bisects the central portion of the H-zone, which 
delineates the centre of the sarcomere (figure 1 .3b). 
Within the sarcoplasm of skeletal muscle is a network of membranous channels called 
the T- tubules, which are extensions in to the depths of the muscle cell provided by 
the sarcolemma. These T-tubule channels surround each myofibril. The sarcoplasmic 
reticulum (SR) forms a longitudinal system of calcium (Ca 2 ) containing tubules and 
sacs and at localised regions called the terminal cisternae these come into close 
apposition to the T-tubules. The membranes of the two compartments form a structure 
in which two terminal cisternae sandwich a transverse tubule to give rise to a triad 
arrangement (Powers & Howley 1998). 
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Figure 1.3. Diagram of skeletal muscle ultra-structure. (a) The portion of a myofibril 
between two Z-lines constitutes a single contractile unit, termed a sarcomere. (b) 
Further categories of areas within the sarcomere are: the A-band: area containing 
myosin; the U-zone: centre of A-band containing only myosin; 1-band: the area 
containing actin, troponin, tropomyosin; the Z-line: centre of I-band, sarcomere 
border. (c) When actin and myosin interact they shorten each sarcomere. Diagram 
taken from Powers & Rowley (1998). 
1.1.4 Excitation-Contraction (E-C) coupling 
Motor units consist functionally of three separate components: a single efferent 
neuron, the several muscle fibres that it innervates, and the synapses (neuromuscular 
junction) between the neuron and the muscle fibres (Clark et aL, 2002). The 
neurotransmitter substance acetylcholine (ACh) is received at receptor sites on the 
motor end plate. These end plate potentials are always excitatory, and a single end 
plate potential is induces an action potential in the muscle fibre (Powers & Hawley 
1998). A muscle action potential propagates into the 1-tubular system, carrying 
excitation into the depths of the fibres axial core. The T-tubular action potential 
contributes a long-lasting (20-30 ms) after-depolarisation to the muscle (Powers & 
Howley 1998). This depolarisation of the skeletal muscle cell begins the process of E-
C coupling. In the membrane of T-tubules are voltage sensors called dihydropyridine 
(DHP) receptors, which detect changes in the membrane potential. Structures that 
project between the SR membranes and the T-tubular membranes are hypothesised to 
form a mechanical link between DUP and the ryanodine receptors (RyR) (Bianchi, 
1997). Depolarisation of the T-tubular membrane causes a conformational change in 
the DHP receptors which is thought to produce a conformational change in the SR 
Ca2 channels through interaction with the RyR. This process leads to the opening of 
SR channels and subsequent Ca2 release (Ikemoto & Yamamoto, 2000). Increased 
[Ca2+li leads to the subsequent opening of the Ca 2 sensitive RyR allowing Ca2 ions 
to flow out of the SR down their electrochemical gradient, raising concentrations 
within the fibre cytoplasm, and at the same time causing more Ca 2 channels to open. 
This process is termed calcium-induced calcium release (Fabiato, 1983), although the 
precise necessity for this mechanism in muscle contraction is questionable. 
iA 
1.1.5 The sliding filament theory 
The physiological mechanism that explains contraction in response to elevated [Ca 2 ]1 
is known as the sliding filament theory (Huxley, 1985) (figure 1.4). Under resting 
conditions, and low [Ca 2 ]1, tropomyosin inhibits actin and myosin interaction. The 
trigger for contraction to occur is when [Ca 211 is elevated through the aforementioned 
mechanisms (see 1.1.4), before Ca 2 binds to troponin and removes tropomyosin from 
the myosin binding site on actin. Myosin-ADP-Pi complex binds to actin, forming a 
cross bridge and causing the release of ADP and P 1 . The myosin head rotates and pulls 
the thin filament towards the centre of the sarcomere; this is termed the power-stroke. 
When this is complete, the myosin in the actin-myosin complex develops a high 
affinity for ATP, and ATP binds to the myosin on the actin-myosin complex, causing 
the cross-bridge to break and yielding actin-myosin-ATP. The myosin ATPase 
partially hydrolyses the ATP in the myosin-ATP complex to yield myosin-ADP-P1. 
This complex is now primed to form a new cross-bridge. Meanwhile the sarcoplasmic 
[Ca2 ]1 is rapidly decreasing via the action of the Ca 2 ATPase increasing the SR 
stores. Since the Ca 2 bound to troponin is in equilibrium with the free sarcoplasmic 
Ca2t and since the pump has a greater affinity for Ca 2 than troponin, the amount of 
Ca2 on troponin decreases. As more and more Ca2 is re-sequestered, the troponin 
changes shape back to a conformation that moves the tropomyosin back over the 
binding site for myosin on actin (Tonomura & Oosawa, 1972). At this point the 
process of contraction ceases until the next stimulus arrives. 
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Figure 1.4. Schematic diagram of skeletal muscle cross-bridge cycling. The 
mechanism proposes the following chain of events: (1) Release of Ca 2+  -dependent 
regulatory mechanisms allows binding of myosin head to the actin filament. (2) 
Release of AlP hydrolysis products causes a change in myosin head conformation 
that results in the power stroke and generation of increased tension. (3) Binding of 
ATP to the myosin head stimulates the release of myosin from the actin filament. (4) 
Rapid hydrolysis of AlP causes a change in the myosin head conformation to return 
to high actin affinity state. A= Actin, M= Myosin and Pj= inorganic phosphate. 
1.2 Skeletal muscle fibre types 
A Vastus Lateralis muscle of a young male has around 500,000-900,000 muscle 
fibres, and these are some of the largest cells in the body measuring up to 15-30 cm in 
length (Lexell et al., 1988). Skeletal muscles are not identical, and are individually 
composed of different fibre type populations, which affect their ifinctionality. These 
are largely defined as either slow twitch (ST) or fast twitch (FT) fibres. 
1.2.1 Myosin Heavy Chain (MHC) isoforms 
Distinct fibre types are mainly distinguished by the MHC isoforms expressed within 
them. The major component of the whole myosin molecule is the MHC protein which 
contains the ATP hydrolysing myosin head (Tonomura & Oosawa, 1972). The MHC 
isoform that is mainly expressed within a fibre type determines the muscle fibre's 
ATP hydrolysis rate and shortening speed (Barany, 1967). Two developmental 
(termed extraocular, developmental) and seven adult MHCs have been identified. The 
shortening speeds of adult MI-ICs decrease from extraocular> Jim> Jib> lix> ha> 
Ia (cardiac) > 1j3 (Sciote & Morris, 2000). in humans, the extraocular, JIm and iib 
isoforms are only expressed in eye and jaw muscles. Rodents and humans possess 
varying distributions of fibre types even within equivalent muscles (see table 1.1). Not 
all fibres are of mono-MHC isoform expression. There are also hybrid fibres co-
expressing the type I and type II MI-IC isoforms MHC I and MI-IC ha (h+IIA or 1JIIA 
fibres). These fibres are referred to as IC or JIC fibres on the basis of the most 
abundant MHC isoform expressed (MHC I or MI-IC ha, respectively) (Pierobon-
Bormioli ci aL, 1981). It is now widely accepted that the proportion of MHC hybrids 
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and their molecular complexity (as judged by the number of MHC isoforms co-
expressed and the pattern of co-expression) is higher in muscles undergoing 
molecular and functional transformation than in normal muscles (Pette et aL, 1999). 
Each skeletal muscle contains specific ratios of fibre populations making them 
unique. The expression of MHC in developing and adult muscle is regulated by 
neural, hormonal, mechanical factors and exercise (Schiaffino & Reggiani, 1994). 
Table I.I. Myosin Heavy Chain (MHC) isoform composition of the Soleus and 
Vastus Lateralis muscles in rat and human. Taken from Talmadge, (2000). 
Muscle Species MHC 113 MHC ha MHC lix MHC lib 
Soleus Rat 89±3 11±3 0 0 
Soleus Human 67±6 27±6 6 ± 4 0 
Vastus Lateralis Rat 0 0 2 98 
Vastus Lateralis Human 39 ± 3 43 ± 2 18 ± 4 0 
1.2.2 Physiological and metabolic differences between fibre types 
Distinct muscle fibre types possess other unique properties aside from MHC isoforms. 
Electron microscopy of skeletal muscle fibres shows evidence of wider Z-bands and 
wider M-bands in slow twitch muscle of which this diminishing size pattern linearly 
narrows from ST>FTa>FTx, successively (Sjostrom et aL, 1982). The rate at which 
myosin-ATPase splits adenosine 5' triphosphate (ATPase activity) is a prime 
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determinant of muscle twitch property and is differentiated by the multi-molecular 
isoforms of motor proteins within each fibre (Pette & Staron, 1988). As a result of 
different expression of these isoforms, and of SR ATPase activity, ST fibres have a 
longer time to peal tension, whereas FT fibres reach peak tension in a shorter time 
(Termin el aL, 1989). 
FT fibres reportedly possess ATP stores 60 % higher than ST fibres, and creatine 
phosphate content is reported to be up to 100 % higher in FT muscles (Kraus el aL, 
1994). Triglyceride stores are also higher in ST fibres and glycogen substrate is also 
reported to be more abundant in these fibres (Ren & Hultman, 1990). ST fibres are 
well endowed with enzymes for oxidative phosphorylation, and possess a low 
anaerobic capability in tandem with low T-tubular, sarcoplasmic reticulum (SR) 
concentrations, and slow isoforms of the contractile proteins MHC, tropomyosin, and 
troponin which regulate contractile patterns of cross-bridge cycling (Kraus et aL, 
1994). FT fibres have been shown to contain greater densities of glycolytic enzymes, 
T-tubular systems, and SR due to their supenor Ca 2+  -processing requirement and also 
possess FT isoforms of the contractile proteins, thus giving limited aerobic capacity 
and promoting anaerobic metabolism (Pette & Staron, 1990). To illustrate this, the 
activities of mitochondrial enzymes 3-hydroxyacyl-CoA dehydrogenase (13-
oxidation), succinate dehydrogenase, and citrate synthase are -50 % higher in ST than 
FT fibre groups (calculated by flux through the Krebs cycle); whilst lactate 
dehydrogenase, phosphorylase, phosphofructokinase activities are higher in FT 
muscle (Pette & Staron, 1990) (see table 1.2). These differences are equivocal in that 
an overlap between fibre type, enzyme activity and MHC, troponin and tropomyosin 
is existent between fibre species (Kraus et aL, 1994). 
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Table 1.2. Table illustrating the common characteristics denoting classification of 
skeletal muscle fibre types. Taken from Spangenburg & Booth, (2003). 
Characteristic Type I Type ha Type IN Type lib 
Contractile speed Slow-twitch Fast-twitch Fast-twitch Fast-twitch 
Myosin heavy chain Type I Type ha Type IN Type hib 
Metabolic Oxidative Oxidative Glycolytic Glycolytic 
Anatomical (colour) Red Red White White 
Fibre CSA Small Medium Large Large 
Type Jib fibres are not expressed in human locomotory muscles (Smerdu et aL, 1994). 
1.3 Exercise, disease and nutrient-induced cell signalling-
Mechanisms of signal transduction 
A major focus in skeletal muscle research over the past few years has been the 
investigation of signal transduction pathways that regulate muscle mass and 
phenotype (Caifrey et aL, 1999). It is the sensing and signalling of specific signals 
which leads to genetic responses that produce characterised physiological changes 
within muscle. Exercise and disease lead to changes in intracellular and extracellular 
environments, and it is such changes that provide the stimulus to initiate signalling 
cascades. These stimuli can take many fonns, and all the following are implicated 
initiation of signalling: cellular energy status (Frosig et aL, 2004), [Ca211 (Chin et aL, 
1998), free radical production (Jackson, 1999), mechanotransduction (Goldspink, 
1999), growth factors (Goldspink & Yang, 2001), hormones (Smilios et aL, 2003), 
stretch (Baar el aL, 2000), cell swelling (Nygren & Kaijser, 2002), muscle damage 
(Clarkson & Hubal, 2002) and nutrients (Proud, 2004a). 
13 
Once initiated by stimuli such as those named above, signal transduction pathways are 
'activated'. These pathways are usually cascades of proteins that alter the activity of 
their substrates via phosphorylation (kinases) or in other cases dephosphorylation 
(phosphatases). A kinase transfers the terminal phosphate of ATP to a hydroxyl group 
on a protein, whilst a phosphatase catalyses removal of the phosphate by hydrolysis: 
Protein Kinase 	
'jj 
Protein—OH + ATP ci. Protein-0-1 —0 + ADP 
p1 	 H20 
Protein_Phospd 
Exercise has been shown to activate many such pathways and the increased activation 
of just one protein may stimulate multiple pathways. The following proteins are 
examples of those implicated in mediating responses to exercise and even disease: 
adenosine monophosphate kinase (AMPK) (Winder, 2001), calcineurin (Meissner et 
aL, 2001), calmodulin kinase (CaMK), peroxisome proliferator activated receptor 
gamnia co-factor I alpha (PGC-lcz) (Wu ci aL, 2002), extracellular regulated kinase 
(ERKI/2), p38 MAPK (Widegren et aL, 2001), phosphatidyl inositol 3-kinase /protein 
kinase B/mammalian target of rapamycin (PI-3K/PKB/GSK3I3/mTOR) (Turinsky & 
Damsau-Abney, 1999), and protein kinase C (PKC) (Richter ci aL, 1987). Following 
activation of these proteins a signalling cascade will culminate in the activation of a 
transcription factor which has the potential to regulate the expression of genes by 
conveying the signal in to the myonucleus. Proteins that shuttle in and out of the 
nucleus usually have nuclear loealisation signals or nuclear export signals (NES) 
(Cyert, 2001). Once inside the nucleus they may directly bind to the DNA or activate 
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other transcription factors via phosphorylation (Widegren €1 at, 2001). Some proteins 
do neither of these things, instead acting as co-factors or co-activators. An example of 
this is PGC-lu which binds to transcription factors but not DNA directly (Knutti & 
Kralli, 2001). In fact, most genes are regulated by combinatorial control exerted by 
numerous signal transduction factors binding to their DNA regulatory elements 
(Arnone & Davidson, 1997). The activation of transcription will result in higher 
mRNA concentrations, which need to be translated. Protein synthesis may then be 
activated by the PI-3KIPKB/mTOR pathway (Bodine el at, 2001), which directs the 
ribosome to increase protein translation of multiple RNA species. 
1.3.1 Regulation of signalling proteins 
Signalling proteins are of great importance in mediating cellular responses, yet their 
regulation is poorly understood. The output of a signal transduction pathway depends 
both on the strength of the input signal and on the signal amplification by the pathway 
(Rommel et at, 2001). Since the amplification of a given signal is a result of the 
concentration and specific activity (control coefficient) of signal transduction proteins 
within a pathway, this means that signalling protein concentration has important 
consequences (Lion et at, 2004). To illustrate this, increasing or lowering the 
concentration of a signal transduction protein often has effects on the function and 
phenotype of a cell. For example heterozygous mouse knockout models where the 
concentration of signal transduction proteins is lowered compared to wild-type can 
cause gross phenotype differences and even fatality. Cellular levels of many protein 
groups in muscle prove to be of key importance, and muscle metabolic enzymes are 
an example of proteins whose variations in content have gross effects upon muscle 
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metabolism. For example, individuals with higher concentrations of oxidative 
enzymes have enhanced aerobic capacity (Pette et ciL, 1976). Moreover, enzyme 
concentrations are under regulation by physical activity, and an increase in 
concentration of oxidative enzymes following endurance training improves endurance 
fuel metabolism. If signal transduction proteins activated by contraction were also 
regulable and responded to exercise and disease then this could have important 
implications for adaptive processes and functionality, and thus warrants attention. 
An interesting characteristic of signalling proteins is that they appear to have the 
unique ability to distinguish specific signals. Therefore, further to their role in 
mediating response to any exercise type, it could be that their selective activation 
could be linked to controlling responses, by discerning signals produced by specific 
type of stimulus. An example for this discerning activation was first demonstrated in a 
study which showed that signalling pathways could be selectively activated by 
different intensities of one signal. The authors found that a large, transient increase in 
[Ca2+]i stimulated NFiB and iNK whereas a low, sustained [Ca 2 ]1 rise activated 
nuclear factor of activated T cells (NFAT) (Dolmetsch et at, 1997). Before discussing 
the specific signalling which controls the responses of changes in muscle architecture 
and function, it is first necessary to systematically describe the typical physiological 
changes associated with these states. Therefore, the next section will focus upon the 
physiological adaptations to phenotype altering endurance training and then describe 
the signalling associated with producing these changes; whilst the section following 
this will follow the same pattern, but this time in regard to hypertrophy promoting, 
resistive training. Finally, the physiological changes in muscle atrophy, ageing and 
disease and the signalling controlling these changes will be discussed. 
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1.4 Physiological adaptations of skeletal muscle to endurance training 
Skeletal muscle is a remarkably plastic tissue and MHC and fibre type characteristics 
have the potential to undergo phenotypic change in response to physical activity (table 
1.2). The predominant physiological adaptation to endurance exercise is an 
incomplete fast-to-slow phenotype shift (Pette & Staron, 2001) with mitochondrial 
biogenesis (Freyssenet et at, 1996). This is accompanied by increases in enzymes of 
the Krebs cycle such as succinate dehydrogenase, citrate synthase and malate 
dehydrogenase (Flenriksson et at, 1986). Given that the MHC isoform is the major 
determinant of fibre type, it has been under great scrutiny as to what extent this might 
be influenced by chronic endurance activity. There is evidence that increased 
contractile activity through electrical stimulation promotes a slow fast-to-slow 
phenotype conversion in a dose-dependent manner in rodents. However, in humans 
and in response to actual exercise, this remains a contentious area. 
1.4.1 Do human skeletal muscle fibre types change with training? 
Many studies and different groups have attempted to define the nature of any changes 
in fibre type produced by physical activity in humans. One group examined the fibre 
composition of biopsy samples from the Vastus Lateralis muscle of six subjects 
before and after a six month training programme, consisting of bicycle exercise at 70 
% of V02, where the quadriceps muscle would undergo extensive employment 
(Gollnick et at, 1973). The oxidative potential of the muscle was doubled following 
the 6 month period, although the actual fibre composition as determined by 
histochemical staining procedures was not altered by training. This study, however, 
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failed to further differentiate between sub-groups of FT muscles. Another group 
carried out a longitudinal study to examine the fibre composition of the Vastus 
Lateralis of four subjects after 11 weeks of endurance training and again after 18 
weeks of training. During the initial endurance training period, the subjects ran 110 
km/week, whilst the second training cycle included some high intensity exercise at 
90-100 % V02  max. Unfortunately, no samples were taken prior to initialisation of 
endurance training so comparisons between sedentary and initial endurance training 
programmes were not available. However, following the second training bout there 
was a 17 % reduction in ST fibres, accommodated by an increase in type [IC hybrid 
fibres suggesting that a conversion away from ST, or at least hybridisation could 
occur as a result of mixed training (Jansson et aL, 1978). This change of ST to FT 
fibres due to high intensity exercise is not in agreement with another study, where 
each group exercised one leg with sprint, or endurance training and the other leg 
oppositely or not at all. Fibre composition of legs in untrained, endurance trained and 
sprint-trained had no significant differences (Saltin et aL, 1976). 
Another group examined the effect of a 50-day programme of endurance training 
(skiing 18 miles/day) on the fibre composition of the triceps brachii muscle. There 
was no difference in the overall proportion of ST fibres after training cessation (pre-
training proportionality of ST area and number withheld), although there was a 
reduction of about 6 % in the total population of type IN fibres, which was in part 
compensated for by a 4 % increase in type ha intermediate fibre type population 
(Schantz et aL, 1982), thus suggesting a shift to a slower phenotype from lix to ha. 
Mother longitudinal study over 20 years assessed the fibre compositions between 11 
highly trained athletes, 10 fitness trained and 7 untrained individuals. They found a 
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significant increase in the type I fibre percentage in the fitness trained and untrained 
groups. However, the type I fibre percentage did not increase further in the group of 
highly trained subjects where the type I fibre percentage was above 70 % at the 
baseline (Trappe et aL, 1995). The shift to slow fibres appeared attenuated in the 
highly trained athletes, although this may be attributable to some of the elite 
performers originally possessing up to 90 % ST fibre proportions. These data also 
suggest that an increase in type I fibre percentage is probably more an effect of ageing 
more than an effect of training, in agreement with another study (Short et aL, 2005). 
Another cross-sectional study tested the muscle fibre composition and enzyme 
activities from the gastrocnemius of 14 elite male distance runners in comparison to 
untrained males. On average, it was found that the trained athletes showed evidence 
of significantly more ST fibres than the untrained males (Costill et all, 1976), 
although this could of course be genetic predisposition. A longitudinal study assessed 
the effects on skeletal muscle fibre type alteration with high-intensity intermittent 
training consisting mainly of series of supramaximal exercise lasting 15 s to 90 s on a 
cycle ergometer. Their results indicated that sedentary subjects elicited an increase in 
the percentage of type I fibres and decreased type IN fibres, whilst the proportion of 
type ha remained unchanged (Simoneau et all, 1985). These data are atypical, in 
denoting a shift from type IN to I with high-intensity training. 
Another study on seven young females subjected to 24 weeks of intensive endurance 
training found that the relative amount of type I fibres before and after the training 
period was unchanged and for type ha fibres was 26.4 and 31 .5 %, for type IIx fibres 
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9.2 and 3.4 % and for type IIC fibres 0.4 and 2.2 %. Therefore, showing interchange 
between fast twitch sub-groups with a decrease in type lix and increase in type ha 
(Ingjer, 1979). Mother study examined orienteers, where comparisons were made 
between their trained leg muscles, against the leg muscles of untrained 16-18 years 
old boys. Whilst type I fibres were not different, the distribution of type II sub-groups 
in the leg muscles of the orienteers differed from the leg muscles of the controls, the 
relationship Ila/lIx being altered in favour of the more oxidative ha. The leg muscles 
of the orienteers also showed an increased occurrence of TIC fibres (Jansson & 
Kaijser, 1977). These latter findings point at the possibility of a training induced 
alteration in the fast sub-group pattern, again reducing the population of IN in favour 
of ha, and an increase in group C hybrid fibres. 
A more recent study examined subjects of different training background. Subjects 
were classified into three groups according to their physical activity and sport 
discipline: untrained students (group A), national and sub-national level endurance 
athletes (group B, 7.8+1-2.9 years of specialised training) and sprint-power athletes 
(group C, 12.8+1-8.7 years of specialised training). Significant differences regarding 
composition of muscle fibre types and MHC were found only between groups A 
(41.7+1-1.6 % of MFIC I, 40.8+1-4.0 % of MHC ha and 17.5+/-4.0 % of MHC lix) 
and B (64.3+1-0.8 % of MFIC I, 34.0+1-1.4 % of MHC ha and 1.7+1-1.4% of MHC 
JIx) and groups A and C (59.6+1-1.6 % of MEC 1, 37.2+1-1.3 % of MI-IC ITa and 
3.2+/-1.3 % of MI-IC lix) (Zawadowska et aL, 2004). Interestingly, endurance athletes 
(group B) such as long-distance runners, cyclists and cross country skiers did not 
differ from the athletes representing short term, high power output sports (group C) 
such as ice hockey, karate, ski-jumping, volleyball, soccer and modem dance. 
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Furthermore, the relative amount of the fastest MHC IN isoform in Vastus Lateralis 
muscle was significantly lower in the athletes from group C than in students (group 
A). Therefore it appears that probably any form of training reduces MHC lix, but may 
also increase MI-IC I, at least as is evident from this cross-sectional study. In 
conclusion in human beings, endurance training usually does not cause type II fibres 
to turn into type I fibres (Gollnick et aL, 1973), but that does not eliminate the 
possibility after very long periods of training. It is most likely that there is a decrease 
in lix MHC and an increase in ha MI-IC (Jansson & Kaijser, 1977; hngjer, 1979), and 
increases in hybrid fibres such as IIC. Furthermore, even power events probably 
changes fibre types from MI-IC lix to MI-IC ha. Many of these changes are also 
muscle-dependent, which might explain some variations in the reported data. 
1.4.2 Chronic motor nerve stimulation promotes a fast-to-slow 
phenotype shift and provides a model mimicking endurance training 
Chronic electrical motor nerve stimulation (CMNS) is a model that has been 
employed for studies within chapters 4 and 5 of this thesis. CMNS has been adopted 
to study the effects of muscle plasticity, and is used for its efficacy to mimic 
physiological responses to endurance training at the extreme end of the continuum. 
CMNS, carried out over several weeks can induce fibre type shifting from fast-to-
slow twitch, and robustly reproduce adaptations elicited by endurance exercise 
(Henriksson et aL, 1989). CMNS is advantageous as a model since no habituation is 
required; stimulations are reproducible; stimulus is restricted to the muscles of choice 
thereby elminiating systemic effects; and all motor units are synchronously activated. 
Detailed below are the typical morphological, ultrastructural and performance 
21 
characteristics of changes at the muscle as a result of CMNS. When applied 
permanently for several weeks at 10 Hz, fast isoforms of MHC (discussed in 1.4.1) 
and myosin light chain are gradually replaced by slow varieties as a result of 
repression of fast isoform expression in conjunction with increased slow isoform 
expression. The 'nearest neighbour' theory proposes that fibre types will usually shift 
along the following continuum depending upon starting MHC: 
HCIIb (Staron & Pette, 1993). This pattern of change also transpires for the other 
motor proteins such as troponin and tropomyosin (K.raus ci ciL, 1994). These increases 
in the expression of slow motor proteins, and especially the type I MHC consistently 
occurs in CMNS models, although to different extents dependent upon species and 
duration of stimulation. For example, rabbit EDL muscle undergoes a 100 % shift to 
type 1 MFIC following 7 weeks of stimulation (Sutherland ci aL, 1998), whereas rat 
and especially mouse muscle, are more resilient to CMNS and thus slower to transit 
(Jarvis ci aL, 1996). There are also concomitant increases in mitochondrial volume 
and numbers with CMNS (Chi et aL, 1986), coupled with an increased number of 
nuclei per fibre (Kraus ci aL, 1994) resulting in a decrease in the area managed by 
individual nuclei (Joplin ci al. 1987). The decondensation of hetrachromatin in 
myonuclei and nucleolar enlargement suggest increased transcriptional activity 
(Joplin ci aL, 1987). In support of this, increases in ribosome and polyribosomes in 
the sarcoplasm suggest increased transcriptional activity from DNA to RNA (Kraus ci 
aL, 1994). CMNS leads to a rapid loss of force within a very short time period and 
ultimately there is an increase in time to peak twitch tension due to the underlying 
changes in myosin isoforms as the fast muscle begins to take on slow characteristics 
(Henriksson ci aL, 1986). The Ca2tATPase  activity decreases, eaxplained by the shift 
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from fast SERCAI to slow SERCA2a isoforms. There also appears a reduced 
capacity for Ca 2 uptake by the SR as well as a decrease in cytosolic Ca 2 buffering, 
secondary to a decline in parvalbumin content (Eisenberg & Salmons, 1981). 
Phospholamban levels also decrease, and since the phosphorylation-state of this 
protein is responsible for co-localising intracellularly with the slow isoform of 
Ca2 ATPase, this further underlines a shift towards a slower phenotype (Kraus el al., 
1994). There is marked restructuring from an anaerobic to aerobic system shown by a 
collapse of the adenylate and creatine systems (PCr); although the muscle maintains a 
remarkable ability to recover from the initial insult on the ATP generating system 
which has been demonstrated by a temporary super-compensation in glycogen levels 
(+25 %) (Flenriksson et aL, 1986). Enzymes of the Krebs cycle such as succinate 
dehydrogenase, citrate synthase and malate dehydrogenase increase their turnover 
(Henriksson ci aL, 1986) to counteract increased contractile work-loads. Changes in 
enzymes involved in n-oxidation parallel this citric acid cycle modulation in showing 
an increase in 3-hydroxyacyl-CoA dehydrogenase, and carnitine acyltransferase 
which are coupled with increased extracellular albumin (fatty acid transporter), and an 
increase in fatty-acid binding proteins that function as intracellular lipid traffickers 
(Henriksson et at, 1986). Increases in oxidative enzymes and machinery, are 
accompanied by an increase in myoglobin and capillarisation thus allowing oxygen 
utilisation to be maximised (Kraus ci at, 1994). These physiological changes mirror 
those encountered with chronic endurance training, yet on a much accelerated level. 
However, aside from the rate in which CMNS elicits physiological change, there are 
other negative points as a physiological model. Under normal circumstances, 
Henneman's size principle dictates that smaller motor units (type I) are recruited at 
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low levels of force and are therefore active most often, whereas larger motor (type II) 
units are recruited less frequently (Henneman et al., 1965). However, if the force 
exerted by a muscle is increased from a sub-threshold level of CMNS, then there is a 
tendency for the larger axons to be depolarised first, which creates an inversion of 
normal recruitment patterns since larger motor units are permanently in use. 
Moreover, CMNS excites all the motor units at the same frequency and 
synchronously, resulting in a contraction which is grossly oscillatory and superficial 
to the asynchronous discharge rate seen in reality. In support of this it has been shown 
that CMNS produces more limited changes in myosin if applied intermittently or at a 
frequency lower than 10 Hz. Therefore, artificially applied CMNS is often far and 
above any frequency/time scale likely to be training induced (Pette et aL, 1975). 
Nevertheless, CMNS is a useful model and produces changes in physiology that 
parallel those obseved with chronic endurance exercise, as discussed in section 1.4. 
1.5 Cell signalling mediating physiological adaptations of skeletal 
muscle to endurance exercise training 
Recent literature has implicated many candidate pathways that mediate the well 
characterised physiological responses to endurance training. These pathways are 
contraction responsive and have been shown to be involved in phenotypic change 
such as control of fibre type or mitochondrial biogenesis, the key muscular 
adaptations to endurance exercise. Below, each pathway implicated in these responses 
will be sequentially analysed in order to dissect the mechanisms by which activation 
of these proteins might create phenotype changes through changed genetic responses. 
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1.5.1 Control of mitochondrial biogenesis 
Mitochondria are the 'cellular engines' that provide an ATP supply through oxidative 
phosphorylation and increase in their numbers and size is associated with endurance 
training (Freyssenet et at, 1996). Endurance exercise activates signal transduction 
pathways that either stimulate or affect expression of transcription factors that 
regulate the expression of genes encoding mitochondrial proteins. One such protein is 
the adenosine monophosphate kinase (AMPK) which has been shown to be activated 
in response to contraction (Frosig et at, 2004) and mediate many cellular responses to 
exercise (figure 1.5). AMPK is a heterotrimeric protein kinase with multiple isoforms 
for each subunit (alpha, beta, and gamma). Whereas only the alpha-i and alpha-2 
subunits are catalytic, the beta and gamma subunits are regulatory and necessary for 
full enzymatic activity. AMPK is activated by low glycogen, increased AMP levels 
and inhibited by phosphocreatine (PCr) aggregation (Winder & Hardie, 1996). These 
are situations which are common in endurance activity with the chronically elevated 
AlP turnover, and thus provide the stimulus for AMPK activation. 
The link between AMPK and mitochondrial biogenesis comes from PGC-ia, since 
AMPK activation is known to induce PGC-la (Suwa et at, 2003). PGC-la was first 
shown to be increased in response to cold and led to induction of nuclear respiratory 
factor I (NRF- 1) and mitochondrial transcription factor A (TFAM) to control 
mitochondrial biogenesis (Wu et at, 1999). Studies have shown that PGC-ia is 
upregulated as a result of exercise and that pharmacological activation of AMPK by 
5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) increases POC- I a 
expression as well (Terada et at, 2002). Finally, over-expression of the transcription 
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factor PGC-Iu upregulates not only mitochondrial genes, but also non-mitochondrial 
genes such as myoglobin and slow troponin (Lin el at, 2002) and muscles of 
transgenic mice over-expressing PGC-lu are visibly redder and contain a higher 
proportion of type I oxidative fibres. Therefore, activated AMPK is likely to be 
responsible for increases in NRF-1 which is a key factor involved in nuclear gene 
transcription (Wu et at, 1999) and act in concert with PGC-lcz and TFAM to regulate 
mitochondrial biogenesis and slow fibre formation. The protein p38 is also thought to 
induce PGC-la (Barger et at, 2001). Since p38 MAPK has shown to be significantly 
activated (through increased phosphorylation) in response to CMNS some of the 
effect is probably mediated through this MAPK. Thus, AMPK is a major activator of 
mitochondrial biogenesis when cellular energy metabolism is under increased stress 
(Bergeron et at, 2001) as during endurance exercise. 
Once nuclear genes are expressed, genes from mitochondrial DNA must also be, since 
mitochondrial biogenesis requires the coordinated expression of nuclear and 
mitochondrial genes in concert. It has been shown that TFAM is capable of activating 
rnitochondrial DNA replication and expression (Fisher et at, 1989). In support of this, 
TFAM expression increases as a response to chronic exercise, suggesting that TFAM 
is indeed involved in activation of mitochondrial biogenensis as a result of endurance 
exercise (Gordon et at, 2001). TFAM knock-out mouse embryos die because of a 
complete absence of oxidative phosphorylation and a severe depletion of 
mitochondrial DNA, highlighting the essential role of TFAM in mitochondrial DNA 
replication (Larsson et at, 1998). Therefore it appears that AMPK activated PGC-la 
is the master controller of mitochondrial biogenesis through TFAM and NRF to 
control the expression of both nuclear and mitochondrial DNA. 
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Figure 1.5. Diagram to show the known physiological target proteins and pathways 
regulated by the 'master regulatory' AMPK system. AMPK is switched on by cellular 
stresses that either interfere with ATP production (e.g. hypoxia, glucose deprivation, 
or ischemia) or by stresses that increase ATP consumption (e.g. muscle contraction). 
It is also activated by hormones that act via Gq-coupled receptors, and by leptin and 
adiponectin, via mechanisms that remain unclear. Once activated, the AMPK system 
switches on catabolic pathways that generate ATP such as through enhancing fatty 
acid oxidation, while switching off ATP-consuming processes that are not essential 
for short-term cell survival, such as the synthesis of lipids, carbohydrates, and 
proteins. Therefore AMPK activation by exercise is not only limited to affecting 
mitochondrial biogenesis and fibre type. Diagram taken from Hardie, (2003). 
27 
1.5.2 The Calcineurin (CnA) pathway and fibre type regulation 
One of the major signals associated with adaptation to endurance exercise are 
contraction-induced intracellular free Ca 2 ' ([Ca2 ]1) oscillations. Muscle fibre type 
characteristics are thought to be dependent on the frequency of motor nerve 
stimulation and some of this effect is proposed to be controlled by Ca 2 -dependent 
signalling. This is supported by the fact that increased (Ca 2+]i levels have been 
reported in muscles undergoing transition to a slower phenotype (Sreter ci aL, 1987). 
One such candidate pathway implicated in mediating response to Ca 2 signalling has 
been the calmodulin-dependent protein phosphatase, calcineurin (figure 1.6). The 
model proposes that tonic motor nerve activity sustains [Ca 2 ]1 at levels sufficient to 
activate the calcineurin-nuclear factor of activated T cells (NFAT) pathway. The 
protein phosphatase activity of calcineurin leads to dephosphorylation and nuclear 
localisation of NFAT proteins. In the nucleus, NFAT proteins bind DNA in 
conjunction with other transcriptional regulators, including myocyte enhancer factor 2 
(MEF2). Binding sites for these regulators are clustered in promoter/enhancer regions 
controlling transcription of genes encoding proteins of the slow-fibre programme such 
as myoglobin and troponin I (Chin ci aL, 1998). This is supposedly specific to 
endurance-like activity since high amplitude [Ca 2+]i transients stimulated by 
infrequent, phasic firing of the motor nerve are of insufficient duration to maintain 
calcineurin in the active state, so NFAT protein in remain phosphorylated and are 
excluded from the nucleus (Chin ci aL, 1998), (figure 1.6). Therefore the calcineurin 
pathway is an example of a network which can be activated selectively depending 
upon the specific type of contractile activity. 
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It is, however, contentious as to the precise significance of calcineurin in control of 
phenotype. It appears that calcineurin is important for controlling fibre type since 
administration of the calcineurin inhibitor, cyclosporin A (C5A), reduced slow fibre 
gene expression in vivo, suggesting a key role of calcineurin in activation of the slow 
muscle fibre phenotype (Chin et aL, 1998). In support of this, the calcineurin specific 
ithibitor, FK506, was administered and whilst the control overloaded plantaris muscle 
showed fast-to-slow muscle fibre type transition and decrease in MI-IC lIb, increase in 
MHC Ila+d/x, and new expression of MHC I; in the FK506-administered group, 
overload-induced muscle fibre-type transition was completely prevented (Miyazaki ci 
at, 2004). Furthermore, in transgenic mice that express activated calcineurin there is 
an increase in slow muscle fibres (Talmadge et at, 2004), whilst in calcineurin knock-
out mice, overload-induced fibre type switch is inhibited (Parsons c/ at, 2004). 
However, in contrast to these findings it has also been shown that not only slow 
muscle promoters but also the fast muscle promoters for phosphoglycerate mutase, 
skeletal muscle sarcoplasmic reticulum Ca2tATPase,  and MI-IC lIb were activated by 
over-expressed calcineurin in cultured muscle cells (Swoap ci at, 2000). These 
experiments suggested that calcineurin also activates some "fast" genes in skeletal 
muscle. Furthermore, the role of calcineurin operating in tandem with NFAT is 
unclear, since NFAT over-expression had no effect upon SERCAI promoters in 
C2C12 cells, whilst constitutively active calcineurin increases SERCA1 promoter 
activity (Swoap et at, 2000). Therefore, there remains some controversy over the 
importance of calcineurin and calcineurin-NFAT interactions in control of fibre type. 
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Figure 1.6. A summary model for the calcineurin (CnA)-dependent pathway which 
links contrasting motor nerve activity to gene expression that produces phenotypic 
differences between fibre types. Calcineurin, is activated by chronic elevation of 
[Ca2 ]1 casued by the release of Ca 2  from the SR in response to contraction. Ca 2 
binds to coth calmodulin and the B sub-unit of Calcineurin. Once activated, 
calcineurin has a phosphatase activity that dephosphorylates the nuclear factor of 
activated T cells (NFAT), unmasking the nuclear localisation signal on NFAT. 
Nuclear import of NFAT bound calcineurin leads to the collaboration with myocyte 
enhancer factor 2 (MEF2) to promote expression of the slow gene programme. The 
four MEF2 isoforms (A-D) belong to the super-family of MADS (MCMI, agamous, 
deficiens, and serum response factors nuclear phosphoproteins), which bind to DNA. 
The specific activation of calcineurin would be expected with endurance-like 
exercise. Conversely, high amplitude short duration [Ca 24]1 oscillations, such as in 
high intensity resistance-like intermittent exercise, means that calcineurin remains 
inactive and thus does not affect the expression of slow genes. Treatment of cells with 
cyclosporine inhibits calcineurin activation. Diagram taken from Chin €1 aL, (1998). 
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1.5.3 Ca2 '/calmodulin kinase dependent protein kinases and control 
of fibre type 
Members of the Ca2 /ca1modulin dependent protein kinase (CAMK) family are 
serine/threonine protein kinases, and can be distinguished according to whether they 
have a single substrate such as phosphorylase kinase, CAMKIII and myosin-light 
chain kinase or are multi-flinctional having several substrates such as CAMK,I, II and 
IV (Hook & Means, 2001). Specifically, CAMKI and CAMKIV are implicated in 
regulating Ca24 dependent transcription in cells (Hook & Means, 2001). In C2C12 
myotubes, CAMKJV acts synergistically with calcineurin to increase transcription 
from MEF2-dependent enhancers through interactions with histone deacetylases (Wu 
et aL, 2000), thus suggesting effects on slow gene expression. Furthermore, transgenic 
mice that expressed a constitutively active form of CAMKIV in type II fibres, 
exhibited increased mitochondrial biogenesis and number of type I fibres, probably 
through increasing the expression of PGCIa (Soderling, 1999). These data suggest 
that CAMK isoforms may control fibre type, although much of the data centres 
around CAMKIV, which is not, or only lowly expressed in skeletal muscle 
(Soderling, 1999). However, CAMKI is expressed in skeletal muscle and whilst its 
role in fibre typing in unclear, it is possible that CAMK proteins have a role in fibre 
type regulation in vivo, although the precise mechanisms remain to be elucidated. 
1.5.4 The ERK1/2 pathway and control of fibre type 
The mitogen activated protein kinase (MAPK) ERK1/2 has also been shown to 
regulate fibre type, especially through controlling transcription of MHC isoforms and 
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muscle enzymes. A study using the MEKI/2 inhibitor 1J0126 on spontaneously 
twitching muscle cells significantly decreased type I MI-IC mRNA levels and 
significantly increased MFIC lix, MHC lIb, embryonal MI-IC and perinatal MI-IC 
mRNA levels (1-ligginson et aL, 2002). Mother group used in vivo transfection in 
regenerating muscle, to show that constitutively active Ras and a Ras mutant that 
selectively activates the MAPK (ERIC) pathway are able to mimic the effects of slow 
motor neurons on expression of myosin genes (Murgia et aL, 2000). Since ERK 
activity is increased by low-frequency electrical stimulation (Atherton et at, 2005) 
and endurance exercise (Yu et aL, 2001), these results indicate that Ras-MAPK 
signalling is involved in promoting nerve-activity-dependent differentiation of slow 
muscle fibres in vivo. 
1.5.5 The PKC pathway and control of fibre type 
There are many distinct isoforms of Protein kinase C (PKC), including those that are 
Ca2 and diacylglycerol sensitive (PKCa, PKCI3, PKC7) and those which are only 
diacylglycerol responsive (PKC8, PKCs, PKCrj, PKCG). Diacyiglycerol stimulates 
PKC activity by greatly increasing the affinity of the enzyme for Ca 2 ions. Treatment 
of cultured avian muscle cells with staurosporine, a PKC inhibitor, increases the 
expression of slow MHC which was not expressed in control cells (DiMario & Funk, 
1999). In a second experiment, PKCa and PKCt were over-expressed and repressed 
slow MHC expression in vivo (DiMario, 2001). Therefore it appears that PKC inhibits 
slow MHC expression and thus the activation of PKC can not explain the endurance-
training effect. Further studies are required on PKC isoforms in mammalian cells in 
order to clarify the effects, if any, of PKC on control of fibre type. 
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1.5.6 The AMPK- PGC-la pathway and control of fibre type 
The transcriptional co-activator PGC-la which as explained previously controls 
mitochondrial biogenesis, also appears to have other effects on phenotype. When 
PGC- I a alpha is expressed at physiological levels in transgenic mice driven by a 
muscle creatine kinase promoter, a fibre type conversion is observed. Those muscles 
normally rich in type II fibres are redder. Notably, putative type II muscles from 
PCIC-Ia transgenic mice also express proteins characteristic of type I fibres, such as 
troponin I and myoglobin, and show a much greater resistance to electrically 
stimulated fatigue (Lin ci aL, 2002). Interestingly, there is also a link between PGC-
I a and calcineurin. One study found a simultaneous increase in PGC- I a mRNA 
which was associated with calcineurin activation (Gamier ci aL, 2005). The results 
provide strong support for a central role for PGC-la and calcineurin activation in 
mitochondrial biogenesis and control of fibre type in skeletal muscles. 
1.6 Cell signalling mediating physiological adaptations of skeletal 
muscle to resistance exercise training 
The predominant adaptation to resistance training is muscle hypertrophy. This 
adaptation is such in contrast to endurance exercise where the muscle sometimes 
actually loses mass and there is a more prominent phenotype shift. The vast majority 
of literature suggests that fibre hypertrophy (growth in size of existing fibres) is the 
main mechanism explaining muscle growth in response to resistance training 
(Gollnick ci aL, 1981; Alway ci aL, 1988; Frontera ci aL, 1988), rather than 
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hyperplasia (increase in the number of fibres). Muscle hypertrophy is accompanied by 
only a limited fibre type effect and there is evidence of reduced IN myofibre 
distribution with a concomitant increase in type ha distribution (see 1.4.1). Resistance 
training-induced hypertrophy predominantly occurs in type II fibre sub-types and only 
little or not in type I fibres (Hather et aL, 1991). This physiological adaptation of 
increased muscle size is of primary importance since the ability to perform feats of 
strength and power is to a large extent, limited by muscle mass. 
1.6.1 Protein synthesis, training and nutrition 
Hypertrophy of skeletal muscle requires a net positive protein balance meathng that 
protein synthesis must exceed protein breakdown. In most models, including exercise, 
when protein synthesis increases so does protein breakdown and when protein 
synthesis falls protein breakdown also falls, adaptively (Cuthbertson et aL, 2004). 
Resistance exercise is a powerful way to increase protein synthesis and thus muscle 
mass, and in fact, after a single bout of resistance training, muscle protein synthesis 
(MPS) remains elevated for >48 It (Chesley a aL, 1992). Nutrients also stimulate 
protein synthesis, and feeding protein or amino acids alone without resistance training 
stimulates protein synthesis, although the effect lasts only for -2 h (Bohe et aL, 2001). 
After a bout of resistance exercise, protein breakdown increases as well (Biolo et aL, 
1995) and without food intake, net protein breakdown results. These studies show that 
both protein synthesis and breakdown increase in response to resistance training, 
however feeding is necessary to stimulate a chronic positive protein balance (Tipton 
et aL, 1999). A post-exercise diet of protein and carbohydrate will enhance protein 
synthesis through increased availability of amino acids whereas carbohydrate-induced 
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insulin increases will reduce protein breakdown (Rennie & Tipton, 2000). Therefore it 
is the combination of resistance exercise and nutrition that produces a long-lasting net 
positive protein balance, and thus potential for hypertrophy. Timing of nutrition also 
seems important and maximum effects are observed when feeding occurs immediately 
post-exercise in comparison to feeding 2 h post-exercise (Esmarek et aL, 2001). 
1.6.2 Role of satellite cells in mediating hypertrophy 
Much research has attempted to resolve the mechanisms of hypertrophy, and one 
major dynamic of this process involves satellite cells. During muscle hypertrophy the 
number of myonuclei tends to increase proportionally with the increase in fibre 
volume, thus maintaining the myonuclear domain cytoplasm ratio (Roy et aL, 1999). 
Since skeletal muscle is a post-mitotic tissue and thus incapable of cell division, this 
additional genetic material must then be derived from satellite cells. Satellite cells are 
located in the basal lamina of muscle fibres (Kadi et aL, 2004a) and are myogenic 
cells attributed with the role of postnatal growth and regeneration in skeletal muscle. 
Following proliferation and subsequent differentiation, these cells fuse with one 
another or with the adjacent muscle fibre, thereby increasing myonuclei numbers for 
fibre growth and repair (Allen & Rankin, 1990). Their importance in hypertrophy is 
highlighted since in response to synergist ablation (a growth stimulus for the 
antagonistic muscle), first satellite cells and then myonuclei increase in the 
hypertrophying muscle, adding further support to the hypothesis that satellite cells 
proliferate first and subsequently fuse with muscle fibres (Snow, 1990). There is 
further evidence that satellite cell proliferation is critical for the muscle growth 
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response. If mild y-irradiation is used to block satellite cell proliferation then rat 
gastrodnemius muscle does not hypertrophy in response to synergist ablation 
(Rosenblatt et aL, 1994). In another study it was confirmed that y-irradiation could 
prevent most hypertrophy achieved by overload in plantaris over the period of three 
months (Adams et aL, 2002). These data support the case that hypertrophy involving 
satellite cell proliferation is a major mechanism of muscle growth. 
Several studies also suggest that satellite cell proliferation and nuclei uptake into 
muscle fibres occur in response to resistance training in human skeletal muscles. 
Subjects that undertake a resistance training programme to elicit muscle hypertrophy 
have been shown to possess a larger number of nuclei per fibre (Kadi et at, 1999). 
Mother study showed that after 10 weeks of resistance training in females, fibre 
hypertrophy is accompanied by both a -70 % increase in the number of nuclei, and a 
46 % increase in the number of satellite cells (Kadi & Thornell, 2000). This 
observation suggests that both satellite cell proliferation and fusion are associated 
with growing muscle fibres in humans. Finally, satellite cells increased by 19 % and 
31 % after 30 and 90 days, respectively, following resistance training and decreased 
following cessation of training confirming that satellite cells respond with 
proliferation to resistance training, and that this is a reversible phenomenon in a 
situation of detraining (Kadi et at, 2004b). Signalling controlling satellite cell 
proliferation is not well established, but probably involves the opposing actions of 
myostatin and IGF-1. Myostatin negatively regulates protein synthesis and the 
satellite cell cycle (McCroskery et at, 2003), whereas IGF-1 (Barton-Davis et at, 
1999) not only increases muscle protein synthesis but also positively mediates 
satellite cell proliferation (Chakravarthy et at, 2001; Barton-Davis et at, 2001). 
36 
1.7 Signalling pathways controlling protein synthesis 
Satellite cells might provide additional genetic material to assist increases in size, but 
hypertrophy requires gross increases in protein synthesis. In recent years there have 
been many muscle growth factors (myostatin, IGF-1, etc) and signalling pathways 
(P1-3K pathway, calcineurin etc) implicated in mediating control of muscle mass. 
1.7.1 Muscle growth factors - Negative regulation by myostatin 
The transforming growth factor (TGFJ3) super-family is a group of proteins that 
regulate growth, differentiation and apoptosis. One subclass within this family are the 
growth and differentiation factors (GDFs). Myostatin is a GDF that was discovered in 
1997, and genetic knock-out of myostatin in mice results in skeletal muscle 
hypertrophy and hyperplasia (McPherron et aL, 1997). Recently, a myostatin mutation 
was shown to promote gross muscularity in a child, thus confirming that a lack of 
fbnctional myostatin can also increase muscle mass in humans (Schuelke et aL, 2004). 
The mouse myostatin knock-out model demonstrated the mechanisms by which 
myostatin exerts its effects through development, and this was shown to be through its 
inhibitory effects on the cell cycle. With ifinctional myostatin during embryonic 
myogenesis, Myf-5 and MyoD specify cells to adopt the myoblast fate. Myoblasts 
then migrate and proliferate. In response to myostatin signalling, p21 is up-regulated, 
inhibiting cyclin-&CDK2 activity, which causes retinoblastoma inactivation and G1 
arrest. Thus, myoblast number and, hence, fibre number, following differentiation, is 
limited. However, in the absence of functional myostatin, the signal for p21 up-
regulation is lost and retinoblastoma remains in a hyperphosphorylated state, resulting 
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in increased myoblast proliferation and thus increased fibre number (Thomas et aL, 
2000). Since myostatin has effects on the cell cycle, this means it may be important in 
hypertrophy through its effects on satellite cells. To illustrate this, there is evidence 
that myostatin has a negative effect on satellite cell proliferation (McCroskery et at, 
2003). This study showed that during development, myostatin up-regulated p21, a 
cyclin-dependent kinase (CDK) inhibitor, and decreased the levels and activity of 
CDK2 protein in satellite cells. Hence, myostatin negatively regulates the Gi to S 
progression and thus maintains the quiescent status of satellite cells. 
This cell cycle effect has important implications given the aforementioned importance 
of satellite cell proliferation in hypertrophying muscle (Rosenblatt et at, 1994) (see 
1.6.2). Support for this comes from the facts that: 1) myostatin null mutants display 
muscle hypertrophy and hyperplasia, both of which may relate to elevated satellite cell 
activity and proliferation, 2) hind-limb unloading causes suppression of satellite cell 
proliferation, which coincides with increased myostatin expression, and 3) fast-twitch 
muscles have lower concentrations of satellite cells, which correlates with the higher 
level of expression of myostatin in fast muscle, and finally 4) the myostatin protein is 
concentrated at myotendinous junctions, where satellite cells are also present in 
greater densities than any other place within muscle cells (Wehling et at, 2000). 
1.7.1.1 Regulation of the myostatin gene 
Several studies have attempted to investigate regulation of the myostatin gene 
expression on a molecular level. Putative binding motifs for glucocorticoids, 
androgens, thyroid hormones, myogenic differentiation factor 1, MEF2, PPAR1, and 
(1:3 
NFiB were predicted in one study (Ma ci at, 2001) (figure 1.7). Of these, the 
predicted upregulation of myostatin expression by glucocorticoids was experimentally 
verified (Ma ci at, 2003). In another study it was shown that growth hormone 
suppressed the expression of myostatin in growth hormone-deficient patients and in 
cultured skeletal muscle cells (Liu ci at, 2003). The transcription factor and binding 
site by which the growth hormone effect is mediated are currently unknown and could 
be indirect via induction of IGF- 1. Support for this hypothesis comes from the fmding 
that IGF-l/IGFBP-3-complexes were shown to reverse the alcohol-induced increase 
in myostatin expression (Lang ci at, 2004). 
In animal experiments, it was shown that myostatin mRNA increases in some muscles 
during atrophy-inducing hind-limb unloading (Carlson ct at, 1999) and space flight 
(Lalani cI at, 2000). In contrast, myostatin inRNA decreases during recovery and 
muscle re-growth after muscle injury (Kirk ci at, 2000). Surprisingly, in myostatin 
knock-out mice, hind-limb unloading leads to greater atrophy than in their wild-type 
controls (McMahon ci at, 2003), due to a repressed myogenic response to atrophy. In 
humans, myostatin mRNA levels have been shown to increase in disuse atrophy 
(Reardon ci at, 2001) and ageing (Yarasheski ci at, 2002). The role of myostatin in 
exercise adaptation is contentious. In rats, myostatin mRNA decreases in fast muscle 
in response to short-term endurance training consisiting of swimming 5 days/week 
(Matsakas ci at, 2005). In human beings some reports suggest that myostatin mRNA 
or circulating myostatin does decrease in response to resistance training (Zambon ci 
at, 2003) whereas others found no effect (Willoughby, 2004). Myostatin and 
endurance training has not yet been examined. Therefore the role of myostatin in 
controlling responses to training and disease in humans remains largely unidentified. 
-A 
1.7.1.2 Myostatin regulates post-development muscle mass by 
affecting transcription and translation 
Increasing systemic myostatin leads to cachexia (Zimmers ci al., 2002) and an 
increased muscle and serum myostatin concentration was found in HIV-infected men 
whom undergo muscle wasting (Gonzalez-Cadavid ci aL, 1998). Therefore it appears 
that myostatin is not just solely controlling the developmental programme but is also 
regulated by other stimuli. Mechanisms by which myostatin might be regulated 
through exercise or disease could come through regulatory proteins linked to 
myostatin. Myostatin is under regulation from follistatin, the follistatin-related gene 
(FLRG) (Lee & MePherron, 2001), the myostatin propeptide and a protein named 
Gasp-i (Hill ci aL, 2003) all of which are proteins that can bind and inhibit myostatin. 
The formation of myostatin-inhibitor protein heterodimers is likely to prevent activin 
type II receptor binding of myostatin. This has been demonstrated for the genetically 
similar bone morphogenetic protein 7 (BMP7) and the protein Noggin, which 
dimerise and the resulting heterodimer cannot bind to the receptor (Groppe ci aL, 
2002). Perhaps these binding proteins may be affected by exercise or disease stimuli 
to affect myostatin signalling, either positively or negatively. 
It appears then that myostatin can modulate adult skeletal muscle, yet the mechanisms 
controlling this remain to be elucidated. When not inhibited by its regulatory proteins 
in circulation, it is possible that myostatin may exert its effects through changing gene 
expression. Myostatin is a secreted protein that signals through TGFO receptors which 
stimulate the phosphorylation of receptor-regulated mothers against decapentaplegic 
homolog (SMAD) proteins, which in turn form complexes with SMAD4 that 
accumulate in the nucleus and regulate the transcription of target genes (ten Dijke & 
Hill, 2004). Inhibitory SMAD7, reduces myostatin-induced transcription and SMAD7 
expression is stimulated by myostatin via the interaction between SMAD2, SMAD3, 
SMAD4 and the SBE (Smad binding element) in the SMAD7 promoter. These results 
suggest that the myostatin signal transduction pathway is regulated by SMAD7 
through a negative feedback mechanism (Zhu et aL, 2004), and positively through 
SMAD 2,3,4. There is also evidence that myostatin has a negative effect on protein 
synthesis in cultured muscle, as cells treated with recombinant myostatin exhibit a 
decrease in protein synthesis (Taylor et aL, 2001). The mechanisms behind this effect 
are unclear although knowledge of this process would yield interesting information 
regarding the way in which myostatin negatively regulates growth. 
In summary, myostatin is a secreted protein that acts as a negative regulator of 
skeletal muscle mass. During embryogenesis, myostatin is expressed by cells in the 
myotome and in developing skeletal muscle and acts to regulate the final number of 
muscle fibres that are formed by controlling the cell cycle. During post-mitotic adult-
life, myostatin protein is produced and secreted by skeletal muscle, circulates in the 
blood, and acts to limit muscle fibre growth. The precise mechanisms by which 
myostatin inhibits muscle growth remain to be eulicidated, although involves the 
negative effect on satellite cell cycle and MPS. Interestingly, the existence of such 
circulating tissue-specific growth inhibitors of this type was hypothesised over 40 
years ago to explain how sizes of individual tissues are controlled, but examples of 
such factors remained elusive. Skeletal muscle appears to be the first illustration of a 
tissue whose size is controlled by this type of negative regulatory mechanism, and 
thus myostatin appears to be the first example of the long sought 'chalone'. 
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Figure 1.7. Schematical overview depicting the control of myostatin expression and 
subsequent effects on cell cycle and transcription. (1) Myostatin expression is 
regulated via DNA binding elements for glucocorticoid, androgen, thyroid hormone, 
myogenic regulatory factors (MRFs), MEF2, PPARy, and NFKB (Ma et al., 2001). 
Only the glucocorticoid binding site has been experimentally verified (Ma et aL, 
2003). (2) Myostatin is modified post-translationally and secreted. (3) Secreted 
myostatin will be present as a homodimer or (4) heterodimer. Fleterodimers of 
myostatin with either follistatin or gasp 1 can not bind to receptors. (5) Myostatin 
homodimers bind to activin type RuB and RIJA receptors. This is likely to lead to the 
recruitment of an activin type I receptor and receptor phosphorylation. (6) Receptor 
activation results in SMAD3 and/or SMAD2 phosphorylation. SMAD signalling can 
potentially be modified by Co-SMADs or (7) inhibitory I-SMADS. (8) Activated 
SMAD enters the nucleus and binds to SMAD binding elements. This is likely to 
mediate part of the growth inhibition possibly via repression of MyoD expression 
(Langley et aL, 2002). Cell cycle regulation occurs either via the expression of 
proteins regulating the cell cycle or (9) via regulation of cell cycle proteins. 
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1.7.2 Muscle growth factors - Positive control by Insulin like growth 
factor 1 (IGF-1) splice variants and the P1-3K pathway 
IGF-1 is part of the system that regulates growth, and is a diametric opposite to 
myostatin in that it is a potent positive regulator of muscle mass. Growth hormone 
increases circulating IGF-1 as a second messenger through increasing IGF-1 
expression in the liver (Butler & Le Roith, 2001). Apart from growth hormone, IGF-1 
expression also increases in response to testosterone but decreases in response to the 
known atrophy-inducing factors such as glucocorticoids, TNFa and interleukin-1 
(Frost & Lang, 2003). As in the case of myostatin, IGFs are found in association with 
a family of high-affinity insulin-like growth factor binding proteins (IGFBP 1-6) that 
affect their biological activity (Firth & Baxter, 2002). IGFBPs fulfill important 
functions demonstrated by the examples that only the IGFBP3-IGF-1 complex but not 
TGF-1 alone increased protein synthesis in muscles of alcohol-fed rats (Lang c/ aL, 
2004); whilst binding of IGF-I to JGFBP-3 and the acid-labile subunit (ALS) forms a 
ternary complex that maintains circulating levels of IGF-I by slowing its rate of 
clearance (Svanberg et aL, 2000). Transgenic mice show the importance of JGF- I 
since muscles and other organs of IGF-1 knockout mice are smaller than in the wild-
type and few mice survive into adulthood (Liu et aL, 1993). In contrast, IGF-1 
infusion into skeletal muscle results in skeletal muscle hypertrophy (Adams & 
McCue, 1998) and skeletal muscle specific over-expression of IGF-1 causes 
hypertrophy (Musaro et aL, 2001). IGF-1 is also synthesised in skeletal muscle and 
rats where hypophysectomy had been performed, still respond to muscle growth-
inducing stimuli with a prolonged increase in IGF-1 expression and hypertrophy 
(DeVol et aL, 1990) thus showing the importance of local IGF- 1. 
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Recently, a splice variant stretch-responsive isoform of IGF-1 was identified which 
was named mechano-growth factor (MGF). In one study, MGF mRNA increased for 
>40 h after exercise in resistance-trained rat muscles (Haddad & Adams, 2002). 
However, muscle stretch can also increase anabolic signalling without the activation 
of the P1-3K or PKB which probably excludes IGF-1 or MGF as the growth factors 
mediating this response (Hornberger et cii., 2004). The effect of resistance training on 
IGF-1 expression in human skeletal muscle is unexpectedly unclear where studies 
have found little or no increase in circulating IGF- 1 and MGF in response to 
resistance training (Walker et aL, 2004; Borst et aL, 2001). It is therefore unclear as 
yet as to the importance of IGF- 1 splice variants in human muscle hypertrophy. 
1.73 IGF-1 and Forkhead (FOXO) transcription factors 
The so-called forkhead (FOXO) factors have important relation to IGF- I signalling. 
In cultured myotubes undergoing atrophy the activity of the PI-3KIPKB pathway 
decreases, leading to activation of FOXO transcription factors and atrogin-1 
induction. IGF-1 treatment or PKB overexpression inhibits FOXO through nuclear 
exclusion, thus showing that activation of the P1-3K pathway can inhibit FOXO 
mediated expression of atrophy factors. Therefore, it appears that the forkhead family 
of transcription factors are inhibited by IGF-1 signalling and thus hypertrophy 
mediated through this pathway could be at least in part due to nuclear exclusion of 
FOXO transcription factors as well through the characterised effects on protein 
synthesis. This conclusion is further supported by the fact that P1-3K signalling is also 
required for transcriptional changes in muscle, demonstrated by the downregulation of 
the atrophy genes MuRF-1 and MaFbx in response to IGF-1 (Latres et aL, 2005). 
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1.7.4 Role of the IGF-IIPI-3K pathway in hypertrophy 
1.7.4.1 P1-3K, PDK1 and PKB 
IGF-1 exerts its growth effects through the P1-3K pathway, and even though the role 
of IGF splice variants in human hypertrophy in response to exercise is contentious, 
the importance of this pathway is nevertheless critical in mammalian protein 
synthesis. The following discussion assumes the chain of events following the binding 
of IGF-1 to the insulin/IGF-1 receptor in order to layout the process by which 
stimulation of this pathway results in enhanced protein synthesis. Once the receptor 
has been stimulated, insulin receptor substrate (IRS) proteins, which possess binding 
sites for P1-3K (White, 2002), phosphorylate the phosphoinositols (Ptdlns) 
(Vanhaesebroeck et at, 2001). P1-3K uses ATP to phosphorylate Ptdlns(3,4)P2 (PIP2) 
to Ptdlns(3,4,5)P3 (PIP3) (Vanhaesebroeck et at, 2001). The increased production of 
PIP3 stimulates interaction between pyruvate dehydrogenase kinase 1 (PDK1) and 
PKB. Both PDK1 and PKB have a PIP3 binding site, named the pleckstrin homology 
domain (Vanhaesebroeck & Alessi, 2000). The production of PIP3 stimulates 
translocation of PDKI and PKB from the cytosol to the cell membrane. This 
localisation of PKB enables PDKI to phosphorylate PKB at Thr308 and an unknown 
kinase (sometimes termed PDK2) to phosphorylate PKB at Ser473 (Vanhaesebroeck 
& Alessi, 2000). Both PDKI and PKB regulate muscle growth as is evident from the 
phenotypes of PDKI knockout (Lawlor et at, 2002) and PKB transgenic mice (Yang 
et at, 2004). The effect of PKB activation on skeletal muscle growth was 
demonstrated in an experiment where a constitutively active PKB construct was 
expressed in regenerating skeletal muscle (Pallafacchina et at, 2002) and the fibres 
that expressed the construct were much larger. There are three PKB isoforms - PKBcz 
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(Aktl), PKB3 (Akt2) and PKB1 (Akt3) (Yang ci aL, 2004). The most important 
isoform regulating growth appears to be PKBa since knockout mice have defects in 
foetal and postnatal growth that persist into adulthood (Cho ci at, 2001) and 
furthermore, the activation of PKBct signalling in mouse gastrocnemius muscle is 
sufficient to promote myofibre hypertrophy (Takahashi ci aL, 2002). Once the 
stimulus activating P1-3K has gone, a lipid phosphatase called phosphatase and tensin 
homolog on chromosome ten (PTEN) converts of PIP3 into PIP2 thus reversing the 
effect of IGF-1 regulated P13-kinase and "switching" off this pathway. 
1.7.4.2 PKB and AMPK signalling via TSC2 
PKB is a major upstream kinase which is capable of directing activation of protein 
synthesis by phosphorylating tuberin (TSC2), mTOR and GSK-30, to affect 
translational regulators, of which each will be discussed in turn. Recently TSC2 has 
been identified as a link to growth regulation by indirectly connecting PKB to mTOR 
and thus translational regulation. The complex of hamartin (TSC1) and TSC2 were 
originally shown to cause the autosomal dominant disorder tuberous sclerosis 
complex when mutated (Kwiatkowski, 2003). PKB phosphorylates TSC2 at Ser939 
and Thr1462 resulting in the inhibition of TSC2 (Manning ci at, 2002). The TSC2 
protein has a domain that is termed a GTPase-activating protein (GAP). GAPs 
catalyse the activity of GTPases of 0 proteins which convert guanosine triphosphate 
(GTP) to guanosine diphosphate (GDP). The G protein Rheb was recently shown to 
be the TSC2 substrate (Inoki ci at, 2003a), and without stimulus, TSC2 acts as a GAP 
to inactivate Rheb by directly stimulating GTP hydrolysis. However, when IGF- 1 
activates the P-13K cascade, and PKB phosphorylates TSC2 on Thr1462 and Ser939, 
there is an inhibition of TSC2 which leaves Rheb in its GTP-bound active state. Rheb 
is not a kinase but the TSC2-Rheb downstream target, mTOR is phosphorylated at 
residues such as Ser2448 in response to insulin and muscle loading (Reynolds et at, 
2002). Therefore, Rheb probably activates an unknown kinase that phosphorylates 
mTOR on Ser2448 unless the Ser 2448 site is phosphorylated directly by PICB as was 
reported in the time before the identification of TSC2 of a PKB downstream target 
(Nave et at, 1999). Interestingly, TSC2 does not only activate protein synthesis in 
response to IGF- 1 but also inhibits protein synthesis in response to energy stress. It 
was recently shown that AMPK could directly phosphorylate TSC2 at the PKB 
independent sites of Thr1227 and Ser1345 (Inoki et at, 2003b). Phosphorylation at 
these sites is predicted to stimulate GTP hydrolysis on Rheb and thus provide a 
mechanism preventing energy-consuming protein synthesis when a cell is 
experiencing chronic energy stress. 
1.7.4.3 mTOR, p70 S6K, 4E-BP1 (PHAS-1) and eEF2 
The mammalian target of rapamycin (mTOR) is the next substrate in the pathway, and 
is a large >200 kDa serine/threonine kinase controlling cell growth. mTOR detects 
IGF-1, IGF-2 or insulin receptor binding (PKB-TSC2 signalling); energy stress 
(AMPK-TSC2 signalling); and amino acid availability (via an unknown pathway). 
The requirement for mTOR mediating signalling in hypertrophy has been 
demonstrated pharmacologically; blockade with rapamycin decreases muscle 
hypertrophy in vitro and in vivo and blunts the hypertrophy-associated 
phosphorylation of p70 S6K and 4E-BPI (Bodine et at, 2001). An important 
regulatory mechanism controlling mTOR activity appears to be the phosphorylation 
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of Thr2446 and Ser2448 (Cheng et aL, 2004). Phosphorylation of Thr2446 increases 
when AMPK is activated and is low in response to nutrients and insulin. In contrast, 
Ser2448 phosphorylation is decreased in response to AMPK but increased in response 
nutrients and insulin (Cheng et a/l, 2004). Thus, Thr2446 and Ser2448 seem to be 
phosphorylated in opposite directions and the more Ser2448 is activated the greater 
the effect of mTOR on protein synthesis; whereas the opposite is true for Thr2446 
phosphorylation. It is unclear whether the phosphorylation state of Thr2446 and 
Ser2448 are both mediated by TSC2 or whether PKB or AMPK have independent 
effects on both TSC2 and mTOR. mTOR is also activated by amino acids as is 
evident from an amino acid-induced phosphorylation of Ser2448 phosphorylation 
(Nave et aL, 1999), although it is not currently known how amino acids stimulate 
phosphorylation of mTOR. In response to increased phosphorylation (at least of PKB-
mTOR and PKB-TSC2 phosphorylation sites) mTOR is capable of activating 
downstream effectors of protein synthesis. mTOR directly or indirectly 
phosphorylates and activates the translational regulators 4E-binding protein 1 (4E-
BP1/PHASI) and the 70 kDa S6 phosphorylating ribosomal protein (p70 S6K), 
resulting in increased protein synthesis. 
As mentioned, p70 S6K is a downstream target of mTOR and another protein 
indirectly stimulated by IUF- 1. In mammalian cells a short sequence of 5-15 
pyrimidine nucleotides immediately following the m 7GTP cap (the 5'-terminal 
oligopyrimidine tract or 5'TOP) is an invariant feature of ribosomal inRNA species 
(Shah ci aL, 2000). This sequence has been demonstrated to be essential for 
translational regulation of these rnRNAs in response to different growth stimuli, 
including mitogens, amino acid starvation and differentiation, and mutation of this 
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sequence abrogates this regulation. p70 S6K phosphorylates the ribosomal protein S6 
and has been shown to regulate the selective translation of mRNA5 with this 5'TOP 
sequence, and thus specifically regulates translation of the ribosomal machinery (Shah 
ci aL, 2000). It has been demonstrated that p70 56K and protein synthesis are 
increased concomitantly for up to 24 h after a bout of resistance exercise, and 
correlates with muscle protein synthesis (Hernandez et al., 2000) thus highlighting the 
importance of this pathway in growth response. Translation elongation also depends 
indirectly on mTOR (Browne & Proud, 2002). mTOR activates p70 S6K which in 
turn can phosphorylate and deactivate eEF2 kinase (eEF2K, formerly known as 
Ca2 Vcalmodulin dependent kinase III) which decreases the phosphorylation of eEF2 
at Thr56. Dephosphorylated eEF2 is more active and promotes the elongation of the 
amino acid chain during translation. Similar to the regulators of translation initiation, 
eEF2 activity is inhibited when AMPK is activated (Horman ci aL, 2002; Browne ci 
aL, 2004), again suggesting a way in which at times of chronic high energy 
consumption, protein synthesis is reduced. 
Mother protein downstream of mTOR and activated indirectly by IGF-1 named 4E-
BP1 also controls protein synthesis. 4E-BP1 controls the regulatory step involving the 
binding of mRNA to the 435 pre-initiation complex, which is mediated by eIF4F, a 
complex of several subunits (Proud, 2002). One of the subunits, eIF4E, binds the 7-
methylguanosine 5'-triphosphate cap structure present at the 5'-end of eukaryotic 
mRNAs to form an eIF4E mRNA complex. During translation initiation, the eIF4E 
mRNA complex binds to eIF4G and eJF4A to form the active eIF4F complex. The 
binding of eIF4E to eIF4G is controlled by the translation repressor protein 4E-BP1. 
Binding of 4E-BPI to eIF4E is hypothesised to limit eIF4E availability for formation 
of an active eIF4E - eIF4G complex (Proud, 2002). Therefore, the phosphorylation of 
4E-BP1 at various sites including thr37/46 removes 4E-BP1 from eIF4E, allowing 
eIF4E to participate in initiating translation by the process described (Proud, 2002). 
4E-BP 1 has a role in exercise-induced hypertrophy and its phosphorylation has been 
shown to increase following acute resistance exercise (Bolster et aL, 2003). 
1.7.4.4 PKB, GSK-313, and eIF213 
PKB regulates protein synthesis not only via the TSC2-Rheb-mTOR-p70 S6K-4E-
BP1 connection but also via PKB-GSK3I3-eIF2B pathway. PKB inhibits GSK-313 by 
phosphorylating it at Ser9 and this can be activated by IGF-1 in skeletal muscle cells 
(Rommel et aL, 2001). The inhibition of GSK3P in cultured muscle cells has been 
shown to induce hypertrophy (Vyas et aL, 2002), suggesting the importance of this 
section of the pathway in protein synthesis. The phosphorylation and inhibition of 
0SK3J3 leads to a decreased phosphorylation of eukaryotic initiation factor 2B 
(eIF2B) (Kimball, 2001). eIF2B is an important factor regulating the first step 
controlling peptide-chain initiation: binding of initiator methionyl-tRNA to the 40S 
ribosomal subunit to form the 43S pre-initiation complex. This reaction is mediated by 
eukaryotic initiation factor 2 (eJF2) and is regulated by the activity of eIF2B. The a 
sub-unit of eIF2B has a catalytic activity and is a guanine nucleotide-exchange factor 
which mediates the exchange of GDP bound to translation initiation factor eIF2 for 
GTP (Kimball et aL, 1998). Decreased phosphorylation of eIF2B at Ser53 5 increases 
the activity of eIF2Bc and promotes initiation of translation (Proud, 2002). This 
mechanism provides more scope for increases in global protein synthesis through 
stimulation of the P1-3K pathway by IGF-1 splice-variants. 
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In summary, a required mediator of skeletal myofibre enlargement is increased 
protein synthesis, which is controlled at the levels of translation initiation and 
elongation. Therefore the IGF-1IPI-3K pathway is a necessary mediator of myofibre 
enlargement through its characterised effects upon protein synthesis. 
1.7.5 Role of the Calcineurin pathway in hypertrophy 
It was first suggested that IGF-1 induced skeletal muscle growth via the calcineurin 
pathway (Semsarian ci at, 1999) which a year earlier was shown to promote 
hypertrophy in the heart (Molkentin ci at, 1998). A paper in Nature reported that 
IGF-1 induces calcineurin-mediated signalling and activation of GATA-2, a marker of 
skeletal muscle hypertrophy, which co-operates with NFATc isoforms to activate 
gene expression programmes (Musaro ci at, 1999). Later to this it was reported that 
administration of cyclosporine A, (CsA, a calcineurin inhibitor) abolishes the increase 
in fibre size seen in mouse plantaris due to overload synergist ablation (Dunn ci at, 
1999). However, recently controversy has surrounded the role of calcineurin in 
mediating skeletal muscle cell hypertrophy. One study examined the ability of 
calcineurin-deficient mice to undergo skeletal muscle hypertrophy following 
mechanical overload stimulation or IGF-1 stimulation. Two distinct models of 
calcineurin deficiency were employed which show approximately 50% and 80 % 
reductions in total calcineurin in skeletal muscle. Calcineurin deficient mice 
demonstrated no defects in muscle growth in response to IGF-1 treatment or 
mechanical overload stimulation. Both groups of gene-targeted mice show normal 
increases in PKB activation following mechanical overload or IGF- I stimulation 
(Parsons ci at, 2004). Furthermore, calcineurin knock-in transgenic mice show no 
51 
muscle hypertrophy in skeletal muscle (Naya ei at, 2000). The role of calcineurin has 
been further refuted since pharmacological inhibition with CsA and transgenic 
blockade of calcineurin does not prevent hypertrophy in response to synergist ablation 
(Bodine ci at, 2001). In agreement with this, CsA does not block JGF- I-induced 
hypertrophy of C2C 12 myotubes (Ronmiel ci at, 2001). It therefore seems likely that 
the major effect of calcineurin is regulation of the fibre phenotype as was previously 
discussed (see 1.5.2), and reported (Chin ci aL, 1998; Parsons ci at, 2003). 
1.7.6 Role of interleukin-15 in hypertrophy 
Interleukin-15 (IL-15) is a growth factor which is highly expressed in skeletal muscle, 
and has been shown to be a novel growth factor. IL- 15 used at concentrations of 10 or 
100 ng mE' increased MHC accumulation five-fold in myoblast cultures and 2.5-fold 
in primary bovine myogenic cultures. Moreover, myotubes formed in the presence of 
IL-iS appeared larger than controls (Quinn ci at, 1995). These findings indicate IL-
15 can stimulate differentiated myocytes and muscle fibres to accumulate increased 
amounts of contractile proteins. Mother study agreed finding that IL-15 
overexpression induced a hypertrophic myotube morphology similar to that described 
for cultured myotubes which overexpressed IGF-1 (Quinn ci at, 2002). However, in 
contrast to IGF-I, the hypertrophic action of IL-iS on skeletal myogenic cells does not 
involve stimulation of skeletal myoblast proliferation or differentiation. Recently it 
was fcxmd that IL-IS protein was increased immediately after acute resistance 
exercise but did not change with chronic training (Riechman ci at, 2004). The 
significance and mechanisms of IL-IS in muscle hypertrophy warrants further 
research and could be a good target for treatment of muscle wasting. 
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1.8 Pathways mediating skeletal muscle atrophy 
Muscle atrophy is the opposite of hypertrophy in that it is the reduction in muscle 
fibre size and volume. In some cases loss of muscle fibres attributes to overall 
wasting, although this is not tecimically, atrophy. In contrast to hypertrophy, skeletal 
muscle atrophy is mediated by a chronic net protein breakdown (Latres et aL, 2005). 
There are many circumstances in which muscle undergoes atrophy and this may be in 
response to ageing (sarcopenia), AIDS, HIV, severe diabetes, sepsis, inactivity, 
chronic bed-rest, space flight (Glass, 2003) and perhaps even chronic endurance-like 
physical activity. During these conditions, cellular environments change, and there are 
many factors that have been implicated in mediating atrophy including TNFa-NFicB, 
angiotensin II, glucocorticoids, reactive oxygen species, myostatin and other 
cytokines; all of which can induce muscle protein loss under specific conditions. 
1.8.1 Atrophy requires net protein breakdown 
Atrophy is characterised by increases in protein degradation processes, particularly 
the ATP-dependent proteolytic ubiquitin-proteasome pathway (Latres el aL, 2005). 
Therefore, recent studies have focused on molecular cascades that control the 
activation of ubiquitin ligases, and have commonly indicated that an induction of the 
ubiquitin proteasome is common to a range of atrophic stimuli. The ubiquitin-
proteasome pathway functions widely in intracellular protein turnover and plays a 
central role in degradation of short-lived and regulatory proteins important in a variety 
of processes, including regulation of the cell cycle, modulation of cell surface 
receptors and ion channels, and antigen processing and presentation (Lecker, 2003). 
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The ubiquitin-proteasome pathway employs an enzymatic cascade by which multiple 
ubiquitin molecules are covalently attached to a protein substrate. Binding of the 
ubiquitinating enzyme complex at the N-terminus of targeted cytosolic proteins 
facilitates the polyubiquitination of the s-amino moieties on the internal lysine 
residues (see diagram below). The ubiquitin molecules serve as tags that allow 
recognition of the targeted protein by the 19S regulatory sub-unit on the proteasome, 
leading to eventual funneling into the proteasome where it is proteolytieally degraded 
(Lecker, 2003). To highlight the importance of this pathway, inhibitors of the 
proteasome decrease protein breakdown in atrophy conditions (Tawa, Jr. et aL, 1997). 
Recently, a microarray study examined the transcriptional responses to various 
muscle atrophy-associated states. They looked at fasted mice, rats with cancer 
cachexia, streptozotocin-induced diabetes mellitus, and uremia induced by sub-total 
nephrectomy, thus covering a number of disease-induced atrophy states (Lecker et aL, 
2004). From the cIJNA arrays, they identified a common set of genes that were 
induced or suppressed in muscles in these four catabolic states. Among the strongly 
induced genes were many involved in protein degradation, including polyubiquitins, 
ubiquitin fusion proteins, the ubiquitin ligases atrogin-1, muscle atrophy F-box 
proteins (MAFbx) and muscle ring finger 1 (MuRF-1), multiple (but not all) subunits 
of the 20S proteasome, it's 19S regulator, and cathepsin L. These atrophy induced- 
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genes constituted a major portion of the ubiquitin-proteasome pathway. The authors 
termed these genes 'atrogins' and upregulation of these indicate an increase in 
proteolysis in all of the muscle wasting states examined. Several growth-related 
mRNA species were also down-regulated, including p311, c-jun and IGF-1 binding 
protein 5, which is important in mediating IGF-l-induced hypertrophy (Musaro & 
Rosethal, 1999). Therefore, it appears that during many disease states there is a 
common change in gene expression, primarily involving upregulation of proteolytic 
mechanisms. It must be stated that actual increases in these proteins of the ubiqutin-
proteasome pathway, as has been suggested in many states, does not necessarily 
induce a larger net protein breakdown. Bearing in mind the fact that muscle protein 
breakdown (MPB) is facilitative to changes in MPS; in situations of cancer and HIV 
atrophy, it is thought that MPS is depressed and if this is the case then MPB is 
probably actually also suppressed in these situations. However, even though MPB is 
lower than normal it still exceeds MPS, leading to a net negative protein balance. 
Conversely, in patients with bums and renal failure, there is a hypermetabolic state 
which is indicated by an increase in MPS in an attempt to minimise the effect of large 
increases in MPB, and since MBP still exceeds MPS, a negative net balance occurs. 
1.8.2 Sarcopenia in the healthy elderly 
Whilst most forms of atrophy described in disease seem to follow a common 
programme and often involve gross changes in MPSIMPB ratios (Jackman & 
Kandarian, 2004), sarcopenia is a unique, gradual, but progressive situation that 
appears not to involve significant changes in these synthesis/breakdown ratios 
(Cuthbertson et aL, 2004). Also, whilst disease related atrophy only affects a small 
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percentage, sarcopenia is a unique biological situation that affects or will affect the 
entire population to some extent. Sarcopenia is specifically the gradual loss of muscle 
mass with advancing age, and wasting in the elderly is associated with atrophy and a 
—50 % loss of muscle fibres (particularly type II) between 20-80 y (Lexell el al., 
1988). Physically inactive adults exhibit a greater loss of muscle mass than physically 
active adults as has been shown by numerous studies identifying the benefits of 
exercise in the elderly (Hunter et at, 2004; Rogers & Evans, 1993). However, 
sarcopenia is not completely prevented by exercise, as it is also evident, but to a lesser 
degree, in physically active individuals (Evans I 995a). Some of this effect may be 
because the physical activity is not of sufficient intensity as to recruit FT fibres thus 
not inhibiting the preferential atrophy of these fibres and development of sarcopenia. 
Muscle weakness induced by sarcopenia reduces general activity levels in elderly 
individuals which in turn elevates the risk of osteoporosis and frailty due to a decrease 
in overall mechanical loading of the skeleton; as well as many other complications. 
Current research is finding that the development of sarcopenia is a multifactorial 
process. Many factors including, inflammatory factors (Grimble, 2003), physical 
inactivity (Evans, 1995b), decreased hormone levels (Butterfield et aL, 1997), 
deranged protein synthesis/breakdown (Welle et aL, 1993), inadequate nutrition 
(Campbell & Evans, 1996) and disease conditions may all contribute to sarcopenia. 
Of all of these factors, perhaps the most potentially influential mechanism would be a 
shift to prolonged negative net protein balance. There is disagreement in whether 
basal protein synthesis falls with ageing with studies by (Yarasheski et aL, 1993), 
(Balagopal et aL, 1997; Hasten et aL, 2000) suggesting a decrease. However, it seems 
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unlikely that the rates of basal, post-absorptive MPS rates are diminished by as much 
as 20-30 % (Volpi et at, 2001; Paddon-Jones et at, 2004) or muscle protein 
breakdown elevated by -50 % (Chevalier et at, 2003; Trappe et at, 2004) because 
the rates of muscle wasting should be much greater than are noted. Other studies 
disagree and these results seem more cogent in finding no changes in MPS in the 
elderly compared with the young (Volpi ci at, 2001; Volpi ci at, 1999). Since most 
gradual changes in muscle protein mass are mainly due to alterations in MPS with 
alterations in MPB usually being adaptive to the changes in synthesis (Halliday ci at, 
1988), there is little evidence that MPB is elevated either. Therefore, the lack of 
unification in agreement of these studies makes, coupled with the fact that the rate of 
atrophy is very gradual, it unlikely that this is the primary mechanism for sarcopenia. 
Deranged hormone/growth factor levels have been shown to have potential effect on 
sarcopenia. As an example of this, the anabolic growth factor, IGF-I has been shown 
to be significantly reduced in aged rats, 60 % in females and 21 % in males as was 
circulating IGF-binding protein 3 (IGFBP-3) (Severgnini ci aL, 1999). Reduced levels 
of growth hormone, thyroid hormone and testosterone are usually also noticed in 
advancing age suggesting that anabolic signalling may be reduced (Roy ci at, 2002). 
Consistent with this, decreases in lean body mass, increased fat, and other changes 
consistent with hormone deficiencies occur during ageing (Harman & Blackman, 
2004). Therefore, reduced growth factor levels might partly contribute to sarcopenia. 
Since exercise is such an important stimulus for protein synthesis, perhaps the typical 
reduction in physical activity with advancing age could contribute to sarcopenia. In 
older age, physical activity usually declines, and whilst those who remain more active 
elicit reduced sarcopenia it is nevertheless still evident in this population (Roubenoff, 
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2003). Therefore, whilst being a contributory factor it is not causative. The 
physiological responses to exercise in elderly is still positive although blunted 
somewhat. This could be related to compromised satellite cell activation, proliferation 
and differentiation, and blunted responses to hypertrophic stimuli (Kadi et at, 2004a). 
There is also an inflammatory theory of ageing. Pro-inflammatory cytokines such as 
interleukin-6 (IL-6) and TNFa are found at elevated levels in sarcopenia and are 
associated with lower muscle mass and lower muscle strength in well-functioning 
older men and women (Visser et at, 2002). TNFa is implicated in skeletal muscle 
atrophy through activation of NF,cB, a protein known to induce atrophy responses 
(Ladner et at, 2003). Since these cytokines are partly derived from the adipose tissue 
bed, those with increased fat mass such as type II diabetics, are at further risk of 
chronic inflammation that occurs during ageing. There are often other predisposing 
factors for the chronic inflammation that occurs during ageing. These include 
increased oxidative stress, a decrease in ovarian function (women), a decrease in 
stress-induced glucocorticoid sensitivity of pro-inflammatory cytokine production, 
obesity, and an increased incidence of asymptomatic bacteriuria (Grimble, 2003). 
Inflammation is a key factor in the progressive loss of lean tissue and impaired 
immune function is observed in ageing. Polymorphisms in the promoter regions of 
pro- and anti-inflammatory cytokine genes influence the level of cytokine production 
and the ageing process (Grimble, 2003). Thus, a genotype for high pro-inflammatory 
cytokinc production results in high cytokine production and may accelerate the rate of 
tissue loss. Conversely, polymorphisms in genes for anti-inflammatory cytokines may 
result in a slowing of tissue loss. Another study suggested that the increased serum 
myostatin may be a biomarker of sarcopenia (Yarasheski et at, 2002), giving a 
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potential role for this negative muscle mass regulator in age-related muscle loss. It 
could be suggested that some of the discrepant findings upon MPS/MPB and, 
cytokines and growth factors that are reported are probably due to the failure of 
experimenters to differentiate healthy elderly from those with additional conditions 
The blunting in anabolic responses to nutrients has recently been implicated in age-
related atrophy. Amino acids are powerful stimulators of MPS, and in rat, leucine-
dependent stimulation of translation initiation in vivo occurs via a rapamycin-sensitive 
pathway, suggesting a role for mTOR in nutrient signalling (Anthony et all, 2000). 
Initial studies examining the responsiveness of MPS to essential amino acids (EAA) 
indicated there may be a deficit in anabolic response in aged animals. Measurements 
made on isolated muscles from young and elderly rats showed that the sensitivity and 
responsiveness of MPS to the EAA leucine, is diminished in the elderly rats (Dardevet 
et aL, 2000). These data underline the importance of EAA in mediating protein 
synthesis provide another area which may be under altered regulation with ageing. 
1.8.3 Sarcopenia in elderly with type II Diabetes Mellitus 
It has been suggested that since muscle disease symptoms and myopathics are not 
uncommon in the elderly, the associated inflammatory and non-inflammatory 
myopathies lead to proximal extremity or axial weakness and are superimposed on the 
intrinsic changes that occur in muscle with ageing (sarcopenia) (O'Rourke, 2000). An 
example of such a situation is the metabolic disease, type II Diabetes Mellitus (type II 
DM). Type II DM is common in the elderly population and by the age of 75, 
approximately 20 % of the population are afflicted with this illness (Meneilly & 
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Tessier 2001). Typically, type II DM develops in the elderly through the following 
steps: natural ageing leads to a loss in muscle mass which accounts for the age-
associated decreases in basal metabolic rate, muscle strength, and activity levels, 
which, in turn is the cause of the decreased energy requirements of the elderly. In 
sedentary individuals, the main determinant of energy expenditure is fat-free mass, 
which declines by about 15 % between the third and eighth decade of life (Evans, 
1998). Furthermore, declining caloric needs are not matched by an appropriate decline 
in caloric intake, with the ultimate result an increased body fat content with advancing 
age. Increased body fatness along with increased abdominal obesity are thought to be 
directly linked to the greatly increased incidence of Type II DM among the elderly 
(Evans, 1998). Type II DM, characterised by insulin resistance, is a typical condition 
of such a muscular disease state which leads to many complications (Sartorelli & 
Fulco, 2004). Individuals displaying type II DM commonly suffer peripheral 
neuropathy due to their chronic hyperglycaemic state. This neuropathy is 
characterised by severe loss of synaptic vesicles, electron-dense bodies, and myelin-
like figures as well as degeneration of mitochondria (Sartorelli & Fulco, 2004). 
Interestingly, these ultrastructural changes in neuromuscular junctions are similar to 
those that have been described in ageing. Therefore, it remains to be shown whether 
the effects of disease states such as type II DM lead to greater susceptibility to 
sarcopenia and do in fact, overlay the progression of age-related atrophy. It should be 
stated that in such situations of metabolic disease and ageing it is widely accepted that 
increased mechanical loading of the musculoskeletal system (e.g. resistive exercise) 
can have a beneficial effect on both skeletal muscle and the supporting skeleton 
resulting in a significant reduction in the risk of developing age-related problems such 
as type 11 DM, and can also counteract sarcopenia (Clarke, 2004). 
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1.9 Research Objectives 
The main hypothesis of the study was that specific and distinct cell signalling is 
responsible for the change in phenotype and muscle growth/atrophy in response to 
exercise, sarcopenia and disease. The work encompassed novel studies investigating 
many levels of regulatory control to answer the specific aims, which were: 
(1) Investigating the regulation of myostatin, and how it altered gene 
transcription and translation to affect post-mitotic muscle mass. 
A cell culture model was used to examine the effects of various growth factors on 
myostatin expression using Northern blotting and RT-PCR; microarray experiments 
were performed on cells treated with recombinant myostatin to identi& genome wide 
changes in gene expression; Western blotting was employed to examine how 
recombinant myostatin affects the phosphorylation of elements of pathways 
controlling translation, and ultimately protein synthesis. 
(2) Investigating contraction activated signalling proteins to ascertain if they 
were present at different concentrations between fast and slow muscles. 
Secondly, to investigate whether they are regulable by contractile activity. 
Western blotting of total proteins between fast EDL and slow Soleus were used to 
detect differences in relative protein concentrations; CMNS (fast.to-slow model) was 
used to stimulate EDL in order to assess the effect of CMNS on signalling proteins, 
and see if they were brought in line to relative concentrations of control EDL/Soleus. 
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(3) Investigating the matching of cellular signalling with known physiological 
responses; and examining the specificity in signalling, that mediates the 
contrasting physiological responses to endurance and resistance-like training. 
CMNS was used in attempt to match the cellular signalling produced in this model to 
the known physiological adaptations, using phospho-specific immunoblots. In vitro 
systems of either high frequency intermittent (HFS) to simulate resistance-like 
exercise; or low frequency chronic stimulation (LFS) to simulate endurance-like 
exercise, were employed in order to examine the selective activation of signalling 
pathways between protocols using phospho-specific immunoblotting. The validation 
of HFS was checked by identiing specific increases in MPS using GC-MS. LFS 
validity was assured by measuring specific increases in UCP3 mRNA using RT-PCR. 
(4) Investigating whether sensitivity to amino acids in sarcopenia and disease 
(type II DM) could explain loss (or accelerated loss) of muscle mass. 
MPS using stable isotopes and GC-MS were examined between healthy elderly/young 
and healthy elderly/elderly with Type II DM, both in the post-absorptive period and 
following infusion of essential amino acids. Western blotting of phospho-proteins 
within translation controlling pathways would be used in order to identi&, and 
explain, any differences in muscle protein synthesis. The capacity of the system 
would be further examined by using native antibodies against the same targets to 
asses any concentration differences present. 
Each specific aim stated, formed a chapter of results in this thesis (chapters 3-6) 
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Chapter 2 
Materials and Methods 
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2.1 Cell culture and muscle dissection 
L6 cells were grown in 8 % FBS aMEM supplemented with 2.2 g/l NaHCO3, 
amphoteracin B (1:1000) and Penicillin/Streptomycin (1:100). All dishes containing 
myotubes were treated with 5 riM arabinoffiranosidase C, for 24 h prior to application 
of treatment to remove the effect of any dividing myoblasts remaining. Four 90 mm 
diameter plates were treated for 24 h with four separate 10-fold incremental 
concentrations (Molar, unless stated) of either: insulin-like growth factor 1 (1 o, 10, 
10, 10 °), clenbuterol (10, 10, 10, 10 -v), growth hormone (10, 10 8 , 10.10) ,  
testosterone (l0, iO, 10, 10 -7), dexamethasone (10, I0, 10, 10), cyclosporine 
A (10, 1-5, 10.6,  ioj, and finally with creatine for 24 hand 48 hat 5 mM, 10 mM, 
15 mM and 20 mM. Cells were harvested using cell scrapers and directly 
homogenised in 1 ml Tn-Reagent by pippeting up and down several times before 
being placed in RNAse free safelock Eppendorf tubes and frozen in liquid N2. For raw 
skeletal muscles, male Wistar rats were killed by a blow to the head and then cervical 
dislocation, before a selection of muscles of mixed fibre proportions, were excised 
and frozen in liquid N2. Samples were stored at - 80 °C awaiting assay. All animal 
procedures were in line with governmental law and the relevant ethics committees. 
C2C12 murine myoblasts were cultured to confluence in Dulbecco's modified Eagle's 
medium containing 10 % FBS, and supplemented with amphoteracin B (1:1000) and 
Penicillin/Streptomycin (1:100) and formation of myotubes triggered by switching to 
2 % horse serum. Eight 90 mm dishes were subjected to 10 ng mU' recombinant 
myostatin for 6 h, whilst eight dishes served as controls. Proteins were extracted and 
stored at - 80 °C ready to be used for Western blotting as described under section 2.8. 
2.2 RNA extraction and preparation 
Total RNA was extracted from the L6 cultured cells and skeletal muscle using Tn-
Reagent, based on the acid guanidinium thiocyanate-phenol-chloroform RNA 
extraction method (Chomczynski & Sacchi, 1987). After defrosting, the samples were 
further homogenised with a hand-held polytron and the sample was left at ambient 
temperature for 5 mm. Thereafter, 100 p.1 of 1-bromo-3-chloropropane was added to 
each tube and then vortexed for 15 s and left at room temperature for 15 mm. Tubes 
were then centrifuged at 12,000 g for 15 min at 4 °C. During centrifugation, the 
mixture separates into an upper aqueous phase containing the RNA, an interphase 
containing the DNA and a red lower organic phase containing the proteins, including 
the ribonucleases. Precisely, 500 il of the upper phase was carefully transferred to a 
fresh 1.5 ml Eppendorf tube and 500 p.l of isopropanol added to the aqueous phase to 
precipitate the RNA. This solution was left at room temperature for 10 min before 
being centrifuged at 12,000 g for 8 min at 4 °C. The supernantant was then collected 
and 1 ml 75 % ethanol RJ'JAse free (ribonuclease) was added to the tube and then 
spun at 7,500 g for 5 min at 4 °C. This process was repeated a further two times to 
ensure the guanidinium salts are eliminated. The visible RNA pellet was then air-
dried for 5 min and resuspended, in 20 p.1 RNase-free water. A 10 p.1 aliquot of the 
RNA was then dissolved in Tris-EDTA (10 mM Tris-UCI, 1 mM EDTA, pH 8.0) and 
the absorbance measured at 260, 280 and 240 tim. The concentrations were calculated 
as C= 40 ng/pi • A260. The RNA samples were mixed with formaldehyde loading 
buffer then incubated for 15 min at 65 °C and placed on ice for 2 mm. Incubation was 
then repeated for 15 min at 65 °C and the samples placed at - 80 °C. 
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2.3 Northern blotting - Generation of myostatin probe 
The following constituents were added to a PCR tube: 10 p110 x pfx buffer, 2 p1 50 
mM MgSO4, 10 R1  10 x  PCR enhancer solution, 6 p1 5 p.M dNTP, 3 p1 10 jiM sense 
primer, 3 p110 jiM antisense primer 0.5 p1 cDNA (skeletal muscle), 1.5 p1 2.5 U/pJ 
Pfx polymerase and 64 p1 H20. The PCR reaction was run at 94°, 5' -± {94°, 15" -+ 
550, 30" -> 68°, 1'}x 40 -* 68°, 15' -> V. Precisely 10 J1l of the PCR reaction was 
checked on a 3 %, 3:1 agarose gel, whilst the remaining 90 jil of the PCR reaction 
was purified with the Boehringer High Pure PCR purification kit according to the 
manufacturers protocol. Precisely, 50 jtl was eluted in Tris-EDTA (10 mM Tris-HCI, 
1 mM EDTA pH 7.5). 
2.3.1 Preparation of the vector 
The following components were mixed in an Eppendorf tube: 2.5 jig pBlueScriptll 
SK(+), S jil 10 x  reaction buffer, I jil 10 U/pit Smal, to a total of 50 pl with H20. The 
plasmid was incubated at room temperature for 1 h to cut the plasmid, before being 
heated to 70 °C to denature the Smal enzyme. The vector was then checked on an 
agarose gel, where a band of 3 kb was detected, confirming cutting of the vector. For 
the ligation, two controls were made, one without the PCR product to check for false 
positives and one ligation without the ligase to check that the vector has been 
sufficiently cut. The purified PCR product was substituted for H20 in the 
aforementioned controls. Next, an Eppendorf tube was loaded with 6 p1 of the 
purified PCR product, 2 p1 5 x  ligase buffer, I p1 vector cut with Smal, 1 p1 1 U/p1 T4 
DNA ligase. Sample and controls were incubated for 4 h at room temperature and 
then at 70 °C for 15 min to destroy the ligase. 
Precisely, 50 psI of competent DH5a cells was added to 5 p1 aliquots of the ligations 
and incubated on ice for 30 mm. Then tubes were incubated at 42 °C for 45 s in a 
water bath and then quickly put back on ice. Cells were plated on plates with 
ampicillin, X-Gal and JPTG and incubated at 37 °C overnight. Providing that there 
were few colonies on the negative ligase control; mainly blue colonies on the positive 
ligase control; and mainly white colonies on the PCR ligated plate then (positive) 
white colonies were streaked onto new plates to isolate single colonies. These new 
plate colonies containing the PCR product incorporate into the vector were incubated 
in 8 ml LB with ampicilin and grown overnight at 37 °C with gentle shaking. The next 
morning, 900 pt outgrown cell culture was mixed with 600 p1 50 % sterile glycerol in 
a 2 ml cryotube to preserve the cells at -80 °C. A volume of 4 ml of the remaining 
outgrown culture was then purified with the Boheringer High Pure Plasmid Isolation 
Kit according to the protocol. Thereafter, 100 p1 was eluted in Tris-EDTA, and the 
plasmids checked by cutting with restriction enzymes and separating the fragments on 
an agarose gel. 
2.3.2 Hot long single-stranded DNA probe by PCR and biotinylation-
DNA probe synthesis 
A PCR mix containing 2 psI 10pM M13 primerl bio, 2 psI 10 jiM M13 primer 2,2 p1 
I ng psi' template plasmid, 1 pit 10 x PCR buffer excluding Mg 2 , 10 psI 50 mM 
MgCl2, 4 psI 5 mM dNTP's, I psI 5 U/psI Platinum Taq polymerase and then 78 psI H 20 
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was used to make up a final volume of 100 jil. The PCR cycle was then run as 
follows, 94°, 4' -* {94°, 5" -), 56°, 30" -> 72°, I'} x 30 -* 72°, 15' -* 4°. In 
preparation, 5 x1 Dynabeads M280 Streptavidin (10mg mr') were washed twice in 20 
sl 6 x SSC, and resuspend in 20 p1 6 x SSC. Precisely, 5 pJ of the PCR product was 
added to the pre-washed dynabeads and incubated at room temperature for 5 mm. 
Next, the dynabeads were collected with immobilised template by placing tube in 
magnet stand, and after 30 s the supematant was removed with a pipette. Next, the 
dynabeads were resuspended in 100 il melting solution (0.125 M NaOH, 0.1 M 
NaCI) and incubated at room temperature for a further 5 mm. Following this, the 
supernatant was removed and the beads were washed twice in 100 p1 1 x SSC. After 
the first washing step, the dynabeads were transferred to a new tube to ensure no 
NaOH droplets were left on tube walls before being resuspended in 10.5 j.tl H 20. 
Addition of I j.tI 5 j.xM antisense primer was put in to the mix and incubated at 42 °C 
for 5 mm. On ice, 5.0 p1  5 x Strip-EZ buffer -dATP/-dCTP, 2.5 p110 x Modified 
dCTP, 5.0 i.tl a32P-dATP (3000 Cilmmol), 1.0 p1 Exonuklease-free Klenow were 
mixed and added to the DNA/primer mixture which was incubated for 15 min at 42 
°C. Finally, the beads were washed twice with 100 p1 1 x SSC and 40 p1 melting 
solution was added and left to incubate for 3 min at room temperature. Supernatant 
(the probe) was collected and I p1 of the probe counted for radioactivity. 
2.3.3 Formaldehyde agarose gel 
An amount of 0.8 g Gibco agarose was dissolved in 68.8 ml distilled water through 
boiling until the agarose dissolved and then cooled to 55 °C in a water-bath before the 
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addition of 8 ml 10 x morpholineopropanesulfonic acid buffer. A volume of 3.2 ml of 
37 % (12.3 M) formaldehyde was then added and swirled gently. Thereafter the gel 
was poured into a gel tray (12 xl 4 cm) and combs put in place to create wells. 
2.3.4 Electrophoresis and blotting 
Following polymerisation, the solidified gel was placed in the electrophoresis tank 
and the combs removed before 1 L I x  morpholineopropanesulfonic acid was poured 
into the tank, so that the buffer could reach the top of the gel, but not cover it. A 
volume of 10 p1 of each sample was loaded per well amounting to 2 .xg RNA per 
sample. The electrophoresis was then run at 100 V until the bromophenol blue die 
marker had migrated 4.5 cm in the gel. Following completion of electrophoresis, the 
gel short was then rinsed in deionised water and then in a tray with SYBR green II 
(diluted in deionised water 10,000 times) on a tilt table for 30 mm. The gel was then 
placed in saran wrap and photographed on an ultra-violet illuminator and then 
scanned on a phosphorimager to detect SYBR green II. Following acceptance of RNA 
quality (see 3.2.1) the formaldehyde gel was then rinsed in a tray with deionised water 
before addition of 1 litre of 25 mM freshly prepared NaOH and shaken for 10 mm. 
Three sheets of 3 mm paper were placed on top of a stack of paper towels with a 
further three sheets of 3 mm paper pre-wetted in 25 mM NaOH positioned on top. The 
Appligene nylon membrane pre-wetted in 25 ruM NaOH was then placed on top 
before placing the formaldehyde gel on the membrane. Any air bubbles were removed 
by rolling a pipette gently over the gel, and then the stack covered with saran wrap 
and left for I h. After completion of transfer, the blot was rinsed in 2 x  SSPE to 
remove agarose and neutralise. 
2.3.5 Hybridisation - Long single-stranded DNA probe from PCR 
Hybridisation solution was first pre-heated to 68 °C to dissolve the precipitates. 
Following transfer, the membrane was rolled and placed in a hybridisation tube filled 
with distilled water. Addition of 5 ml hybridisation solution to the tubes followed 
before tubes were put into a hybridisation oven at 50 °C to avoid precipitation. Blots 
were incubated with rotation at 50 °C for I h. An appropriate amount of probe was 
diluted in I ml hybridisation buffer to allow 7000 counts per blot and centrifhged for 
I min at full speed to precipitate any residual beads before 900 p1 of the labelled 
probe was transferred to the hybridisation tube. The membrane was then incubated 
with rotation at 50 °C overnight. The following morning, the membrane was washed 
with 250 ml 2 x SSPE and 0.1 % SDS at room temperature and incubated on a tilt 
table for 5 min before pouring off the wash buffer and repeating these steps. Washing 
buffer was then poured off and incubated with 250 ml 0.1 x SSPE and 0.1 % SDS 
preheated to 60 °C and incubated for 15 min at 60 °C, before pouring the wash buffer 
off and repeating these steps. Following washing, the membrane was removed, 
wrapped in two layers of plastic film and exposed to a phosphorscreen after 24 h. 
2.4 RT-PCR 
2.4.1 Semi-quantitative RT-PCR for myostatin 
RNA was extracted using Tn-reagent according to the Manufacturer's protocol, and 
as described (see 2.2). Reverse transcription was performed with I .xg of RNA as 
template using first strand cDNA synthesis kit. PCR amplification was carried out on 
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a 2 R'  aliquot of the resultant cDNA using the primer sequences below. For internal 
standards, primers for the 'housekeeping' gene, glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), were used. 
Rat myostatin forward: 5'-ATGAGGACAGTGAGAGAGAGG-3' 
Rat myostatin reverse: 5'-GCACAAGATGAGTATGCGG-3' 
GAPDFI forward: 5 '-ATCAGTGCCACCCAGAAGACT-3' 
GAPDI-I reverse: 5'-CATGCCAGTGAGCflCCCGfl-3' 
Thermal cycling conditions were denaturation at 94 °C for 2 mm, amplification 
(94°C—*30 s, 58°C—*30 s, 72°C—.50 s) and a final elongation at 72 °C for 10 min for 
30, 35 and 40 cycles. Amplification products were separated by electrophoresis on 2 
% agarose gels and then stained with ethidium bromide prior to scanning. 
2.4.2 Quantitative RT-PCR for UCP-3 
Quantitative RT-PCR for uncoupling protein-3 (UCP-3) was assayed in order to 
verify that LFS could induce a marker gene for the adaptive response to endurance 
training (Stoppani et aL, 2002). RNA was extracted using Tn-reagent according to the 
manufacturer's protocol, as described (see section 2.2). Reverse transcription was 
performed with 1 gg of RNA as template using first strand cDNA synthesis kit 
(Roche: 1 483 188). PCR was carried out for 35 cycles using the lightCycler FastStart 
DNA masteILfl5  SYBR Green 1 kit, following melting curve analysis to ensure 
specific gene amplification. The primer sequences for rat UCP3 and GAPDH were 
designed using nt-specific sequence data, and are listed below. 
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Rat UCP-3 forward primer: 5'-GAACCATCGCCA000AAGAAGGAGTCAG-3' 
Rat UCP-3 reverse primer: 5'-GGGGGAGCG11TCATGTATCGGGTCTTTA-3' 
GAPDH forward: 5 '-ATCAGTGCCACCCAGAAGACT-3' 
GAPDI-1 reverse: 5' -CATGCCAGTGAGC11TCCCG11T-3' 
Conditions were 35 cycles at 92 °C—*60 s, 60 °C-30 s and 72 °C—.1 10 s. A final 5- 
min extension step at 72 °C was performed. Amplification products were separated on 
a 2.5 % agarose gel and stained with ethidium bromide for visualisation. Changes in 
UCP-3 expression were normalised to changes in GAPDI-I following RT-PCR, in 
order to allow for differences in efficiency of cDNA synthesis following RI. 
2.5 Electrical stimulation 
2.5.1 Chronic in vivo electrical stimulation (CMNS) 
Miniature neuromuscular stimulators were implanted in the peritoneal cavity of 16 
adult male, 200 g Wistar rats, with electrodes placed near to the common peroneal 
nerve in the left hind limb. The devices were activated remotely after surgery to 
provide continuous activation of the muscles of the anterior compartment of the lower 
hind limb at 10 Hz for six weeks. In all cases stimulation caused palpable oscillatory 
dorsiflexion of the foot throughout the experimental period showing that stimulation 
was effective. Following the stimulation period, the rats were humanely killed by a 
blow to the head followed by cervical dislocation before muscles were harvested 
rapidly with sterile instruments, frozen in liquid N2 cooled isopentane and stored 
below —80 °C. This part of the study had ethical clearance from the University of 
Liverpool Ethics Commitee. 
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$ Electronic stimulators were constructed, implanted and performed by members of 
Professor Salmons Laboratory, University of Liverpool. Muscle was then dissected at 
Liverpool following 6 weeks of in vivo stimulation, frozen in liquid N2 and sent on 
dri-ice to University of Central Lancashire for further analyses. 
2.5.2 Isolated Muscle Stimulation 
Young adult male Wistar rats were maintained on a constant 12:12 h light-dark cycle. 
Animals were between 8-10 weeks old and weighed 220 ± 12 g in all experiments. 
Food and water were available ad libitum. The rats were humanely killed by a blow to 
the head and then cervical dislocation and then either one EDL or Soleus, and their 
contralateral muscles, were dissected and placed in Krebs Henseleit buffer (118.5mM 
NaCl, 4.7 mM KCI, 1.2 mM KH2PO4, 1.2 mM MgS0 4 7H20, 25 mM NaFIC03, 3.4 
mM CaCl2 , 35 mM Mannitol, 5 mM glucose, 1 g/F' bovine serum albumin) gassed 
with 95% 02 and 5 % CO2. Muscles were incubated at 25 °C to aid tissue oxygenation 
(Bonen et at, 1994) and set to their resting length. Pilot tests showed that EDL and 
Soleus twitch:tension ratios did not change when left resting in the organ bath up to 
12 h. Maximal contraction voltage was determined in preliminary experiments using a 
Grass isometric force transducer, Grass stimulator and Student Harvard chart 
recorder. Stimulation began 30 min after incubation of the muscle. The high-
frequency stimulation (HFS) protocol was chosen based on its efficacy in inducing 
skeletal muscle hypertrophy whilst the low frequency stimulation (LFS) protocol has 
been shown to be effective in inducing endurance-like adaptations when applied 5 
days per week for 3 weeks in rats (Nader & Esser, 2001). LFS protocol was 
performed using isometric contractions at 50 V and 10Hz with a 90 ms delay and 10 
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ms duration, continuously for 3 h. HFS protocol was performed with isometric 
contractions involving 10 sets of 6 repetitions at 50 V and 100 Hz with a 7 ms delay 
on contractions. Each repetition was 3 s in duration and there was a 10 s recovery 
between repetitions and a I min rest period between sets. EDL and Soleus muscles 
were either control (incubated in a separate organ bath for the same time period as 
their stimulated equivalent) or LFS and HFS at 0 h post stimulation or at 3 h post 
stimulation. At the end of the experiment, samples were quickly frozen in liquid 
nitrogen and stored at -80 °C prior to processing. This study had ethical clearance 
from the Ethics Committee of University of Central Lancashire. 
2.6 Protein synthesis measurements 
2.6.1 Myofibrillar and sarcoplasmic fractional protein synthesis rates 
in isolated rat muscles 
In order to verify that HFS was capable of increasing protein synthesis relative to 
control and LFS, the fractional protein synthesis rate was measured in 6 control EDL, 
6 EDL 3 h after LFS and 6 EDL 3 h after HFS. The incubation media contained 
amino acids at fasting physiological levels (Taylor el aL, 1996) and protein synthesis 
was measured using a flooding dose of 13C labelled proline (20 atoms percent) over 
15 mm (Garlick & Cersosimo, 1997). The labelling of proline in the incubation 
medium measured by gas chromatography-mass spectrometry and the incorporation 
of proline into myofibrillar and sarcoplasmic fractions was carried out as described in 
detail elsewhere using our standard techniques (Schwenk a aL, 1984). Briefly, 
muscle (30-40 mg) was ground in liquid nitrogen to a fine powder and hand 
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homogenised in a low salt buffer; the myofibrils and collagen were pelleted by 
centriftigation. The sarcoplasmic fraction was aspirated off and the myofibrils 
separated from the collagen by dissolving in 0.7 M KCI. The incorporation of proline 
into the myofibrillar and sarcoplasmic protein fractions was then measured by gas 
chromatography-combustion-isotope ratio mass spectrometry (GC-C-I RMS), after 
hydrolysis, purification and derivatisation as their N-acetyl-n-propyl ester (NAP) 
derivative. The fractional synthetic rate (FSR) was calculated as the rate of increase of 
labelling of protein-derived °Cproline compared to the average labelling of the 
proline in the incubation media. 
2.6.2 Myolibrillar and sarcoplasmic fractional protein synthesis rates 
in human subjects 
Two groups of 20 and 24 healthy young and elderly males (28 ± 6, 70 ± 6 y; BMI 24 
± 3, 25 ± 4 respectively; means ± SD) participated in a study examining differences 
between young an elderly. In the second study, 8 elderly males with type II DM were 
compared with 8 healthy age and near weight-matched controls (means ± SD: 66±3 
vs. 70 ± 6; BMI: 25 ± 4 vs. 32 ± 2 kg.m 2). The subjects received a primed constant 
infusion of [I- 13C] ketoisocaproic acid (KIC)(8.8 gmol kg', 13.2 iamol kg' W')over 
3.5 h in the post-absorptive state. Insulin and glucose were clamped at basal values. 
Octreotide (1.8 .tg kg' W') and insulin (360 piU m 2 W') were infused throughout and 
maintained insulin ('-'10 1.tU mr') and glucose (-4-5 mM) at post-absorptive values. A 
medical doctor then took muscle biopsies from the Vastus Lateralis before and 3 h 
after ingestion of a solution in the first study containing 0, 2.5, 5.0, 10.0, 20.0 and (in 
elderly only) 40.0 g of mixed EAA in 500 ml of water; whilst in the second study 
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diabetic only 0 g and 20 g. Fractional synthetic rates (FSR) of myofibrillar and 
sarcoplasmic proteins were determined in quadriceps biopsies by measuring the rate 
of incorporation of [ 13C]leucine during a primed, constant inThsion of [1- 13CIa-
ketoisocaproic acid over 3 h after they drank water or the EAA solution. Plasma was 
separated by centrifugation at 1600 x g and stored at -80 °C until analysis. An aliquot 
of 200 sl was taken for determination of amino acid labelling. Derivatised leucine 
was separated by gas combustion ((IC) and its 13C/12C isotope ratio determined by 
selected ion monitoring MS (Bohe ci at, 2003). Muscle samples were homogenised 
in a high ionic strength buffer containing inhibitors of phosphatases and proteases. 
Myofibrillar and sarcoplasmic protein fractions were separated, acid hydrolysed and 
derivatised as NAP esters before measurement of bound leucine ' 3C/' 2C by (IC-
Combustion IRMS (Finnigan DeltaPlus XL). Fractional synthetic rates (FSR) were 
calculated as the rate of increase of labelling of muscle protein bound leucine 
compared to the average plasma KIC labelling. This study had ethical clearance from 
Ethics Committees of the University of Dundee and University of Nottingham. 
* EAA infusions and human muscle protein synthesis experiments completed without 
my involvement by members of Professor Rennie's Laboratory, University of Dundee 
and University of Nottingham. 
2.7 ATP-ase fibre type staining and NADH-Tr mitochondrial staining 
The Soleus and Extensor Digitorum Longus (EDL) muscles were excised from the 
hind limb of a Sprague-Dawley rat. Muscles were then frozen using liquid N 2 cooled 
isopentane, and after obtaining 10 pm sections of the muscle, heated gently for 5 mm. 
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Pre-incubation medium of (100 mM glycine, I % CaCl2, 10 % formaldehyde, pH 
7.25) was dropped onto the sections for 5 min at 25 °C, and then rinsed, three times 
with distilled water. Slides were then placed in a staining jar with incubation medium 
(2.8 mM ATP, 100 mM sodium barbital, 2 % CaCl2 anhydrous) and incubated for 90 
min at 37°C in a water bath. A 1 % CaCl2 solution was then placed on the sections 
three times for 2 mm. A 2 % Cobalt Chloride solution was then placed on the 
sections, again three times for 2 min before washing with distilled water three times 
for 2 mm. Next, a drop of 2 % ammonium sulfide solution was placed on the sections 
for 90 s, before washing with distilled water, and then under running tap water for 10 
min in the staining jars. Finally, the sections were dehydrated in ascending alcohols 
(50 %, 60 %, 70 %, 80 %, 90 %, and 95 %) with a drop of each placed on the section 
for 30 s. The slides were then cleaned, and cleared with two changes of histoclear, 
before being mounted with histomount. Under the microscope, Type I fibres have no 
staining, type ha fibres have heavy staining and type lIb fibres show light staining. 
The NADH-Tr stain was performed on chronically stimulated and control EDL 
muscles. Muscles were quickly excised and then frozen using isopentane cooled in 
liquid N2, and after obtaining 10 p.tm sections of the muscle, heated gently for 5 mm. 
A tris buffer (0.2 mM of tris-HCL, trizma base, pH 7.4) was made up with I mg ml' 
of nitro blue tetrazolium (NBT), before readjusting to pH 7.4. Then I mg mr' of 
NADH was added to the tris buffer. The sections were then covered with incubation 
solution and placed above the water bath at 37t for 25 mm. Under the microscope, 
the darkest fibres indicate higher mitochondrial densities and are thus theoretically 
type ha fibres or type I, with type JIb fibres yielding little staining. Light microscopy 
was used to examine the results of both the ATP-ase and NBT histochemistry. 
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2.8 Western Blotting 
2.8.1 Protein extraction 
Proteins were extracted from rat EDL and Soleus muscles. Approximately, 30 mg of 
muscle was homogenised on ice in 0.6 ml of homogenisation buffer (50 mM Tris-
HCL; 0.1 % Triton-X; 1 mM EDTA; 1 mM EGTA; 50 mM NaF; 10 mM 3-
glycerophosphate; 5 mM Na pyrophosphate; 0.1 % 2-mercaptoethanol; 100 nM 
okadaic acid; 50 jiM sodium orthovanadate; I tablet of a protease inhibitor cocktail). 
Samples were rotated for 60 min at 4 C, before being centrifuged at 13,000 g for 10 
mm. Protein concentration was measured using the Bradford assay (Bradford, 1976) 
and adjusted to 2 mg mr' by diluting in SDS sample buffer (3.55 ml deionised water, 
1.25 ml 0.5 M Tris-HCL, pH 6.8; 2.5 ml glycerol; 2 ml 10% (w/v) SDS; 0.2 ml 0.5% 
(w/v) bromophenol blue). 
2.8.2 Electrophoresis and Blotting 
Protein samples (20 pig) were electrophoresed in running buffer (I % SDS; 192 mM 
glycine; 25 mM tris-base; pH 8.3) on a 10 % (13.5 % high-bis gel for 4E-BPI) SDS-
polyacrylamide gel electrophoresis gel at 100 V for 30 min through the stacking layer 
and then 200 V until the dye marker reached the bottom of the gel. Precisely, 10 pd of 
a rainbow molecular size marker was loaded in to the final lane in order to later 
confirm detection of the correct protein size. Following conclusion of electrophoresis, 
the polyvinylidene difluoride (PVDF) membrane was permeabilised in 100 % 
methanol for I min before both the gel and pit-wetted membrane were equilibrated in 
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transfer buffer (192 mM glycine; 25 mM Tris base; 20 % w/v methanol; pH 8.3) for 
30 mm. The transfer was run for 2 hat a constant 100 V. Upon completion of transfer, 
the uniformity of loading was checked with Ponceau S before the membrane was 
incubated in 30 ml of blocking buffer (TBS with 0.1 % Tween-20; 5 % w/v non-fat 
milk powder) for 2 h. Following incubation with the blocking buffer the membrane 
was washed 3 times for 5 min with wash buffer (TBS with 0.1 % Tween-20) in 30 ml 
with gentle agitation. Stimulated samples were exposed to the following pan 
antibodies: anti-calcineurin (Sigma C 1956; 1:2000); anti-NFiB (NEB3034; 1:2000); 
anti-PKB/AKT (Courtesy of Prof Sir P Cohen; 1:2000); anti-p70 S6K (NEB9202; 
1:2000); anti-GSK3I3 (Chemicon AB8687; 1:2000), anti-eIF213 and anti eEF2 (both 
courtesy of Prof CG Proud; 1:1000) anti-p44/42 (NEB9 102; 1:2000); anti-
p38a,3/SAPK2 (Biocompare 50096-0IA; 1:2000); anti-p38y (Upstate 07-139; 
1:2000); anti-AMPK NE132532; 1:2000); anti-SAPK/JNK (NEB9252; 1:2000); anti-
myostatin (Santa Cruz sc-6885; 1:500); anti-4E-BPI (courtesy of Prof CG Proud; 
1:1000); anti-ubiquitin (NEB3936; 1:2000) or anti- SMAD2/3 (Santa Cruz sc-6033; 
1:500) overnight at 4°C. Phosphorylation status was measured using: phospho-AMPK 
(NEB253 1; ThrI 72; 1:2000); phospho-PKB (NEB9271; Ser473; 1:2000); phospho-
p70 S6K (NEB9205; Thr389; 1:2000); phospho-ERKI /2 (p44/p42) (NE139 101; 
Thr202/Tyr204; 1:2000); phospho-p38 (NE8921 1; ThrI 80/Tyrl 82; 1:2000); 
phospho-SAPKIJNK (NEB925 1; ThrI 83/Tyr 185; 1:2000); phospho-GSK3c43 
(NEB933 1; Ser2 1/9; 1:2000); phospho-SMAD2/3 (Santa Cruz sc-I 1769; Ser433/435; 
1:500); phopsho-UBF (Santa Cruz sc-2 1639; Ser637; 1:500); phospho-eEF2 (courtesy 
of Prof CG proud; Thr56; 1:2000); phospho-elF2Bc (Courtesy of Prof CU Proud; 
5er535; 1:2000) and phospho-4E-BPI (NEB9459; Ser37/46; 1:2000) also overnight at 
4 °C. The following morning, the membrane was rinsed in wash buffer 3 times for 5 
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min each time in 30 ml. The membrane was then incubated for I h at ambient 
temperature with gentle agitation in 30 ml of blocking buffer containing the 
appropriate secondary antibody, either: horseradish peroxidase linked anti-mouse 
immunoglobulin (NEB7072; 1:2000); anti- rabbit immunoglobulin (NEB7074; 
1:2000) or anti-sheep immunoglobulin (courtesy of Prof Chris Proud; 1:5000). The 
membrane was cleared 3 times for 5 min in 30 ml wash buffer. Membranes were 
exposed to ECL chemiluminescent detection reagents mixed 1:1 in 10 ml for 1 mm. 
Membranes were partially dried, wrapped in saran and exposed to X-ray film. 
2.8.3 Densitometry 
X-ray films were scanned using a Biorad Imaging densitometer (Model GS-670) to 
detect the relative band intensity. Each band was identified and the optical density 
volume adjusted by subtraction of the background. All values obtained from one blot 
were normalised to the average resting control band intensity which was set to 1. 
2.9 Microarray analysis 
Spotted microarrays of Mus musculus (about 15,000 cDNAs on two slides) were 
obtained from The Human Genome Mapping Project Resource Centre Microarray 
Programme (Harwell, UK). Description of the arrays and links to the cDNA clone 
information can be found on: 
http://www.hgmp.mrc.ac.ukfResearchfMicroarrayfflGMP -
RC Microarrays/description of arrays.jsp#2 
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2.9.1 Experimental design 
C2C 12 mouse myoblasts were cultured to confluence in DMFM containing 10 % 
FBS, supplemented with amphoteracin B (1:1000) and Penicillin/Streptomycin 
(1:100), and formation of myotubes was triggered by switching to 2 % horse serum. 
Five 90 mm dishes were subjected to lOng mr' recombinant myostatin for 6 h whilst 
5 dishes served as controls. Mouse NIA Clone Set Arrays ('-15k cDNAs) from the 
Rosalind Franklin Genomic centre for Research were used which consisted of both 
'A' and 'B' slides. Therefore, five biological repetitions were performed. 
2.9.2 RNA extraction, cleanup and cDNA synthesis 
Following treatment, total RNA was extracted from C2C12 cells according to the 
manufacturer's protocol, as described (see 2.2). RNA was then purified by Qiagen 
RNeasy cleanup as according to the manufacturers protocol. Eluted RNA was then 
vacuum centrifuged and adjusted to 2 pg pr' in preparation for cDNA synthesis using 
the FairPlay Microarray labelling kit. For generation of cDNA 1 p1 of 500 ng pr' 
oligo(dT) was added to a 12 p1 aliquot of the RNA preparation, mixed and heated at 
70 °C for 10 mm. Samples were then allowed to cool for 10 min to allow primers to 
anneal to template. For each reaction the following was added: 2 pl 10 x  Statascript 
reaction buffer; I j.il 20 x  dNTP mix; 1.5 pl 0.1 M D'fl'; 0.5 p1 RNase block (40 U pF 
5 and finally I p1 Statascript reverse transcriptase (RT). This mixture was then 
vortexed briefly and incubated at 48 °C for 25 mm. Following this 1 pl of of reverse 
transcriptase (RT) was added and incubated at 48 °C for a further 35 miii. RNA-DNA 
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hybrid bonds were then hydrolysed by addition of 10 psI sodium hydroxide and 
incubation at 70 °C, before being neutralised with 10 p.s1 HCI. Following this, the 
following constituents were added to the tube: 4 psI 3 M sodium acetate, pH 5.2; 1 nI 
20 mg mF' glycogen; 100 jil 100 % ethanol. The mixture was then briefly vortexed 
and stored at -20 °C overnight. 
2.9.3 cDNA labelling, purification and quality control 
The following morning, the reaction mixture was then spun at 15,000 g for 30 mm, 
supernatant removed and washed with 250 M1  of 70 % ice-cold ethanol before 
centrifugation at 15,000 g for a further 30 mm. The supernatant was removed and 
pellet allowed to air dry for 15 min. Precisely, 5 psI of 2 x  coupling buffer was added 
to each tube and heated at 37 °C for 15 min to ensure resuspension. To each control 
sample, 5 p.tl of Cy3 red fluourescent dye was added and to each myostatin treated 
sample 5 p.sl of Cy5 green fluourescent dye was added before being thoroughly mixed 
and incubated at room temperature for 1 h in the dark. To each reaction 90 p.s1 of DNA 
grade water was added before purification of DNA fragments from dye-labelled 
reactions was performed using the Qiaquick PCR purification kit as according to 
manufacturers instructions. The quality of labelling was checked on a 2 % agarose gel 
where 5 nil labelled cDNA was mixed with 5 jil xylene cyanol FF/bromphenole blue 
buffer diluted in glycerol. Scanning on a proXPRESS imager on Cy3 and Cy5 specific 
filters would reveal a bright 'smear' along the vertical stream of cDNA if labelling of 
cDNA was successful. Once the quality of labelling was ensured, samples were 
placed in a vacuum centrifuge to concentrate the sample, before resuming under 
section 2.9.5. 
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2.9.4 Preparation of microarray slides 
Prehybridisation of microarray slides was performed for 1 h at 42 °C in I % bovine 
serum albumin, 5 x SSC, 0.1 % SDS. Slides were then washed in water and then 
isopropanol before centrifugation at 500 g for 5 mm. 
2.9.5 Hybridisation of cDNA to arrays 
Labelled cDNA was then resuspended in 50 1.il of hybridisation buffer (50 % 
formamide; 5 % dextran sulphate; 3 x SSC; 1 % SDS; 5 x  Denhardt's solution) before 
Cy3 and Cy5 fluourescent dyes were combined. Samples were mixed and 2 Wpl 
polyA was added. Combined samples were placed at 100 °C for 5 min, briefly 
centrifuged and cooled to 25 °C. Following this, the samples were carefully applied to 
the microarray slides using a pipette, before being protected with a plastic cover-slip. 
Finally, the microarray slides were then incubated in a 3 x  SSC humid chamber for 18 
hat42°C. 
2.9.6 Washing 
Cover-slips were removed from slides by immersion in I x  SSC, 0.2 % SDS. Slides 
are then immersed in this same buffer and washed 2 x  5 mm. Slides were then washed 
again for 2 x  5 min in 0.1 x  SSC, 0.1 % SDS, and further for 2 x 5 min in 0.1 x  SSC. 
Slides were then stored in the dark at ambient temperature awaiting scanning and 
analysis. 
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2.9.7 Analysis of microarrays 
Microarrays were scanned with arrayWoRxe  scanner and resulted images analysed by 
array WoRx Software Suite 2.0 (all from Applied Precision Instruments, USA). Data 
were generated for spot and their background intensities as means and standard 
deviations. Spot intensity data were imported into locally installed BioArray Software 
Environment, BASE (Saal ci aL, 2002) and pre-processed by local background 
subtraction, filtering out spots with unreliable intensities (SNR<3), lowess 
normalisation, averaging normalised intensities across replicated spots on array, and 
choosing only genes with intensity data for two or more array replicates. 
For analysis, gene's experiment to control ratios were imported into TIOR 
Multiexperiment Viewer (MeV) software (Saeed a aL, 2003), log2-transformed and 
normalised. Differentially expressed genes were determined as those with ratios 
deviated from expected ratio of one (one-sample t-test, p<0.05) and having unusual 
ratio (z-test, P<0.05). No multiple comparisons corrections were applied. 
* Microarray scanning and spot analysis was perfonned by Dr Viacheslav Bolshakov, 
University of Dundee without my involvement. 
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2.10 Statistics 
All statistical data in chapters 3 and 4, and the first study examining protein 
phosphorylation following in vivo muscle stimulations in chapter 5, are displayed as 
mean ± standard error (±SE) in the figures. Analysis for statistical significance 
between treatments (chapter 3); EDL and soleus muscle types (chapter 4); between 
stimulations in vivo (chapter 5), was done using the Student's t-test. Differences were 
considered significant when p<0.05. 
All statistical data for the in vitro l-IFS/LFS stimulations in chapter 5 are displayed as 
mean ± standard error of the mean (±SEM) in the figures. Changes in phosphorylation 
were normalised to total levels of both phosphorylated/unphosphorylated forms using 
native antibodies. Means were compared using an independent, three-factorial 
ANOVA (muscle: EDL, Soleus; stimulation: HFS, LFS; time: control, directly after 
stimulation, 3 h control, 3 h after stimulation). A one-factorial ANOVA (control; 3 h 
after LFS; 3 h after HFS) was used to analyse the protein synthesis and RT-PCR data 
(chapters 5 & 6). Tukey's test was used as a post hoc test and p<0.05 was used as a 
threshold for statistical significance. 
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Chapter 3 
Role of myostatin in the control of 
muscle mass: regulation of transcription 
and translation 
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3.1 Introduction 
Myostatin is a powerful negative regulator of skeletal muscle mass. However, it 
remains largely unknown how myostatin might affect muscle mass in post-mitotic 
situations, even though there is evidence that systemic myostatin causes cachexia 
(Zimmers et aL, 2002), and is elevated in disease atrophy states (Jackman & 
Kandarian, 2004). Myostatin may also be subject to regulation by resistance exercise 
(Walker ci aL, 2004), and endurance exercise, although the latter has not been 
examined to date. Therefore, myostatin is an important component in the control of 
muscle mass in relation to both exercise and disease. 
However, precisely how myostatin affects transcription and translation to control 
muscle mass has not been elucidated, and is poorly understood. Also inadequately 
characterised is the regulation of the myostatin gene. For although myostatin 
regulation has been linked putatively by many factors (Ma et al., 2001), only 
glucocorticoids have been experimentally verified to increase myostatin expression. 
Therefore, the aims of these studies were to perform a battery of experiments in order 
to gain insight in to both how myostatin exerts its effects in adult muscle, and what 
factors regulate the myostatin gene. Specifically, these studies aimed to examine how 
various growth factors and hormones including IGF-1, clenbuterol, growth hormone, 
testosterone, dexarnethasone, cyclosporine A, and finally creatine would affect 
myostatin gene expression in L6 cultured muscle cells using Northern blotting and 
RT-PCR. This should yield important information about the regulation of expression 
of the myostatin gene. Secondly, to elucidate the signalling mechanisms behind the 
inhibitory effect of myostatin on protein synthesis by using Western blotting to 
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examine the phosphorylation of components of the IGF-l-P1-3K-PKB-mTOR 
pathway in the presence of recombinant myostatin in C202 skeletal muscle cells. 
Finally, to examine the transcriptional effects of recombinant myostatin on C2C12 
skeletal muscle cells using genome-wide cDNA microarrays in order to identi& genes 
involved in mediating the negative effect of myostatin on muscle mass. 
The specific hypotheses of these studies being: 
I. Treatment of L6 skeletal muscle cells with growth factors can suppress 
myostatin mRNA expression, whereas glucococortioids, such as 
dexamethasone will increase myostatin gene expression. 
2. Myostatin can inhibit elements of the P1-3K pathway responsible for directing 
increases in muscle protein synthesis. 
3. Recombinant myostatin treatment of C2C12 skeletal muscle cells can affect 
genes involved in controlling muscle mass. 
Methods 
As described in Chapter 2. 
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3.2 Results 
3.2.1 RNA quality 
RNA viability of C2C12 and L6 skeletal muscle cells was checked by 
spectrophotometry and was within recommended levels, indicating minimal DNA, 
protein and guanadinium salt contamination (absorbance 260 / absorbance 280 = 1 .8-
2). Furthermore, when electrophoresed and stained with ethidium bromide on an 
agarose gel, RNA had a 2:1 ratio of 28s: I 8s ribosomal RNA (rRNA), as determined 
by densitometry. Finally, there was no evidence of RNA degradation or DNA 
contamination as shown by 'streaking' between ribosomal bands. 
3.2.2 Northern blots detected no myostatin transcript in L6 cells 
Northern blots of all L6 samples at 2 jig RNA, showed no expression of myostatin 
following exposure to a phosphorscreen after a 24 h probe hybridisation period. 
Therefore, the time before exposure to the phosphorscreen was increased for up to 72 
h, and RNA the quantity electrophoresed on agarose gels was increased to between 4 
and 20 jig of RNA, at 2 jig increments. RNA at 1 5-20 jig was not able to migrate on a 
horizontal gel due to the high viscosity, although concentrations between 4 and 14 jig 
electrophoresed effectively. These modifications however, yielded only ribosomal 
RNA (rRNA) banding, thus indicating non-specific binding of the myostatin probe to 
rRNA. Consequently, no myostatin mRNA was detected in any of the L6 samples, 
regardless of treatment; and this was also true for control L6 cells. Lack of myostatin 
mRNA using Northern blotting detection methods was therefore regardless of RNA 
concentration and probe exposure times. 
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Following this failure to detect expression of myostatin mRNA in the L6 cells, it was 
decided to examine myostatin inRNA of various skeletal muscles, heart, primary 
skeletal muscle cells, and the L6 cells at higher RNA concentrations (14 jig), 
including those treated with Dexamethasone (known to increase myostatin mRNA). 
Again, myostatin mRNA was not detected in L6 cells, whilst also undetected in the 
primary skeletal muscle cells. However, myostatin mRNA was detected in rat muscle 
extracts and was present at higher levels in muscle with a greater proportion of type II 
muscle fibres such as EDL, tibialis anterior (TA), epitrochlearis and gastrocnemius 
than in slower muscles such as Soleus (figure 3.1). These data showed that the 
myostatin probe generated was successful in detecting native myostatin mRNA and 
could not be responsible for the lack of detection in the L6 cells. 
1 	 2 3 4 5 	 6 	 7 8 9 10 11 12 	 13 14 15 16 17 18 19 20 
Figure 3.1. Example of myostatin Northern blots at 2 ig RNA of primary muscle 
cells, 2 jig various muscle tissue extract and 14 jig of Cyclosporine A and 
dexamethasone treated L6 cells. Lanes 1-4 primary cultured muscle cells; lane 5 
plantaris; lane 6, EDL; lane 7, heart; lane 8, tibialis anterior; lane 9, Soleus; lane 10, 
epitrochlearis; lane 11, vastus intermedius; lane 12, gastrocnemius; lane 13, Vastus 
Lateralis lane 14, tibialis posterior; lane 15, flexor digitorum longus; lanes 16-18 
Cyclosporine A treated L6 cells; lanes 18-20 dexamethasone treated L6 cells. Blots 
area typical example of 4 such experiments, (n4). 
Next, it was necessary to check the viability of the L6 cells since although the RNA 
was checked, there remained a possibility of sample contamination and therefore it 
was decided to attempt Northern blotting using a different probe, other than 
myostatin. Figure 3.2 shows Northern blots for GLUTI on the L6 treated cells. 
GLUT! was chosen as an additional probe since it was previously shown by 
GeneCards to be expressed highly and ubiquitously in skeletal muscle. Furthermore, it 
is also known from the literature to be regulated by IGF-! and dexamethasone, two of 
the treatments exposed to the L6 cells. As expected from the literature, GLUT1 was 
upregulated mainly in response to !GF- 1 and dexamethasone (figure 3.2). These 
results indicated that the treatments of the L6 cells were effective and the RNA from 
the L6 cells was apparently viable and not contaminated. 
1 	 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Figure 3.2. Example of GLUT 1 Northern Blot of L6 cells. Treatment of L6 cells with 
growth hormone (lanes 1-4), creatine 24 h (lanes 5-8) and Cyclosporine A (lanes 9-
12) showed small increases (and a larger increase for CsA at high concentrations) in 
GLUT1 mRNA following exposure to phosphorscreen after 24 h. Treatment of cells 
with IGF-1 (lanes 13-16), and dexamethasone (lanes 17-20) robustly upregulated 
GLUTI mRNA at various concentrations, except !GF-1 at the highest concentration, 
lane 16) which had limited effect. Blots are a typical example of 4 such experiments, 
(n4). 
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3.23 RT-PCR detected no myostatin transcript in L6 cells 
The RT-PCR shown in figure 3.3 was attempted since it could give more sensitive 
detection of myostatin mRNA, and moreover it could confirm the negative results of 
the Northern analyses. Reverse transcription (RT) was checked through completing 
the L6 RT alongside various other muscle homogenates. Furthermore, the samples 
were spiked with cDNA from fresh skeletal muscles in order to ascertain whether the 
L6 cells contained any substance inhibiting the detection of myostatin. Muscle 
homogenates alone showed myostatin expression, as did L6 cells 'spiked' with cDNA 
from skeletal muscle homogenates. However, L6 cells treated with dexamethasone 
and all other treatments showed no myostatin expression, thus further confirming the 
lack of myostatin expression in these cells (note the mis-primings in L6 cells). 
Figure 3.3. Myostatin RT-PCR in various tissue types. Lanes 1-5, dexamethasone 
treated L6 cells; lanes 6-9, L6 samples 'spiked' with cDNA positive control to ensure 
there was nothing in the L6 samples which inhibited detection of myostatin; lanes 10-
14 mixed L6 samples; lanes 15-19, various muscle homogenate RNA reverse 
transcribed alongside L6 samples to ensure RT reaction was successful; lane 20 
positive control eDNA. End lanes are 100 Kb size markers. Primary and L6 cells 
again showed no presence of myostatin transcript. tLane 2 not at the same size as 
myostatin detected in skeletal muscles. Image typical of 4 such experiments, (n=4). 
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3.2.4 Myostatin increases SMAD2 phosphorylation and inhibits the 
phosphorylation of elements of the P1-3K pathway 
Treatment of C2C12 cells with recombinant myostatin causes an increase in 
phosphorylation of SMAD2 (35 %) (figure 3.4). Since SMAD proteins are 
implicated in myostatin signalling, the increased phosphorylation is presumably 
indicative of an increased SMAD2 signalling in response to recombinant myostatin. 
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Figure 3.4. Immunoblots (a) and representative bar chart (b), showing that SMAD2 
phosphorylation is increased in response to recombinant myostatin. Representative 
Western blots above, C= Control cells, M = myostatin, 10 ng mr' (data are mean 
±SEM n8, * p = <0.05). 
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Treatment of the murine C202 skeletal muscle cells with 10 ng mr' recombinant 
myostatin (+) reduces the phosphorylation of many key signalling proteins in the 
insulinflGF pathway (figure 3.5), suggesting a mechanism for suppression in protein 
synthesis. PKB phosphorylation decreased by —30 %, mTOR by —50 %, p70 S6K by 
—60% and 4E-BP1 remained unaffected. 
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Figure 3.5. Immunoblots (a) and representative bar chart (b), showing that myostatin 
inhibits signalling through PKB, mTOR and p70 S6K in C202 cells (data are mean 
±SEM n8, * p = <0.05). 
3.2.5 cDNA microarrays - Myostatin inhibits transcription 
The Rosalynd Franklyn Centre provided the eDNA microarrays on which probes from 
the National Institute of Ageing 15K Mouse cDNA clone set have been printed on an 
A and B array. The quality of cDNA labelling with Cy3 and Cy5 dyes was indicated 
to be very good as shown by the high intensity of the 'smear' on an agarose gel. 
Following analysis of the data, the major finding of this study is that recombinant 
myostatin leads only to a down-regulation of genes in C2C12 skeletal muscle cells. 
Therefore, myostatin is indirectly, a transcriptional inhibitor. Gene lists have been 
produced using two levels of stringency. The first list contains genes likely to be 
downregulated by myostatin and the second list genes less likely to be downregulated. 
Only the first list of genes was systematically analysed. For known genes, information 
regarding the differentially expressed genes was obtained using GeneCards to obtain 
information on expression in skeletal muscle compared to other tissues (Rebhan et aL, 
1998; Safran et aL, 2002). If available, links to Mendelian Inheritance in Man (MIM 
or OMIM) or LocusLink were followed. 
A selection of genes, were initially identified that are potential regulators of the 
atrophy/anti-proliferation effect of myostatin. It is very likely that many other genes 
in this list mediate the negative effects of myostatin on muscle mass, although it was 
beyond the scope of this thesis to investigate all of these. For unknown genes 
expressed sequence tags (ESTs) and other unnamed genes, the identifier was entered 
into the National Institute of Ageing 15 K mouse cDNA clone set website (these 
clones have been used to print the arrays) to search for updated information. Listed 
below are two sets of data from the microarray data. 
(a) List of genes likely to be down-regulated by myostatin: 
Identjfier Gene description 
Mm_NIA_H3004A06 Tetratricopeptide repeat domain 
Mm_NIA_1-13010D06 
Caseinolytic protease, ATP-dependent, proteolytic subunit 
homolog (E. coli) 
Mm_NIA_H3025C07 
GO1O3GI 1-3 NIA Mouse E7.5 Embryonic Portion cDNA 
Library Mus musculus cDNA clone G0I03G1 1 3', mRNA 
Mm_NIA_1-13028G01 DNA segment, Chr 16, ERATO Doi 454, expressed 
MmNIAH30I2EI2 RIKEN eDNA D0300541119 gene 
Mm NIA 1-130 1 5D03 ESTs 
Mm_NIA_E13009F07 Kinesin family member 5B 
MmNIAH3034F1 1 ESTs 
MmNIAH3062HO6 RJKEN eDNA 11 90006A08 gene 
MmNIAH305OGO7 ESTs 
Mm_NIA_1-13025G01 Splicing factor, arginine/serine-rich 3 (SRp20) 
Mm_NIAH3029A07 Nuclear protein 220 
Mm_NIA_113074E1 1 RIKEN cDNA 2210401J1 I gene 
Mm_NIA_1-1301 1E06 
11301 1E06-3 NIA Mouse 15K cDNA Clone Set Mus 
musculus cDNA clone 11301 1E06 3', mRNA sequence. 
Mm_NIA_1-13029G08 Neural-salient serine/arginine-rich 
MmNJA_H3017B03 
C0176A09-3 NIA Mouse E7.5 Extraembryonie Portion 
cDNA Library Mus musculus cDNA clone COl 76A09 3', 
mRNA sequence. 
Mm_NIAH3051AOI 
C85250 Mouse fertilized one-cell-embryo cDNA Mus 
musculus cDNA clone J0204H03 3', mRNA sequence. 
MmNIAH305OB 12 ESTs 
Mm_NIA_H301 1F07 Protein tyrosine phosphatase 4a2 
Mm_NIA_H3051E01 Hypothetical protein MGC12O7O 
MmNIAFI300 1 E07 ESTs 
Mm_NIA_l-13020F07 RIKEN cDNA 3110001 HI 5 gene 
Mm_N1Aj13062E08 Epoxide hydrolase 2, cytoplasmic 
Mm_NJA_H3076D12 Similar to erythrocyte protein band 4.1-like 4b 
Mm_NIA_H300IFOI Ephrin Al 
Mm_NIA_H3029F01 P53 apoptosis effector related to Pmp22 
Mm_NJA_H3002A03 RIKEN cDNA 11 10002B05 gene 
MmNIAH30I 3H07 RIKEN cDNA 181001 0A06 gene 
Mm_NIA_H3031E02 RIKEN cDNA 2810410M20 gene 
Mm_NIA_H3010H12 PHD finger protein 5A 
MmNIAH3073CO9 
H3073C09-3 NIA Mouse 15K cDNA Clone Set Mus 
musculus cDNA clone H3073C09 3', mRNA sequence. 
Mm_NIA_H3042E06 Protein tyrosine phosphatase, receptor type, A 
Mm_NIA_H30291105 Teratocarcinoma-derived growth factor 
Mm_NIA_F13026F04 RIKEN cDNA 64305731123 gene 
MmNIAH3065FIO Chromosome condensation protein G 
Mm_NIA_H3023G01 Heat shock protein 1, alpha 
Mm_NLk_H3049A07 
H3049A07-3 NIA Mouse 15K cDNA Clone Set Mus 
musculus eDNA clone H3049A07 3', mRNA sequence. 
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Mm_NIA_H3004A05 Transforming growth factor beta regulated gene 4 
MmNIAH306OG 12 ESTs 
MmNTAH3020GO2 RIKEN cDNA 2310081H14 gene 
MmNIAH3017BO1 
H3017B01-3 NIA Mouse 15K cDNA Clone Set Mus 
musculus eDNA clone H3017B01 3', mRNA sequence. 
Mm_NIA_H3001B05 Pan hematopoietic expression 
MmNIAH3025BO7 EST's 
Mm_NIA_H3003A01 
ESTs, Moderately similar to hypothetical protein FLJ233 11 
[Flomo sapiens] [H.sapiens] 
Mm_NIA_113001B04 DNA segment, Chr 9, Wayne State University 20, expressed 
Mm_NIA_H300 1 B02 
Mus musculus 2 days neonate thymus thymic cells eDNA, 
RIKEN fhll-length enriched library, clone:E430020E19 
product:ROD1 homolog [Rattus norvegicus], frill insert 
sequence. 
Mm_NJA_I-13002B04 CUG triplet repeat, RNA binding protein 1 
Mm_NIA_1i3018Fl2 RIKENcDNA 1110017C15 gene 
Mm_NIA_I-13006B03 Interleukin 13 receptor, alpha 1 
Mm_NIA_H300 1 A03 
DNA segment, Chr 11, Wayne State University 99, 
expressed 
MmNIAaaaaaM28723 Peroxiredoxin 3 
Mm_NIA_H3001BOI RIKEN eDNA 9430023L20 gene 
MmNIAhhhhhU49720 
Opsin I (cone pigments), short-wave-sensitive (color 
blindness, tritan) 
MmNIAIiI300 I A06 ESTs 
l3 
Mm_NIA_H3 I 53E06 B-cell receptor-associated protein 29 
Mm_NIA_H3104G01 Myosin light chain, phosphorylatable, fast skeletal muscle 
Mm_NIA_H3 131 D06 
L0212C09-3 NIA Mouse Newborn Ovary eDNA Library 
Mus musculus cDNA clone L021 2C09 3', mRNA sequence. 
Mm_NIA_H3 I 30F01 Serologically defined breast cancer antigen 84 
Mm_N IA_H3 1101105 RIKEN cDNA 111 0023P2 I gene 
Mm_NIA_H3098D04 RIKEN cDNA 1300004C1 I gene 
Mm_NIA_H31271309 RIKEN cDNA D330050P16 gene 
Mm_NIA_H308 I A02 Eukaryotic translation initiation factor 4A2 
Mm_NIA_l-13138F12 Syndecan 4 
Mm_NIA_H3147E02 S-adenosylmethionine decarboxylase 1 
MmNIAH3095E07 
H3095E07-3 NIA Mouse 15K cDNA Clone Set Mus 
musculus cDNA clone H3095E07 3', mRNA sequence. 
Mm_NIA_H3 131 CO2 RIKEN cDNA 2410016006 gene 
Mm_NIA_H3 147F09 RIKEN cDNA D130072021 gene 
Mm_NIA_H3156B04 RIKEN cDNA 0710001E19 gene 
Mm_NIA_1-13105B04 Bone morphogenetic protein 15 
MmNIAH3 147D03 ESTs 
MmNIAH3 I 32B 10 ESTs 
Mm_NIA_1-13095A05 Estrogen receptor 1 (alpha) 
Mm_NIA_H3092C01 Eukaryotic translation initiation factor 4, gamma 2 
MmNIAH3I38C06 
L0235C10-3 NIA Mouse Newborn Ovary cDNA Library 
Mus musculus cDNA clone L0235C10 3', mRNA sequence. 
Mm_NIA_H31 18E03 RIKEN cDNA 2810442122 gene 
Mm_NIA_H3083A04 V-crk sarcoma virus CT1O oncogene homolog (avian) 
Mm_NJA_H3 1 26D06 
1131 26D06-3 NIA Mouse 15K cDNA Clone Set Mus 
musculus eDNA clone H3 1 26D06 3', mRNA sequence. 
Mm_NIA_H3 11 9C06 Nucleolar protein 5 
Mm_NIA_H3083H 12 Synaptosomal-associated protein 23 
Mm_NIAH3 13 8B03 RIKEN cDNA 111001 7P05 gene 
Mm_NIA_H3 131 A03 Heat shock protein 1, alpha 
MmNIA_113 1 33G1 0 RIKEN cDNA 4933402K! 0 gene 
Mm_NIA_H3 1 37F09 Hypothetical protein MGC36997 
Mm_NIAH3107FO2 Cyclin-dependent kinase 4 
MmNIA_H3084A06 Spindling 
Mm_NIA_H31 12D06 RIKEN eDNA 26100271,16 gene 
Mm_NIA_H31051310 Cyclin Bi, related sequence 1 
MmNIAH3 I 56E01 
ESTs, Moderately similar to 158401 protein-tyrosine kinase 
(EC 2.7.1.112) JAK3 - mouse M.musculus] 
MmNIAH3088EO8 ESTs 
Mm_NIA_F13 1 38D07 Voltage-dependent anion channel 2 
Mm_NIA_H3094E12 RIKEN eDNA 1 190002A17 gene 
Mni_NIA_H3 1 20007 Tribbles homolog 1 (Drosophila) 
Mm_NIA_H3 11 4C06 
L001 1F07-3 NIA Mouse E12.5 Female Mesonephros and 
Gonads eDNA Library Mus musculus cDNA clone 
L00 11 F07 3', rnRNA sequence. 
Mm_NLk_113 1 39H03 ESTs 
Mm_NIA_H3 I 46H 12 RIKEN cDNA 1700021 F05 gene 
110111 
Mm_NIA_H3 I 14H09 Nucleosome assembly protein 1-like 4 
MmNJAH3 I 09H08 
ESTs, Weakly similar to RIKEN cDNA 5730493B19 [Mus 
musculus] [M.musculus] 
MniNIAH3 I 39G0 1 
L0240E12-3 NIA Mouse Newborn Ovary eDNA Library 
Mus musculus cDNA clone L0240E1 2 3', mRNA sequence. 
Mm NIA 113 1 00G02 ESTs 
Mm_NJA_1130841-107 RIKEN cDNA 64305731123 gene 
Mm_N1AH3084G05 RIKEN eDNA D230034E10 gene 
Mm NIA 113 1 00B07 Forkhead box 01 
Mm_NIA_H3129F05 Syntaxin 3 
Mm_NIAH3 103C07 Icos ligand 
Mm NIA 113 103D04 Budding uninhibited by benzimidazoles 1 homolog, beta 
Mm_NIA_113 083B05 Neural-salient serine/arginine-rich 
MmNIAH3145G1 1 ESTs 
MmNIAH3 1 28B 12 
L0204B09-3 NIA Mouse Newborn Ovary cDNA Library 
Mus musculus cDNA clone L0204B09 3', mRNA sequence. 
Mm NIA 113 131 G07 ESTs 
MmNIAH3087F09 
113087F09-3 NIA Mouse 15K eDNA Clone Set Mus 
musculus eDNA clone H3087F09 3', mRNA sequence. 
Mm_NIA_F13131H09 Expressed sequence AW01 1752 
Mrn4IAH3083H03 ESTs 
Mrn_NIA_H3 126G12 RIKEN cDNA 25000011109 gene 
Mm_NIA_H3 128D12 
L0204F02-3 NIA Mouse Newborn Ovary cDNA Library 
Mus musculus cDNA clone L0204F02 3', niRNA sequence. 
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Mm_NIA_l-13147E1 I Mus musculus, clone IMAGE:4161424, mRNA 
Mm NIA 1-131 40B06 
L0242A05-3 NIA Mouse Newborn Ovary cDNA Library 
Mus musculus cDNA clone L0242A05 3', mRNA sequence. 
Mm_NIA_H3092G1 1 Limb region I 
Mm_NIA_H3139C11 Membrane-spanning 4-domains, subfamily A, member 6D 
Mm_NIA_H3083A05 DNA segment, Chr 5, ERATO Doi 605, expressed 
Mm_NIA_F13138Al2 RIKEN eDNA 1810019E15 gene 
Mm_NIA_l-13148D12 
L0267E10-3 NIA Mouse Newborn Ovary cDNA Library 
Mus musculus cDNA clone L0267E10 3', mRNA sequence. 
Mm_NIA_H3 11 5B02 
L0015AOI-3 NIA Mouse E12.5 Female Mesonephros and 
Gonads eDNA Library Mus musculus cDNA clone 
LO0 1 5A0 1 3', mRNA sequence. 
MniNIAH3 151 CO 1 Mitogen-activated protein kinase 8 interacting protein 3 
MmNIAH3 I 52F 12 
L028 I F06-3 NIA Mouse Newborn Ovary eDNA Library 
Mus musculus cDNA clone L028 1 F06 3', rnRNA sequence. 
Mm_NIA_F13 I 40D06 Zinc finger protein 106 
Mm_NIA_F130821-110 RIKEN cDNA 1700021P22 gene 
MmNIAH3 I 26B09 
H3126B09-3 NIA Mouse 15K cDNA Clone Set Mus 
musculus cDNA clone H3 I 26B09 3', mRNA sequence. 
MmNIA_H3 I 27C08 DnaJ (l-Isp4O) homolog, subfamily A, member 1 
MmNlAaaaaaM28723 Peroxiredoxin 3 
MmNIAI-13124B06 Brain cDNA 7 
MmNIA_hhhhhU49720 
Opsin I (cone pigments), short-wave-sensitive (color 
blindness, tritan) 
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MmNIAH3142GO3 DnaJ (Hsp4O) homolog, subfamily C, member 3 
Mm_NIA_H3 141G02 Eukaryotic translation initiation factor 4A2 
Mm_NIA_H3 109B12 RIKEN eDNA 5830484A20 gene 
Mm_NIA_H3099B07 Hypothetical protein A130042E20 
Mm_NIA_H3 1 48D06 
Inosine triphosphatase (nucleoside triphosphate 
pyrophosphatase) 
MmNIA_H3 11 7G02 ESTs 
Mm_NIA_H3082B01 Natural killer tumour recognition sequence 
Mm_NIA_H3 1 3 SF07 RIKEN cDNA 181003 8N08 gene 
MmNIAH3084BO5 ESTs 
Mm_NIA_H3 131 B07 Max dimerization protein 4 
Mm_NIA_H3084B03 T7 gp4-like protein with intramitochondrial nucleoid 
Mm_NL4,_H3 1 44F07 Purinergic receptor P2X, ligand-gated ion channel 4 
Mm_NIA_H3082B04 RIKEN eDNA E3300101122 gene 
MmNIAH3 1 03D06 ESTs 
MmNIAH3088HO8 ESTs 
Mm_NIA_H3 1 39C06 Mus musculus embryo cDNA, full- clone:3002006F 17 
Mm_NIA_H3087B04 Expressed sequence All 82287 
Mm_NIA_H3 I 55F07 RIKEN cDNA 281 0008M24 gene 
MrnNIA_H3083A06 RIKEN eDNA E330013PO4 gene 
MmNIAH3 1 04H07 ESTs 
Mm_NIA_H3135CO2 Lectin, galactose binding, soluble 7 
Mm_NIA_H3088A05 RIKEN eDNA A430079H05 gene 
Mm_NIA_113 103E09 Solute carrier family 37 (glycerol-3-phosphate transporter) 
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(b) List of genes less-likely to be downregulated by myostatin: 
Jdentjfler Gene description 
Inosine triphosphatase (nucleoside triphosphate 
Mm_NIAJ-13 I 48D06 pyrophosphatase) 
Mm_NIA_H3030E02 Pan hematopoietic expression 
Mm_NIA_l-13030E02 GABA(A) receptor-associated protein like 2 
Opsin I (cone pigments), short-wave-sensitive (color 
Mm_NIA_hhhhhU49720 blindness, tritan) 
Mus musculus 0 day neonate kidney eDNA, RIKEN full- 
length enriched library D630017N12 product, clone: 
hypothetical Zinc finger, C21-12 type containing protein, full 
Mm_NIA_U3001B03 insert sequence. 
Mus musculus 2 days neonate thymus thymic cells cDNA, 
RIKEN full-length enriched library, clone:E430020E1 9 
product: RODI homolog [Rattus norvegicus], full insert 
Mm_NIA_l-1300I B02 sequence. 
MmNIAH3002BU2; F13002B02-3 NIA Mouse 15K 
Mm_NIA_H3152F12 cDNA Clone Set eDNA 1­130021302 3', mRNA sequence. 
Mm_NIA_H300IBOI RILCEN cDNA 9430023L20 gene 
Mm_NIA_H3003A06 RIKEN cDNA 27000021,06 gene 
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(b) Table continued 	 . 
Jdentjfier Gene description 
Mm_NLA_H3007A01 RIKEN cDNA C920006C10 gene 
Mm_NTA_1430021305 RIKEN cDNA 94300651,19 gene 
Mm_NL&_1-130011301 RIKEN cDNA 94300231,20 gene 
Mm_NIA_H30061304 RIKEN cDNA 5730466P16 gene 
Mm_NIA_H3046A01 RIKEN cDNA 2210008F15 gene 
Mm_NIA_1-13 I 26G1 2 RIKEN eDNA 2500001 H09 gene 
Mm_NIA_1-130821304 RIKEN cDNA E330010H22 gene 
MmNIAFI300 1 A06 ESTs 
Mm NIA 1-13001 A06 ESTs 
MmNIAH3002AO2 ESTs 
MmNIAU30921309 ESTs 
Mm_NIA_I-130841305 ESTs 
Mm_NIA_H301 2G05 
DNA segment, Chr 13, Wayne State University 177, 
expressed 
Mm_NIA_l-13001 A03 
DNA 	 segment, 	 Chr 	 II, 	 Wayne 	 State 	 University 	 99, 
expressed 
+ No genes were detected to be upregulated in response to 10 ng mF' recombinant 
myostatin treatment, in the murine C2C12 skeletal muscle cell line. 
+ ESTs = Expressed sequence tags. 
105 
3.3 Discussion 
3.3.1 Myostatin was not detected in L6 myotubes 
In this study, myostatin mRNA was not detected in the L6 muscle cells using either 
RT-PCR or Northern blotting (figures 3.1-3.3). Therefore, it is likely that myostatin is 
not expressed in this cell line, at least at the point where the myotubes were harvested. 
However, this is contrary to a study where myostatin expression was shown to be 
present in myotubes, but not myoblasts (Artaza et aL, 2002). This discrepancy might 
be explained by the fact that this was in the murine C2C12 mouse cell line and not the 
L6 rat line that were used in the present study. Failure to detect myostatin is unlikely 
to be methodological error since several control experiments were performed to 
ensure this. For example, raw skeletal muscle extract was processed alongside L6 
samples and also used to 'spike' L6 cells to ensure that there was nothing within the 
culture sample responsible for inhibiting detection of myostatin. Therefore, it is also 
unlikely that probe, reverse transcription, or PCR failure could be responsible for the 
lack of detection since skeletal muscle extracts showed positive for myostatin mRNA 
with both RT-PCR and Northern blotting. It may also be possible that the level of 
myostatin was too low to detect, although magnification by RT-PCR is capable of 
detecting very small quantities of mRNA transcripts so this is unlikely. In addition, 
cells treated with dexamethasone, which is known to upregulate myostatin mRNA 
(Ma et aL, 2001), still failed to show detection of myostatin. When different rat 
skeletal muscles homogenised and assayed, the presence of myostatin mRNA was 
highest amongst predominantly fast muscles in agreement with another study which 
came later (Artaza et aL, 2002) associating myostatin localisation with type II MI-IC. 
Since the expression of myostatin is fibre-type specific, this may have some effect 
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upon how slow and fast muscles respond to exercise training. The failure to detect 
myostatin in the L6 cells leaves an unfortunate gap in information regarding the 
regulation of the myostatin gene, although this could not have been predicted prior to 
the initiation of this study. 
3.3.2 Myostatin inhibits phosphorytation of translation proteins 
Myostatin is a potent negative regulator of muscle mass and whilst it has been shown 
to inhibit protein synthesis, the signal transduction mediating this effect had not been 
previously identified. It had been reported that myostatin signals through the SMAD 
family of proteins, via binding activin II receptors (Zhu et aL, 2004). The present 
results (figure 3.4) support these findings in finding that SMAD2 phosphorylation 
increases in response to myostatin treatment, and it can therefore be assumed that 
recombinant myostatin bound to the receptor. A major pathway directing changes in 
protein synthesis is the insulinflGF (PI-3K-PKB-mTOR) pathway. The PI-3K-PKB-
mTOR pathway is known to be important in IGF- 1 mediated hypertrophy (Bodine et 
aL, 2001), and therefore the identified reduction in phosphorylation of signalling 
components within this cascade may explain how myostatin inhibits muscle growth, 
even in the presence of mitogenic factors. In response to mitogenic signals P1-3 K 
activation leads to the phosphorylation of PKB whose target is mTOR. mTOR, then 
directs increases in protein synthesis through phosphorylation of 4E-BP1 which 
increases the activity of eIF4E the translation elongation factor by releasing its 
inhibitory effect. Secondly, mTOR phosphorylates p70 S6K which targets the S6 
subunit of the ribosome to increase ribosome assembly. These processes act to 
increase cap-dependent/independent translation of multiple mRNA species, thus 
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increasing global protein synthesis (see section 1.7.4). The inhibition of PKB-mTOR-
p70 S6K signalling by myostatin is a possible means by which the negative effect of 
myostatin on protein synthesis could be explained. However, the exact mechanism 
remains to be elucidated, although may involve interactions of SMAD proteins with 
PKB or other downstream constituents of this pathway (Conery et aL, 2004). 
These findings on myostatin have important functional importance for both exercise 
and disease. If myostatin was suppressed in response to resistance training then this 
would reduce the inhibitory effect of myostatin upon the P1-3K pathway and thus 
increase IGF-IIMGF-induced hypertrophy. Conversely, if myostatin was to be 
upregulated during endurance training then this may be able to explain the atrophy 
associated with long term training regimes and the inhibition of protein synthesis 
observed in chronic aerobic exercise (Atherton et aL, 2005). In wasting states where 
myostatin is systemically increased, neutralisation of the protein in circulation would 
function by removing any inhibitory effect on growth though the P1-3K pathway. It 
remains to be seen if activating elements of this pathway, by IGF-1 for example, in 
these conditions could remove the inhibitory effect of myostatin. 
3.3.3 Myostatin microarrays - Myostatin inhibits transcription 
The first observation from these gene arrays is that no genes are upregulated but 
several genes appear to be downregulated. Thus, the first novel data of this study 
reveal that myostatin exerts its effects through inhibition of transcription. The most 
interesting genes related to growth regulation have been further investigated, whilst 
those that are lesser downregulated have been listed under section 3.2.5. 
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The first gene of interest is Mm_NIA_113002B04; CUG triplet repeat, RNA binding 
protein I (CUGBP1). The expression of CUGBP1 in muscle is average compared to 
other tissues according to GeneCard information obtained with Affymetrix 
microarrays in human tissues (Rebhan ci at, 1998). The protein is linked to myotonic 
dystrophy, a disorder among other associated with muscle wasting. Skeletal muscle 
cells from myotonic dystrophy patients fail to induce CUGBP1 while normal 
differentiated cells accumulate CUGBPI in the cytoplasm. Furthermore, patients with 
myotonic dystrophy, display a 70% reduction in expression of CUGPI compared with 
healthy individuals (Watanabe ci at, 2004). Alterations in the activity of CUGBP1 
causes disruption of p21-dependent control of cell cycle arrest (Timchenko ci at, 
2001). The down-regulation of CUGBPI by myostatin might therefore cause a 
CUGBP I -dependent cell proliferation defect. 
Another gene of interest is Mm_NIA_l-13029H07; myristoylated alanine rich protein 
kinase C substrate (MARCKS). The expression of MARCKS is low compared to 
other tissues according to GeneCard information obtained with Affymetrix 
microarrays in human tissues (Rebhan ci at, 1998). MARCKS has been implicated in 
the regulation of muscle function. In cultured skeletal muscle, MARCKS is a 
substrate for several PKC isoforms and a component of an integrin-related signalling 
pathways (Disatnik ci at, 2002). Integrins have been hypothesised to be possibly 
involved in mediating skeletal muscle hypertrophy (Carson & Wei, 2000), through 
detecting changes in mechanical stress (mechanotransduction). Therefore, a potential 
hypothesis is that the myostatin-induced down-regulation of MARCKS inhibits 
integrin signalling which might be linked to myostatin-induced atrophy through yet 
unknown mechanisms. 
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Another gene of potential interest is Mm_NIA_H3025C12; interleukin enhancer 
binding factor 3 (ILF3; NFAR-2). Expression of this gene in skeletal muscle is 
average compared to other tissues according to GeneCard information obtained with 
Affymetrix microarrays in human tissues (Rebhan ci aL, 1998). The protein was 
identified as a protein that could bind double stranded RNA and as a protein that was 
phosphorylated by the RNA protein kinase (P1(R) (Saunders et aL, 2001). In muscle 
cells, PKR has been shown to be capable of regulating myogenesis (Kronleld-Kinar el 
aL, 1999). A potential hypothesis is that myostatin downregulates ILF3 which then 
affects NCR-related myogenic reactions. 
The gene Mm_NIAaaaaaM28723; peroxiredoxin 3 (PRDX3) was also 
downregulated in response to myostatin. The finding that PRDX3 was down-
regulated in response to myostatin treatment is interesting because PRDX3 probes are 
printed as frequent control, "house keeping" probes on the A and B slide of the 
microarray. Expression data in the GeneCards database suggest a high expression in 
skeletal muscle compared to other tissues (Rebhan et aL, 1998). PR[)X3 is a 
mitochondrial thioredoxin peroxidase that uses mitochondrial thioredoxin-2 to 
scavenge hydrogen peroxide (1-1202). The basic reaction is: 
Substrate (oxidised) 	 Product (reduced) 
NADPH + H c thioredoxin reductase (TrxR) c3 NADP 
Trx-S2 	 Trx-(SH2) 
 :::~ 
Protein-(SH)2 	 Protein-S2 
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Low concentrations of 1 -1202 produced by the mitochondria regulate physiological 
processes, including cell proliferation, whilst high levels of H202 are toxic to the cell 
and cause apoptosis. PRDX3 was shown to be required for myc-mediated 
proliferation, transformation, and apoptosis after glucose withdrawal in non-muscle 
cells (Wonsey ci al., 2002). A down-regulation of PRDX3 by myostatin would thus 
suggest higher levels of H202 and make cells more susceptible to apoptosis (Nonn ci 
aL, 2003). However, the present data are not in agreement with the results of another 
study which indicated that there does not exist any myostatin-induced apoptosis in 
proliferating cells as shown by TUNEL assay and flow cytometric analysis (Thomas 
et aL, 2000). Conversely, in support of the current data, a recent study identified that 
the bcl-2 related anti-apoptotic protein (Nr-13) gene was upregulated -10- fold 
following recombinant myostatin treatment, and these authors also noted the 
occurrence of a DNA ladder in C202 cells treated with the recombinant myostatin 
for 72 It in differentiation medium (Yang ct al., 2005). Therefore, a hypothesis could 
be that myostatin induces apoptosis through a down-regulation of the anti-apoptotic 
factor Nr- 13 and PRDX3. 
Another gene downregulated by myostatin is Mm_NIA_H3004A02; nitrogen fixation 
cluster-like (NFU). Expression of this gene in skeletal muscle and heart is highest 
compared to other tissues according to GeneCard information obtained with 
Affymetrix microarrays in human tissues (Rebhan ci all, 1998). NFU is involved in 
the metabolism of iron-sulfur clusters that are co-factors in proteins with redox, 
catalytic, and regulatory functions. NFIJ mRNA splicing results in a mitochondrial 
and cytoplasmic isoform (Tong ci aL, 2003). A link to myostatin-dependent growth 
control can not be established at current, although this is a novel finding. 
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The next gene downregulated by myostatin was Mm_NIA_H308lA02; eukaryotic 
translation factor 4A2 (eIF4A2). Expression of this gene in skeletal muscle is highest 
compared to other tissues according to GeneCard information obtained with 
Affymetrix microarrays in human tissues (Rebhan et aL, 1998). Eukaryotic initiation 
factor 4A2 unwinds secondary and tertiary structures in the 5'-untranslated region of 
mRNA, permitting translation initiation (Zakowicz et aL, 2005). Therefore 
downregulation of this gene suggests that myostatin inhibits translation through 
negative regulation of eIF4A2 transcription. 
Another gene was Mm_NIA_H3 13 8F 12; syndecan-4, a positive regulator of satellite 
cell proliferation. Syndecan4 null muscle, explanted satellite cells are deficient in 
activation, proliferation, MyoD expression, myotube fusion, and differentiation. 
Furthermore, syndecan-4 (-I-) satellite cells fail to reconstitute damaged muscle, 
suggesting a unique requirement for syndecan4 in satellite cell fbnction (Comelison 
et aL, 2004). Therefore, downregulation of eIF4A2 suggests impaired proliferation of 
satellite cells, thus potentially inhibiting growth responses and tissue repair. 
3.3.4 Conclusion 
Reduced MPS in the presence of myostatin is mediated through diminished 
phosphorylation of growth signalling proteins. Microarrays showed that myostatin 
inhibits transcription of muscle regulating genes. However, verification of these data 
by sensitive molecular techniques (RT-PCR, Northerns) and more extensive studies in 
to the other genes identified to be downregulated in this study (p53; apoptosis, CDK4; 
cell cycle; EST's) are both necessary, but outside the scope of this thesis. 
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Chapter 4 
Phenotypic differences in signal 
transduction protein concentrations, and 
the effect of chronic stimulation: 
reguloble or 'housekeeping' proteins? 
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4.1 Introduction 
Chapter 3 examined the role of myostatin in controlling muscle mass, and it was 
suggested that myostatin mediates some of these effects through signalling pathways 
to alter both transcription and translation. Given the critical importance of signalling 
proteins in detecting stimuli and mediating many cellular responses, it followed on to 
dedicate a chapter to signal transduction proteins and their regulation. Signal 
transduction proteins are central in mediating physiological responses to 
environmental stimuli. Furthermore, their specific concentrations have important 
effects upon the magnitude of cellular responses to many stimuli, as laid out by 
metabolic control theory (Lion ci aL, 2004). Many groups have previously reported 
differences in levels of certain proteins and enzymes between different muscles and 
individual fibre types, and many contractile proteins and metabolic enzymes vary 
between 'fast' and 'slow' muscle fibres (Pette & Staron, 1990), and this can have 
much functional significance. Furthermore, muscle enzymes are under regulation by 
exercise and subject to change following chronic contractile activity. 
It was therefore decided to examine the concentrations of these proteins in order to 
link them with adative capabilities, and furthennore examine the regulation of 
signalling proteins, in order to better characterise their plasticity. For these studies, 
numerous proteins that have been implicated in mediating adaptive responses to 
exercise were assessed. Many signal transduction proteins have been previously 
shown to be contraction-responsive (Wackerhage & Woods, 2002) and to mediate a 
fast-to-slow phenotype conversion, mitochondrial biogenesis or skeletal muscle size 
regulation. The chosen proteins could be grouped in to the following categories: 
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Fibre type regulation: 
Calcineurin, the Ca 2 /calmodulin activated protein phosphatase that dephosphorylates 
and activates the nuclear factor of activated T cells (NFAT), which is a transcription 
factor. Inhibition of calcineurin signalling with cyclosporine A induces a faster 
phenotype in slow Soleus muscle (Chin ci at, 1998) and also prevents hypertrophy in 
response to increased muscle loading (Dunn ci at, 1999). Extracellular signal 
regulated kinase 1/2 (ERKI/2) are signalling proteins within a mitogen activated 
protein kinase (MAPK) pathway that are activated by contraction (Wretman ci at, 
2000). Activation of the ERKI/2 pathway in regenerating rat muscle has been shown 
to induce a slower phenotype (Murgia ci aL, 2000). 
Mitochondrial biogenesis: 
The AMP-activated kinase (AMPK) (Winder, 2001) which is activated by exercise 
and p38a43 which is a MAPK pathway protein that is activated by contraction 
(Wretman ci at, 2000). Both of which are implicated in signalling to induce 
nuclear/mitochondrial DNA (Puigserver ci at, 2001). The transcriptional co-factor 
PGC-la, which is known to be induced by AMPK (Terada ci aL, 2002; Zong ci at, 
2002) is also implicated in mitochondrial biogenesis and slow fibre regulation. 
Exercise responsive, yet precise function unknown: 
p38y/ERK6 is expressed at high levels in skeletal muscle (Lechner ci at, 1996) and 
has been linked to exercise activation, increasing 4- fold following a marathon run, 
and also having a role in glucose uptake (Ho ci aL, 2004). c-Jun NH2 kinase 
(SAPKIJNK) has been shown to be activated by mechanical stretch and so could have 
a role in adaptive responses to mechanical stress (Aronson ci at, 1997). 
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Growth: 
PKB is activated by IGF-1 and insulin and one of its main functions is the regulation 
of translation and muscle size (Broziniek, Jr. & Birnbaum, 1998). The p70 ribosomal 
protein So kinase (p70 S6K) which is the kinase that is a downstream substrate for 
PKB, (as is 4E-BP1 through mTOR) and mediates the increased translation of 
mRNAs with a 5' tract of pyrimidine sequences (TOP) (Proud et at, 2001). Glycogen 
synthase kinase 3I (GSK3) has been shown to negatively regulate skeletal muscle 
hypertrophy through phosphorylation of eIF2B (Rommel et at, 2001). 
Atrophy: 
NFicB signalling has been implicated in muscle atrophy due to cachexia (von 
Haehling et at, 2002). Myostatin is a potent inhibitor of muscle growth, signalling 
through SMAD proteins (McPherron ci' at, 1997). Increases in systemic myostatin 
cause cachexia (Zimmers ci' at, 2002) whilst myostatin knockout causes hypertrophy 
(McPherron ci' at, 1997). Myostatin mRNA decreases in response to strength training 
(Roth ci' at, 2003). NFicB is activated in response to exercise (ilollander ci at, 2000) 
and by pro-inflammatory cytokines (Li & Reid, 2000). 
Therefore the first specific aim of this study was to systematically determine the 
relative signalling protein concentrations between fast rat EDL and slow rat Soleus 
muscles using Western blotting, in order to ascertain if any differences exist which 
may specifically affect cellular responses in different muscle types. The second aim of 
this study was to examine whether signalling enzymes are in the class of regulable 
proteins, such as muscular enzymes which are extremely responsive to training, and 
which an adaptive change in concentrations leads to a change in metabolic capacity. 
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In order to do this, chronic in vivo electrical stimulation (CMNS), which leads to an 
incomplete fast-to-slow phenotype conversion (Salmons & Flenriksson, 1981), was 
applied for 6 wk to rat EDL. This was done in order to see whether a phenotype 
altering stimuli could modulate signalling protein concentrations, and to see if they 
were in the category of 'housekeeping' genes or are in fact regulable enzymes. If 
these signalling proteins were under regulation by contraction, then it would be 
interesting to examine whether CMNS, producing a fast-to-slow shift in the 
predominantly fast EDL, could bring the cellular concentrations of a control EDL 
compared with stimulated EDL to comparable ratios of a control EDL and control 
Soleus, as measured in the first study. 
The specific hypotheses of these studies being: 
1. Signalling proteins have different concentrations between muscles and that 
these differences would be predominantly dependent upon fibre type. 
2. CMNS of EDL muscle promotes a fast-to-slow phenotype shift which in turn 
will lead to changes in signal transduction protein concentrations between 
control EDL/Stimulated EDL to minor those those measured in control 
EDL/Soleus muscles, as in the first study. 
Methods 
As described in chapter 2. 
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4.2 Results 
4.2.1 EDL and Soleus ATPase staining 
Adenosine triphosphatase (ATPase) staining was performed in order to further verify 
muscle identification and show the higher proportion of type I fibres in EDL (figure 
4.1a) whilst the converse in slow Soleus (figure 4.1b). Dark staining indicates type lEa 
fibres, slight staining exposes type lib fibres, and the lightest staining type I fibres. 
(a) EDL muscle 
 
=50 pm 
(b) Soleus muscle 
 
=50 pm 
Figure 4.1. Cross-sectional images for ATPase activity using histochemical staining 
of the typically fast Extensor Digitorum Longus (a), and the predominantly slow 
Soleus (b). 1-listochemistry results were typical of 4 such experiments; calibrataion 
bars show 50 micrometres (pm). 
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4.2.2 CMNS induces phenotypic change in EDL 
During the 6 week period of chronic electrical stimulation (CMNS), visible and 
palpable oscillatory dorsiflexion was evident in all animals up to the point of harvest 
of the tissue. Stimulated EDLs had taken on a 'redder' appearance (figure 4.2) 
indicating increased myoglobin and angiogenesis, and had significantly lost -50 % in 
weight, stimulated EDLs weighing 94 ± 9 mg and the control EDLs which weighed 
181 ± 12 mg (n= 4, p= 0.001). Whilst no evidence for a change in myosin heavy chain 
was assessed with more sensitive assays such as MHC immunoblotting, these factors 
demonstrate the efficacy of CMINS in producing a profound phenotypic change. 
Control EDL 
Stimulated EDL 
= 10mm 
Figure 4.2. Control EDL (upper) and CMNS stimulated contralateral EDL (lower). 
Note how the stimulated EDL had a deeper red colouring and displayed a reduction in 
weight when compared to contralateral controls. This information provides evidence 
demonstrating profound phenotypic following CMNS. These results are typical of 4 
such experiments. Calibration bar indicates 10 millimetres (mm); meaurement 
excludes tendons. 
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Following CMINS, mitochondrial density, as indicated by staining for NADFI 
tetrazolium reductase activity (NADH-Tr) was assessed. Staining is more pronounced 
in the stimulated EDL (figure 4.3b) than in control EDL (figure 4.3a), suggesting a 
greater mitochondrial density and oxidative capacity. 
(a) Control EDL 
_____ = 50 jim 
(b) Stimulated EDL 
=50 jim 
Figure 4.3. Magnified images of NADH-Tr mitochondrial stains of unstimulated EDL 
(a) and stimulated EDL (b). The darker staining is a correlative indicator of denser 
mitochondria and oxidative enzymes. Histochemistry results were typical of 4 such 
experiments; ealibrataion bars show 50 micrometres (jim). 
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4.2.3 Concentrations of signalling proteins in rat EDL and Soleus and 
following 6 weeks of CMNS of EDL 
These results show that the concentrations of signal transduction proteins in Soleus 
and EDL are systematically different between the 4 animals studied (figures 4.4 - 
4.14). The mitogen activated protein kinases (MAPK) pathways (JNK, p38, ERKI/2) 
are present in different concentrations between the phenotypes and do not follow an 
orderly pattern. Growth and control of translation pathway proteins are all higher in 
EDL (except GSK3I3), as is the negative regulator of skeletal muscle mass, myostatin. 
However, the cachexia- mediating NFiB is higher in slow Soleus. 
Chronic electrical stimulation of EDL muscle, a stimulus promoting a fast-slow 
transformation, did not consistently bring the concentration levels of signalling 
proteins measured to parallel that of slow Soleus muscle. Those proteins in 
EDL/stimulated EDL that significantly changed concentrations to reflect expression 
levels equivalent to control EDL/Soleus consisted of: p70 56K, 4E-BPI, PGC-lci, 
calcineurin, ERK1/2 and NFiB. Conversely, the following proteins when stimulated 
reflected a concentration shift not of EDL/stimulated EDL being similar to 
EDL/soleus, but in fact moving away from the expected direction: calcineurin, PKB, 
GSK3f3, AMPK, p54 iNK, myostatin and SMAD2/3. Other proteins such as 
p387IERK6, p38ct13 and p46 iNK were not significantly altered by stimulation. 
Selective protein turnover as denoted by ubiquitination patterns of proteins was also 
apparently under altered regulation following the 6 weeks of CMNS. Therefore 
changes in protein concentrations do not follow a set programme, even in the case of 
sub-groups such as growth or phenotype controlling proteins. 
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Proteins implicated in fibre type regulation: The relative calcineurin intensity was 
2.6-fold higher in the EDL than in the Soleus, whereas it was decreased to 0.7 of 
control in response to stimulation. ERKI and ERK2 were both higher in all Soleus 
compared to EDL 1.8 and 1.6-fold, respectively. Stimulation increased ERKI and 
ERK2 protein concentrations by 1.7 and 3.6-fold respectively, moving them in the 
direction of slow Soteus (figures 4.4 & 4.5). 
Protein 
- p Calcineunn 
EDL Sol EDL 5o1 EDL Sol EDL Sot 
See figure 4.5a _. 
 - 
 
---- 
CS CS CS CS 
I  
ERK1/2 	 I 
EDL Sol EDL Sot EDL Sot EDL Sol 
See figure 4.5b,c 	 - - - 
C SC SC SC S 
A1' 	 A2 	 A3 	 A4 
Figure 4.4 Immunoblots showing protein levels of Calcineurin and ERKI /2 in control 
EDL and Soleus muscles and chronically stimulated rat EDL (5) and control EDL (C) 
in four animals. Lanes 1-2, 3-4, 5-6, 7-8 correspond to one animal each. ' A1-A4 
Animals 1-4 (n4). See figure 4.5 for representative bar charts. 
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Proteins implicated in mitochondrial biogenesis: The Soleus has a 1.2-fold higher 
AMPK concentration, whereas there was a decrease in AMPK to 0.7 of control EDL 
in response to stimulation. Whereas, p38a43 protein levels are 1.4-fold higher in EDL, 
and when stimulated protein levels reduce non-significantly to 0.9 of control EDL. 
PGC-la has a 1.4-fold higher concentration in Soleus, and in stimulated EDL 
increases 2.3-fold (figures 4.6 & 4.7). 
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Figure 4.6 Immunob!ots showing protein levels of AMPK, p38 aj3 and PGC-la in 
control EDL and Soleus muscles and chronically stimulated rat EDL (S) and control 
EDL (C) in four animals. Lanes 1-2, 3-4, 5-6, 7-8 correspond to one anima! each. ' 
A1-A4 Animals 1-4 (n=4). See figure 4.7 for representative bar charts. 
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Figure 4.7. Bar charts showing the change in relative concentrations of(a) AMPK, (b) 
p38 a43 and (c) PGC-la in rat EDL and Soleus muscles and in response to CMNS. 
Results are means ±SE arbitrary densitometric units (n=4) * p<0.05. 
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Proteins implicated in adaptation to contractile activity and expressed at high levels 
in skeletal muscle (GenCard information), yet precise function unknown: There is a 
lesser concentration of p38yJERK6 in EDL and this is further reduced in response to 
stimulation, although there are no significant changes (figure 4.8 & 4.9). In contrast, 
p54 JNK is 3-1 -fold higher in EDL, but then increases 2.8-fold in response to 
stimulation; whereas p46 iNK is 5-fold higher in Soleus and not significantly changed 
following stimulation. 
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Figure 4.8 Immunoblots showing protein levels of p387/ERK6, p54 JNK (upper band) 
and p46 JNK (lower band) in control EDL and Soleus muscles and chronically 
stimulated rat EDL (5) and control EDL (C) in four animals. Lanes 1-2, 3-4, 5-6, 7-8 
correspond to one animal each. Al-A4 Animals 1-4 (n=4). See figure 4.9 for 
representative bar charts. 
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Figure 4.9. Bar charts showing the change in relative concentrations of (a) p38y, (b) 
p54 iNK and (c) p46 iNK in rat EDL and Soleus muscles and in response to CMNS. 
Results are means ±SE arbitrary densitometric units (n=4) * p<0.05. 
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IGF- I and insulin-dependent translational and carbohydrate metabolism regulation: 
Growth mediating pathways do not respond uniformly. The EDL has a 1.4-fold higher 
concentration of PKB than Soleus, and there is a 1.6-fold increase in PKB protein 
level with stimulation of the EDL. 4E-BP1 and p70 56K are 5.4 and 6.9-fold higher in 
EDL, and stimulation leads to a decrease in concentrations to 0.12 and 0.4 of control 
EDL, respectively. GSK30, originally I .4-fold higher in Soleus, is reduced in this 
direction in response to stimulation, although not significantly (figures 4.10 & 4.11). 
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Figure 4.10. Immunoblots showing protein levels of PKB, p70  S6K, 4E-BP1 and 
GSK3I3 in control EDL and Soleus muscles and chronically stimulated rat EDL (5) 
and control EDL (C) in four animals. Lanes 1-2, 3-4, 5-6, 7-8 correspond to one 
animal each. 'A1-A4 Animals 14 (n=4). See figure 4.11 for representative bar charts. 
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Figure 4.11. Bar charts showing the change in relative concentrations of (a) PKB, (b) 
p70 S6K, (c) multiple isoforms of 4E-BPI (aji,y) and (d) GSK3I3 in rat EDL and 
Soleus muscles and in response to CMNS. Results are means ±SE arbitrary 
densitometric units (n=4) * 
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Proteins implicated in mediating atrophy: The NFICB concentration is 3-fold higher in 
Soleus, and stimulation leads to a shift in this direction, increasing 5.1-fold in 
stimulated EDL. Myostatin is 2-fold higher in EDL and stimulation leads to a 2.9-fold 
increase in myostatin concentration. SMAD2 is I .6-fold higher in EDL and 
stimulation increases SMAD2/3 concentration by 2.7-fold (figures 4.12 & 4.13). 
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Figure 4.12 Immunoblots showing protein levels of NFiB, Myostatin and SMAD2/3 
in control EDL and Soleus muscles and chronically stimulated rat EDL (5) and 
control EDL (C) in four animals. Lanes 1-2, 3-4, 5-6, 7-8 correspond to one animal 
each. Al -A4 Animals 1-4 (n=4). See figure 4.13 for representative bar charts. 
131 
(b) Myostatin 
6 
C 
3 
cr,2.5 
C 
0 
I- 
< 0.5 
0 
EDL 	 SOL Control EDL 	 Stimulated EDL 
(c) SMAD2/(3) 
5 
.g4 
C 
0 3 
(5 
'-24  
.0 
0 
1.5 
C 
01.5 
(5 
I- 
a 
0 
EDL 	 SOL Control EDL 	 Stimulated EDL 
(a) NFiB 
3 
2.5 
2 
Lz 
€ 1 
0.5 
0 
E 5 
0 
c5 
I- 
-I 
< 1 
0 
* 
 
EDL 	 SQL 
 
Control EDL 	 Stimulated EDL 
Figure 4.13. Bar charts showing the change in relative concentrations of(a) NFB, (b) 
myostatin and (c) SMAD2/3 in rat EDL and Soleus muscles and in response to 
CMNS. Results are means ±SE arbitrary densitometric units (n4) * p<0.05. 
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Proteins involved in mediating protein breakdown: Note the different pattern of 
ubiquitination of proteins following 6 weeks of chronic electrical stimulation. 
Ubiquitintation indicates the 'tagging' of protein for subsequent degradation by the 
proteasorne. There is specific increased ubiquitination around the 10-35 kDa and 75 
kDa areas (figure 4.14). This is not a quantitative assay and would require proteomic 
analysis to pinpoint the nature of these findings. Furthermore this form of 
electrophoresis is limited to proteins of C 200 KDa in mass, and therefore cannot 
divulge the total range of ubiquitination following CMNS of EDL. 
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Figure 4.14. lmmunoblot of ubiquitinated protein in chronically stimulated rat EDL 
(5) and control EDL (C) in four animals. Approximate protein sizes in KDa are 
marked in red around —75 KDa and —10-35 KDa and appear to show areas of altered 
protein turnover following CMNS, as depicted by increased ubiquitination. Lanes 1-2, 
3-4, 5-6, 7-8 correspond to one animal each. 1 Al-A4 Animals 1-4, (n=4). 
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4.3 Discussion 
Following CMNS, the EDL changed in both size and phenotype as is evident from the 
greater NADH-Tr activity in stimulated EDL, and the —50 % reduction in weight of 
the stimulated muscle. This phenotypic change is further evident from the redder 
appearance of the stimulated EDL, indicating increased myoglobin content (figure 
4.2). However, since no biochemical enzyme or MHC characteristics were assessed, it 
cannot be confirmed as to the level of fast-to-slow transition. Nevertheless, after 6 
weeks of CMNS, the fast-to-slow transformation is reportedly well advanced (Jarvis 
et aL, 1996). The current results show differences between the fast EDL and slow 
Soleus muscles in the relative protein concentrations of most signal transduction 
proteins measured. This is likely to reflect different signal transduction protein 
concentrations in type I and type II fibres given the relative predominance of fibre 
types in both EDL and Soleus. Furthermore, chronic electrical stimulation changed 
signalling enzyme concentrations. It should be noted here that although total protein 
change may be significant to the output of a pathway, the specific activity of these 
kinases have not been measured. Therefore, it remains unknown as to the ultimate 
significance of these data, although amplification of a set of signals is theoretically 
limited by the total amount of protein present as laid down in metabolic control theory 
(Lion et all, 2004). The discussion therefore assumes that the change in signalling 
protein levels will have an effect upon the output of a pathway although the 
limitations of this assumption not incorporating specific activities are understood. 
Nevertheless, it is suggested that the changes in protein concentrations will result in a 
different sensitivity of the fast-to-slow transformed muscle for signals that occur 
during exercise but also to insulin and growth signalling. 
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43.1 Fibre type regulating MAPK proteins, p38y  and JNK 
Of the two pathways that have been suggested to promote a slow phenotype, 
calcineurin is expressed at higher levels in fast EDL whereas ERK1 and ERK2 are 
both expressed at higher levels in the slow Soleus muscle (figures 4.4 & 4.5). These 
results are supported by a paper reporting higher levels of calcineurin in Vastus 
Lateralis (intermediate) and plantaris (fast) versus Soleus (slow) rat muscle 
(Spangenburg ci aL, 2001), suggesting that a high calcineurin concentration is related 
to a high percentage of fast fibres. In contrast to this study, higher ERKI and ERK2 
concentrations were reported in rat EDLA compared to Soleus (Wretman et aL, 2000). 
The fact that ERK1/2 increases in response to stimulation of EDL suggests a necessity 
for increased signalling through this pathway, and this makes sense since ERKI/2 is 
implicated in control of phenotype and transcriptional responses (1-ligginson et aL, 
2002). Interestingly, there is a reduction in calcineurin following stimulation which 
may be a negative feedback effect to the changed programme of gene expression. 
Systematic differences were not observed in the p387IERK6 concentration between 
EDL and Soleus muscle, and there was only a non-significant effect of stimulation on 
relative concentrations. Also, whilst p54 JNK is higher in EDL, p46 JNK is higher in 
Soleus. In addition, only p54 iNK responded to stimulation and increased in 
concentration (figures 4.8 & 4.9). The reasons for these discrepancies are not known. 
4.3.2 Proteins implicated in mitochondrial biogenesis 
Exercise has been shown to activate p38cz43 in skeletal muscle (Somwar ci aL, 2000) 
and TNFa-regulated p38 has been shown to induce mitochondrial biogenesis 
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(Puigserver ct aL, 2001). Therefore, contraction-induced p38 activation may have a 
greater magnification of response in fast EDL rather than slow Soleus muscle due to 
the 1.4-fold higher concentration. AMPK was present at a reduced level in EDL, 
perhaps suggesting that there is a reduced sensitivity to AMPK-induced mitochondrial 
biogenesis in fast EDL. Chronic electrical stimulation significantly (p<0.05) 
decreased the AMPK level to 0.7 of control EDL and the p38cxJI3 level 0.9 (not 
significant) of the one measured in the control EDL, respectively. Both AMPK and 
p38 a/P are activated by contraction and mediate mitochondrial biogenesis probably 
via induction and phosphorylation of PGC-lct (Zong ci aL, 2002; Puigserver ci aL, 
2001). The decreases in levels of AMPK and p38 &f3 (figures 4.6 & 4.7) are 
unanticipated because CMNS leads to a large increase in mitochondrial biogenesis 
and content, as is evident by large increases in mitochondrial enzyme activities (Chi ci 
aL, 1986; Henriksson ci aL, 1986). The decrease in AMPK and p38 can possibly be 
interpreted as negative feedback effect, meaning that once the cell has adapted to the 
stimulus, the level of proteins mediating this effect are downregulated. Calcineurin, 
which decreased 0.7 in response to chronic electrical stimulation, has also been 
related to PGC-lct-induced mitochondrial biogenesis (Lin ci aL, 2002). Therefore, 
this might be another example of negative feedback, or possibly exhibits that 
calcineurin is not as important in mediating progression to slower fibre typing with 
chronic contractile activity. 
4.3.3 IGF-1 signalling and regulation of growth 
The P1-3K-PKB-AKT pathway has recently been shown to mediate IGF-1 induced 
hypertrophy through activation of translational regulators (Bodine ci aL, 2001; 
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Pallafacchina et aL, 2002). In this pathway, GSK30 has been shown to be a negative 
regulator skeletal muscle hypertrophy (Rommel et aL, 2001; Vyas et aL, 2002). The 
finding that, PKB/AKT and p70 S6K are 1.4-fold and 6.9-fold higher, respectively, 
and GSK3D I .4-fold lower in fast EDL compared to slow Soleus suggests that fibres 
with a faster phenotype should respond more robustly to IGF-1 (figures 4.10 & 4.11). 
Therefore, individuals with a higher percentage of fast fibres might therefore respond 
more to given IGF-1 concentrations than those with a low percentage of fast fibres 
(Costill et aL, 1976). In these experiments proteins belonging to the PKB pathway 
were expressed at higher levels in EDL than in Soleus with the exception of GSK3I3, 
which is an inhibitor of muscle hypertrophy (Vyas et aL, 2002). Thus, a given IGF-1 
or insulin concentration would activate translation and protein synthesis more in fast 
than in slow fibres. It is therefore hypothesised that the expression pattern of the 
proteins belonging to this pathway might partially explain the larger diameter of type 
II fibres compared to type I fibres. In addition, the higher expression of PKB and 
lower expression of GSK3I3 in rat EDL might partially explain the increased insulin-
stimulated glucose uptake compared to rat Soleus (Shoji, 1988). Chronic electrical 
stimulation led to a decrease in EDL mass and this is consistent with the decrease in 
p70 56K and 4E-BPI to 0.4 and 0.12 respectively, of control EDL that has also been 
measured in this study. However, PKB increased and GSK3D decreased which is 
surprising because a change in the other direction would be expected judging from the 
Soleus and EDL levels of these proteins. The significant (p<0.05) 1.6-fold increase in 
PKB and slight decrease of GSK3[3 to 0.9 of the control EDL might be related to the 
role of these proteins in insulin signalling (Cross et aL, 1995) and could be a partial 
explanation for the increased insulin-stimulated glucose uptake that is observed in 
trained rat skeletal muscle (James et aL, 1985). 
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4.3.4 Atrophy signalling 
Myostatin is a negative muscle growth factor (McPherron et aL, 1997) and increases 
in systemic myostatin induce cachexia (Zimmers et aL, 2002). Myostatin rnRNA has 
also been shown to be correlated with myosin heavy chain isoform lIb expression in 
normal muscle (Carlson et aL, 1999), and the 2-fold higher myostatin protein levels in 
EDL compared to Soleus support this hypothesis. Myostatin levels also increase 2.9-
fold in response to stimulation (figures 4.12 & 4.13). This is indicative of its role as a 
negative regulator of muscle mass, since increased myostatin levels lead to muscle 
wasting (McPherron et aL, 1997; Zimmers et aL, 2002). Myostatin signals via 
SMAD2 and SMAD3 (Langley et aL, 2002; Bogdanovich et aL, 2002). Electrical 
stimulation caused an increase of 2.7-fold for SMAD2/3, making the muscle more 
sensitive to myostatin-induced atrophy. Since chronic stimulation leads to a -50 % 
loss of muscle weight, perhaps myostatin increases might at least partially explain this 
phenomenon. Myostatin-signalling could also be responsible for increasing the rate of 
proteolysis, although this hypothesis awaits testing. 
NFKB has been shown to be activated by exercise (Hollander et aL, 2001) and is also 
implicated in mediating TNFa-induced cachexia (Li & Reid, 2000). The 3-fold higher 
NFiB in slow Soleus than EDL might therefore mean that a slow muscle is more 
susceptible to NFcB-dependent cachexia. Similarly, NFiB which is activated by 
contraction (Hollander et aL, 2001) and has been shown to induce muscle atrophy due 
to cachexia (Guttridge et aL, 1999; Guttridge et aL, 2000), was increased 5.1-fold in 
stimulated EDL compared to control EDL. The strong induction of these atrophy-
signalling proteins in stimulated muscle could be a partial explanation for the drop in 
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muscle mass from 181 ± 12 mg in the control EDL to 94 ± 9 mg in the stimulated 
EDL. Similarly, the higher levels of these proteins in Soleus compared to EDL could 
be an explanation for the smaller size of type I fibres compared to type 11 fibre 
subtypes. 
Finally, chronic electrical stimulation led to a different ubiquitination of proteins in 
stimulated EDL (figure 4.14), therefore showing a change in patterns of protein 
breakdown following CMNS. It is not possible to comment upon the nature of this 
change without further proteomic analysis, although it provides some evidence that 
selective protein turnover is present following CMNS. 
4.3.5 Conclusion 
In conclusion, signal transduction proteins do belong to the class of proteins whose 
èoncentrations vary between slow and fast skeletal muscles, and this is likely to 
reflect differences on a fibre level. In addition, signal transduction proteins that 
promote particular flmctions such as muscle growth or slow phenotype formation are 
not necessarily expressed at higher levels in fibre phenotypes that have that particular 
trait. When chronic stimulation is applied, the levels of signal transduction proteins in 
EDL do not always parallel those seen in the Soleus. The fact that most signal 
transduction pathway proteins were shown to be regulable in muscle implies that 
contraction-activated pathways set the levels of these signal transduction proteins. 
Because of this, animals and possibly humans with differences in their fibre type 
composition are likely to vary in their response to training or insulin because of 
differences in muscular signal transduction protein concentrations. 
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Chapter 5 
The effect of CMNS upon chronic 
signalling and the effects of endurance 
and resistance-like electrical stimulation 
on acute signalling in skeletal muscle: a 
molecular explanation for the specificity 
of physiological responses to training? 
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5.1 Introduction 
Chapter 4 identified the regulation of signal transduction proteins in distinct muscle 
types and in response to CMINS. This chapter focuses upon the specificity of the 
activation of these proteins in response to different modes of contractile activity. 
5.1.1 Signalling involved in responses to CMNS 
As discussed in chapter 1, the mechanisms of adaptation to exercise involve the 
modulation of cellular signalling in response to signals produced by physical activity. 
Thus a major question in exercise physiology is: how does muscle adapt to chronic 
exercise training in the long-term and maintain this state of phenotype? To answer 
this question, the CMNS model was adopted once more, but this time the primary 
intent was to characterise the signal transduction pathways that are activated after 6 
wk CMNS in rat skeletal muscle, through looking at the phosphorylation status of 
contraction responsive proteins. After 6 wk of CMNS, the fast-to-slow transformation 
is well advanced (Jarvis et aL, 1996) and thus the signalling is largely 'maintenance'. 
The aim was thus to characterise the signal transduction pathways that are activated 
by the chronic 10 Hz electrical stimulation in order to identifS' those pathways whose 
ongoing signalling is likely to be responsible for maintaining the changed phenotype, 
and moreover, can explain the characterised physiological adaptations. The signalling 
proteins chosen were examined by Western blotting with phospho-specific antibodies. 
Each protein has been implicated in fast-to-slow phenotype shift or implicated in 
atrophy (since the muscle loses 50 % mass following 6 weeks of CMNS). They 
consisted of the AMP-activated kinase (AMPK) (Winder, 2001), calcineurin (Kubis ci 
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aL, 2002), extracellular regulated kinase 1 and 2 (ERKI/2) (Wretman ci at, 2001), 
p38 MAP kinase (p38a113) (Lee ci at, 2002), c-Jun NH2 kinase (iNK) (Aronson ci at, 
1997), myostatin-"mothers against decapentaplegic homologue" (SMAD) signalling 
(Roth ci at, 2003) and upstream binding factor (IJBF). The role of all these proteins, 
have been discussed previously, apart from UBF which is a protein controlling 
transcription of ribosomal RNA (rRNA), and was examined since it had been 
suggested there is increased RNA content following CMNS. Examination of the 
phosphorylation of these proteins would give an indication of the chronic signalling 
which leads to the phenotypic change in response to endurance type exercise, and 
expand the total protein concentration data in chapter 3 to give a full picture of the 
cellular responses of signalling proteins to chronic contractile activity with CMNS. 
5.1.2 Signalling controlling response to growth or phenotype changes 
Once the chronic signalling involved in changing muscle phenotype is established, a 
second major question in the field of molecular exercise physiology is: what are the 
acute signals controlling these long-term adaptations, and how do they differ between 
endurance and resistance training to produce such distinct physiological adaptations? 
Endurance training and chronic electrical low-frequency stimulation promote 
mitochondrial biogenesis, a fast-to-slow muscle fibre phenotype transformation and 
weight loss (Salmons & Flenriksson, 1981; Kubukeli ci at, 2002). In contrast strength 
training promotes hypertrophy due to the stimulation of protein synthesis (Tipton & 
Wolfe, 2001). These differences between resistance and endurance training 
adaptations suggest that different forms of contractile activity can induce unique 
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signalling responses. For example, since skeletal muscle contraction and the set of 
signals associated with it (i.e. increased tension, [Ca 2 ], energy turnover, nutrient 
usage, energy stress, free radicals) are similar, the adaptations are clearly not. 
Therefore, the aim of this study was to examine whether critical signals activate signal 
transduction pathways to different extents and with specificity in response to 
resistance training-like electrical stimulation and endurance training-like stimulation. 
In order to identify the mechanisms which lead to contrasting physiological 
adaptations to growth versus fast-to-slow phenotype shift, an in vitro isolated muscle 
system was used. Protocols of either 3 h of continuous 10 F[z-frequency electrical 
stimulation to mimic endurance training (LFS), or an intermittent 100 Hz protocol 
(14FS) to mimic resistance training were adopted. Such stimulation patterns were 
shown to induce the known endurance (fast-to-slow phenotype shift) and resistance 
training (hypertrophy) like adaptations at least in fast skeletal muscles in vivo (Nader 
& Esser, 2001). This system had the added benefit of being free of any systemic and 
nutrient effects (especially amino acids), which may have been seen if this was 
performed in vivo. In order to add a further dimension to this study, stimulation 
protocols were applied to both 'fast' extensor digitorum longus, (EDL) and 'slow' 
Soleus isolated rat muscles (Ariano et aL, 1973) in order to also see whether the 
response to specific LFS and HFS stimulations depends on the muscle phenotype. 
The list of signalling proteins examined by Western blotting in this second study was 
extended from those examined following CMNS in order to incorporate hypertrophic 
proteins and to provide a comprehensive set of contrasting signals to both HFS and 
LFS protocols. The additional proteins examined for their individual phosphoiylation 
status were: protein kinase B (PKB), which is a key mediator of growth responses 
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thorough the P-13K pathway; tuberin (TSC2) which is a protein downstream of PKB 
involved in control of growth through modification of mTOR activity; mammalian 
target of rapamycin (mTOR) the protein responsive to amino acids, PKB and AMPK 
signalling; p70 ribosomal S6 kinase (p70 S6K) and 4E-binding protein 1 (4E-BPI) 
both downstream controllers of translational initiation; glycogen synthase kinase 33 
(GSK-3[3), which is downstream of P1KB; eukaryotic initiation factor 2B (eIF2B) 
phosphorylated by GSK3I3 and controls translational initiation; eukaryotic elongation 
factor 2 (eEF2) which controls peptide elongation, and the concentration of the 
transcriptional co-factor peroxisome proliferator activated receptor gamma 
coactivator-lct (PGC-l(x) implicated in slow fibre phenotype and mitochondrial 
biogenesis. 
The specific hypotheses of these studies being: 
I. CMNS can induce chronic signalling of those pathways controlling 
phenotypic change, such as AMPK, ERKI/2 and will cause increased 
activation of atrophy related signals such as SMAD2/3. Specific activation of 
such proteins can explain known physiological adaptations. 
2. FIFS and LFS models will lead to the selective activation of signalling 
pathways which can explain the known physiological responses. 
Methods 
As described in chapter 2. CMNS stimulation parameters were reported in chapter 4. 
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5.2 Results 
5.2.1 CNINS induces chronic signalling of many proteins 
Phosphorylated AMPK (Thr172) was —4-fold higher in the stimulated EDL compared 
to the contralateral EDL, suggesting a marked activation of the AMPK pathway 
(figures 5.1 & 5.2). For all MAPK proteins, phosphorylation changed with CMNS. 
p38aJ (Thri 80/Tyrl 82) phosphorylation was 4.5-fold higher than control thus 
suggesting mitochondrial biogenesis signalling. ERIC 1 and ERK 2 (Thr202/Tyr204) 
phosphorylation were increased 6.3 and 2.7-fold, respectively in response to CMNS 
suggesting the importance of this protein in the control of fibre type. 
Protein 
Phospho-AMPK 
(Thr172; figure 5.2a) 
Phospho-p38 
(Thrl8O/Tyr182; figure 5.2b) 
Phospho-ERKI/2 	
- 	 p ___ 
(Thr 202/Tyr204; figure 5.2c,d) 
CS CS CS CS 
A1' 	 A2 	 A3 	 A4 
Figure 5.1. Immunoblots of proteins implicated in control of fibre type and 
mitochondrial biogenesis. Phospho-AMPK ThrI 72, phospho-p38 Thri 80/Tyr 182, 
phospho-ERK1/2 Thr202/Tyr204 in rat EDL. C= Contralateral control EDL, S= After 
chronic electrical stimulation with 10 Hz for 6 wk. Lanes 1-2, 3-4, 5-6, 7-8 
correspond to one animal each. Al -A4 Animals 1-4 (n'4). 
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Figure 5.2. Bar charts showing the phosphorylation of fibre type and mitochondrial 
biogenesis regulating proteins in response to 6 weeks CMNS of rat EDL. (a) AMPK 
ThrI 72, (b) p38 MAPK ThrI 8OITyrl 82, (c) ERK1 Thr202/Tyr204 and (d) ERK2 
Thr2021l'yr204 in control EDL and chronically stimulated rat EDL. Results are means 
±SE arbitrary densitometric units (n4) * p<0.05. 
The phosphorylation of p54 INK (Thri 83ITyrl 85) was -2-fold higher following 
CMINS, suggesting that this protein has a role in adaptation. The phosphorylation of 
the signalling intermediaries of myostatin, SMAD2/3 (Ser433/435) increased by -2.5-
fold in response to stimulation compared to control. In attempt to find an explanation 
for the increased ribosome biogenesis that takes place during CMINS (Cummins & 
Salmons, 1999) the phosphorylation of UBF, which is known to regulate the 
transcription of ribosomal RNA, was also measured. UBF (Ser637) phosphorylation 
was reduced to 0.7 of control EDL in the stimulated EDL. 
Protein 
Phospho-p54 JNK  
(Thr183/Tyr 185; figure 5.4a) 
Phospho-UBF 	 r n czs a r re 
(Ser637; figure 5.4b) 
Phospho-SMAD2/3 	 p.--- 	 - - - 
(5er433/435; figure 5.4c,d) 
CS CS CS CS 
Al" 	 A2 	 A3 	 A4 
Figure 5.3. Immunoblots of atrophy, growth and mechanotransduction-linked proteins 
in response to 6 weeks of CMNS in EDL. Phospho-JNK p54 Thr183/Tyr185, 
phospho-SMAD2/3 Ser433/435 and phospho-UBF Ser637 in rat EDL. C= 
Contralateral control EDL, S= After chronic electrical stimulation with 10 Hz for 6 
weeks. Lanes 1-2, 3-4, 5-6, 7-8 correspond to one animal each. A1-A4 Animals 1-4 
(n4). 
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Figure 5.4. Bar charts showing phosphorylation of atrophy, growth and 
mechanotransduction-linked proteins in response to 6 weeks of CMNS in EDL. (a) 
p54 JNK Thrl83Il'yr185, (b) UBF Ser637, (c) SMAD2 Ser433/435 and (d) SMAD3 
Ser 433/435 and in control EDL and chronically stimulated rat EDL. Results are 
means ±SE arbitrary densitometric units (n=4) * pc0.05. 
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5.2.2 In vitro IIFS and LFS stimulation induces selective signalling 
5.2.2.1 Tension developed during in vitro LFS and HIFS stimulation 
The stimulation protocols differed significantly (pc0.01) in tension generated in 
response to the two types of stimulation. EDL and Soleus generated a tension of 5.3 ± 
0.4 mN and 4.6 ± 0.4 mN, respectively, during the first 3 s-burst of the HFS protocol 
which significantly decreased to 3.7 ± 0.3 mN and 4.0 ± 0.3 mN, respectively, during 
the last (60th)  burst. During LFS, force stabilised in the EDL and Soleus at 2.3 ± 0.2 
mN and 2.2 ± 0.2 mN after 30 s of stimulation and the force decreased significantly to 
1.6 ± 0.2 mN and 2.0 ± 0.2 after 3 h of stimulation (figure 5.5). The tension generated 
during the LFS protocol was significantly lower than in the HFS (all n8, pc0.05). 
HFS 
Ft 
] 
lOs 
-, 
 
_____ 	 3aw#MnflaaflaM 
RON 
F lSOs 
2mN 
Figure 5.5. Chart recordings of stimulation traces in EDL. HFS showing 3 sets of the 
6 repetitions (top) and LFS showing 90 min of the 3 h protocol (lower). The tension 
generated was >2-fold higher in the HFS protocol. Calibration bars show (F) force in 
mN; (t) time is correct for 10 mm of graph paper (n8, p<0.05). 
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5.2.2.2 Validation of LFS and HFS models by measuring protein 
synthesis and UCP3 expression 
Myofibrillar and sarcoplasmic protein synthesis was measured and UCP3 niRNA in 
control and 3 h after LFS and 1-IFS, respectively, to see whether known adaptive 
responses to endurance and resistance training could be induced (n% EDL per 
group). Under these conditions, myofibrillar and sarcoplasmic protein synthesis were 
5.32 and 2.65 times higher 3 h after HFS compared to control, respectively (p<0.05). 
In contrast in LFS, protein synthesis was only stimulated to a small degree; this, 
however, did not reach significance (figure 5.6a). UCP3 mRNA increased 
significantly (p<O.00I) to (figure 5.6b) 11.70 ± 0.96 of control 3 h after LFS but 
remained at 1.25 ± 0.12 of control 3 h after HFS. 
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Figure 5.6. (a) Myofibrillar and sarcoplasmic protein synthesis in rat EDL muscles 
incubated without stimulation and 3 h after LFS or HFS, respectively (n6 EDL per 
bar; mean ± SEM). (b) UCP3 mRNA relative to control by RT-PCR (n=6 EDL per 
bar; mean ± SEM). All values were normalised to the relative intensity of the control 
bands. *Significantly different from control; f Significant difference between LFS and 
HFS stimulation protocols (ANOVA, Tukey's post hoc, P<0.05). 
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Western blots were carried out for both total and phosphorylated froms of all proteins 
mentioned in the introduction. Examples of such immunobots are shown in table 5.1. 
The phosphorylation status of many proteins was changed, and many of these changes 
were highly specific to LFS or HFS (figures 5.7-5.11). 
Table 5.1. Examples of Western blot results. All results are from Western blots on 
EDL protein extracts; adjacent bands are copied from one blot (n8). 
Target Stimulation Control Post 3 h post 
(phosphorylation stimulation stimulation 
site)  
LFS (10Hz)  
AMPK (Thr172)  
HFS (100 Hz)  
LFS (10 Hz)  
Total PGC-la  
HFS (100 Hz)  
LFS (10 Hz) 
PKB (Ser473)  
HFS (100 Hz) - 
LFS (10 Hz) ___  
TSC2 (Thr1462) 
HFS(lOOHz)  
LFS(lOHz)  
Total TSC2  
HFS (100 Hz)  
LFS (10Hz) 
mTOR (Ser2448)  
HFS(lOOHz)  
LFS (10 Hz)  
P70 S6K (Thr389) -. - 
HFS(lOOHz)  
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Table 5.1 continued 	 . 
Target 
(phosphorylation 
Stimulation 
site)  
Control Post 
stimulation 
3 h post 
stimulation 
LFS (10Hz)  
4E-BPI (Thr37/46)"  
HFS (100 Hz) 
- 
-a 
GSK-313 (Ser9)  
LFS (10 FIz)  
HFS (100 Hz)  
eIF2B (Ser535) 
LFS (10 Hz)  
HFS (100 Hz)  
rL 
eEF2 (Thr56) 
LFS (10 Hz)  
- 
HFS (100 Hz)  
(Thrl8O/Tyr182) 
ERKI/2  
LFS (10 Hz)  
HFS (100 Hz)  
p38 
(ThrI80/Tyr182) 
LFS (10 Hz)  
HFS (100 Hz)  
INK LFS(lOHz) 
(Thr180fTyr182)2  - 
HFS (100 Hz) 
 
- 
r The density of all bands corresponding to the various 4E-BP1 isoforms were 
quantified together due to their close proximity making them indistinguishable by 
densitometry. Isoforms detected were: upper band a, middle band I, lower band y. 2) 
Only JNK2 (p54) was quantified since this had been specifically linked to 
mechanotransduction (Martineau & Gardiner, 2001). For each protein, 4 Soleus and 4 
EDL were examined, and thus n=8. 
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5.2.2.3 AMPK-PGC-la signalling 
The phosphorylation of AMPK at ThrI 72 increased significantly in response to LFS 
but not HFS (figure 5.7a). LFS significantly increased AMPK phosphorylation 2.02 ± 
0.11-fold directly after stimulation and 1.90 ± 0.06-fold 3 h later. In contrast to LFS, 
AMPK phosphorylation was significantly decreased to 0.69 ± 0.08 of control three h 
after I-ifS. The AMPK-activation pattern was matched directly after stimulation by a 
concentration change of PGC- 1 a: PGC-1 a increased significantly by 1.30 ± 0.04-fold 
directly after LFS and fell to 0.82 ± 0.03 of control directly after HFS (figure 5.7b) 
(all n=8, p<0.05). No significant effects were observed 3 h post stimulation. 
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Figure 5.7. (a) AIVIIPK Thr172 phosphorylation relative to total AMPK; (b) total PGC-
1 a (n8; 4 EDL and 4 Soleus per bar; mean ± SEM) of resting muscle (control), 
directly after (post) and 3 h after (3 h post) LFS and HFS. All values were normalised 
to the relative intensity of the control bands. tSignificantly different from control; 
tSigniflcant difference between LFS and HFS stimulation protocols (ANOVA, 
Tukey's post hoc, p<0.05). 
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5.2.2.4 PKB-TSC2-mT0R signal transduction pathway 
The signalling response of the PKB-TSC-2-mTOR-related signalling cascade was a 
mirror image of the AMPK response: HFS activated the signalling through this 
cascade, the translation initiation regulators p70 S6K, 4E-BP1 and eIF2B and the 
translation elongation regulator eEF2. A second finding is that PKB, TSC2 and 
mTOR phosphorylation only increased directly after I-IFS whereas translational 
regulators were activated both directly and three h after HFS, with the exception of 
4E-BPI. Thirdly, LFS markedly inhibited the phosphorylation of TSC2 and 
downstream translational regulators. Finally, the phosphorylation at the Ser2448 site 
on mTOR was not affected by LFS. 
5.2.2.5 The effect of HFS and LFS on P1(1), TSC2, mTOR and GSK-
phosphorylation 
HFS increased PKB Ser473 (figure 5.8a) and TSC2 Thr1462 (figure 5.8b) 
phosphorylation significantly more in the EDL than in the Soleus. HFS increased 
PKB phosphorylation by 8.36 ± 1.52-fold and by 2.09 th 1.04-fold and TSC2 
phosphorylation by 3.66 ± 0.20-fold and to 2.6 ± 1.3-fold in the EDL and Soleus 
directly after HFS, respectively. Neither PKB nor TSC2 phosphorylation were 
significantly changed three h after HFS. The concentration of total TSC2 was also 
measured because of the possibility of ubiquitin-dependent TSC2 degradation (see 
discussion). Total TSC2 significantly decreased to 0.82 ± 0.02 of control after FIFS 
and was not different from baseline 3 h later (figure 5.8c). Finally, the 
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phosphorylation of mTOR at Ser2448 was significantly increased 1.75 ± 0.08-fold 
directly after I-IFS and was 1.23 ± 0.04 of control 3 h later (figure 5.8d), (all p<0.05). 
To summarise, PKB Ser473, TSC2 Thr1462 and mTOR Ser2448 are acutely 
phosphorylated in response to HFS and the phosphorylation is not significantly 
different from control 3 h later. 
In opposition to these findings of I-IFS responses, from TSC2 downstream the 
signalling proteins and translational regulators related to the PKB-mTOR-signalling 
cascade were deactivated in response to LFS. The only exception was mTOR 
phosphorylation at Ser2448 which was not affected by LFS. TSC2 Thr1462 
phosphorylation significantly decreased to 0.24 ± 0.02 directly and 0.55 ± 0.06 of 
control 3 h after LFS (phosphorylation was significantly lower in Soleus than EDL 3 
h after LFS). 
157 
(a) PKB (Ser473) 	 M LFS 	 (b) TSC2 (Thr1462) M LFS 
OHFS 
	
0 HFS 
 
*4.1 
 
*+t 
  
0 
C 
D 
I.. 
'5 
S.. 
4- 
.0 
S. 
'I) 
C 
D 
>1 
S. 
C 
I- 
I- 
0 
I- 
ZI 
  
Control 	 post 	 3 h post 
 
Control 	 post 	 3 h post 
 
(c) Total TSC2 	 M LFS 	 (d) mTOR (Ser2448) 	 LFS 
	
HFS 	 - 	 HFS 
0 
4- 
C 
I- 
C 
I- 
4- 
.0 
I- 
aq 
0 
S.d 
C 
D 
I- 
'5 
1. 
I- 
0 
S. 
El 
Control 	 post 	 3 h post 
Figure 5.8. (a) PKB Ser473 phosphorylation relative to total PKB; (b) TSC2 Thr1462 
phosphorylation relative to total TSC2; (c) total TSC2; (d) mTOR Ser2448 
phosphorylation relative to total mTOR. All n=8; 4 EDL and 4 Soleus per bar; mean ± 
SEM) of resting muscle (control), directly after (post) and 3 h after (3 h post) LFS and 
I-IFS. All values were normalised to the relative intensity of the control bands. 
tSignificantly different from control; tSignificant difference between LFS and I-IFS 
stimulation protocols; tSignificant difference between EDL and Soleus muscles 
(ANOVA, Tukey's post hoc, p<0.05). 
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5.2.2.6 The effect of HFS and LFS on translational regulators 
All translational regulators were significantly activated directly and 3 h after HFS 
with the exception of 4E-BPI, which was only activated directly after stimulation. 
The phosphorylation of p70 S6K at Thr389 significantly increased by 6.85 ± 0.94-fold 
and by 9.76 ± 0.60-fold directly and three h after HFS, respectively (figure 5.9a). The 
phosphorylation of 4E-BP1 at Thr37/46 significantly increased by 3.20 ± 0.13-fold 
directly after HFS but was not significantly different from control 3 h later (figure 
5.9b). The phosphorylation of eIF2B at Ser535 (Figure 5.9d) was 0.51 ± 0.05 and 0.76 
± 0.02 of control directly and 3 h after HFS, respectively (eIF2B is activated by 
dephosphorylation). Similar to PKB, the phosphorylation of GSK-313 at Ser9 
increased 3.08 ± 0.12-fold directly after HFS and returned to 1.13±0.04 of control 
three h post stimulation (figure 5.9c), (all n8, p<0.05). 
In contrast to this, LFS significantly decreased the phosphorylation of p70 S6K to 
0.22 ± 0.03 and 0.17 ± 0.03 of control and of 4E-BPI to 0.36 ± 0.02 and 0.10 ± 0.03 
of control directly and three h after LFS, respectively. The phosphorylation of eIF2B 
was significantly increased 1.19 ± 0.05-fold of control 3 h after LFS stimulation, (all 
n=8, p<0.05). 
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Figure 5.9. (a) p70 S6K Thr389 phosphorylation relative to total p70 S6K; (b) 4E-
BP1 Thr37/46 phosphorylation relative to total 4E-BPI; (c) GSK-30 Ser9 
phosphorylation relative to total GSK-30; (d) eIF213 Ser535 phosphorylation relative 
to total eIF2B. All n=X; 4 EDL and 4 Soleus per bar; mean ± SEM of resting muscle 
(control), directly after (post) and 3 h after (3 h post) LFS and FIFS. All values were 
normalised to the relative intensity of the control bands. *sigr..jficantly  different from 
control; tSignificant difference between LFS and 1-IFS protocols; tSignificant 
difference between EDL and Soleus muscles (ANOVA, Tukey's post hoc, p<0.05). 
The elongation factor eEF2 at Thr56 (figure 5.10), is reduced from 0.78 ± 0.06 and 
0.38 ± 0.03 of control in HFS whereas phosphorylation is increased in response to 
LFS at both times points (eEF2 is activated by dephosphorylation). 
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Figure 5.10. eEF2 phosphorylation in response to stimulation. n8; 4 EDL and 4 
Soleus per bar; mean ± SEM) of resting muscle (control), directly after (post) and 3 h 
after (3 It post) LFS and HFS. All values were normalised to the relative intensity of 
the control bands. tSignificantly different from control; tSignificant difference 
between LFS and HFS stimulation protocols (ANOVA, Tukey's post hoc, pcO.OS). 
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5.2.2.7 MAPK pathways: HFS and LFS effects on ERK1/2, p38 and 
JNK 
In contrast to all other proteins, phosphorylation of the three MAPK studied here was 
not significantly different between the stimulation protocols (figure 5.1 Ia-c). The only 
exception was ERK2 ThrI 80/TyrI 82 phosphorylation which increased in response to 
both protocols directly and 3 h after stimulation but significantly more so in response 
to HFS than LFS (figure 5.1 la). ERKI Thrl80ITyrl82 phosphorylation increased 
significantly after both protocols to --10 fold of control. In contrast, neither 
stimulation protocol had a significant effect on p38 Thrl80/Tyr182 phosphorylation 
(figure 5.11 b). iNK phosphorylation at ThrI 83/Tyrl 85 increased significantly by 1.16 
± 0.03-fold after HFS and then fell both 3 h after LFS and HFS to -0.77 ± 0.05 (figure 
5.1 Ic), (all significant changes p<O.OS). 
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Figure 5.11. (a) ERKI/2 phosphorylation at Thr20211'yr204 (b) Phosphorylation of 
p38 at Thrl80/Tyr182 (c) Phosphorylation of SAPKIJNK at Thrl83/Tyr185. All n8; 
4 EDL and 4 Soleus per bar; mean ± SEM of resting muscle (control), directly after 
(post) and 3 h after (3 h post) LFS and HFS. All values were normalised to the 
relative intensity of the control bands. tSignificantly different from control; 
tSignificant difference between protocols; (ANOVA, Tukey's post hoc, p<0.05). 
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5.3 Discussion 
The results of the in vivo study have demonstrated the activation of multiple signal 
transduction pathways in response to CMINS which can partially explain the 
physiological changes following CMNS and endurance training. Furthermore, the in 
vitro studies showed that AMPK-PGC-la signalling can be specifically induced by 
LFS and that the PKB-TSC2-mTOR cascade and MPS is specifically induced by 
HFS, which can explain the specificity of growth or phenotype changing responses. In 
the following section, the activity (phosphorylation) changes in signalling with 
respect to functions of these pathways is discussed in order to attempt to explain the 
known adaptations to CMNS and furthermore, to explain the contrasting responses to 
resistance-like I-IFS and endurance—like LFS electrical stimulation. 
5.3.1 Myostatin signalling 
CMNS led to an increased signalling through SMAD2/3 (figure 5.3) which was 
evident from the 2.5-fold increase in SMAD2/3 Ser465/467 phosphorylation. The 
cachectic effect of the increase in myostatin (Chapter 4) and signalling through 
SMAD2/3 in the stimulated EDL compared to control, could be a partial explanation 
for the 50 % drop in EDL mass, since increases in myostatin concentrations have 
been linked with atrophy (Zimmers ci aL, 2002). Neither myostatin, nor SMAD2/3, 
were examined in response to isolated muscle stimulation since antibodies were not 
available at that time. However, this would be worthwhile examining in order to see 
if there was a diverse signalling response in HFS and LFS. For example, perhaps if 
HFS could reduce myostatin, then this might explain some hypertrophic responses. 
5.3.2 Regulation of ribosome biogenesis 
About 80 % of cellular RNA is ribosomal (rRNA), and it is the ribosomes that are the 
machinery of protein translation (Nader ci aL, 2002). It has been reported that there 
was an increase in RNA synthesis during CMNS (Cummins & Salmons, 1999) and 
this is likely to be largely a result of increased rRNA synthesis. rRNA is encoded in 
multiple copies in chromosomes and is mainly transcribed by RNA polymerase I in 
response to DNA binding of both the upstream binding factor UBF and promoter 
selectivity factor I (SL-1) transcription factors. Both increased UBF phosphorylation 
(Stefanovsky ci aL, 2001) and overexpression of UBF (Hannan ci aL, 1996) increases 
the transcription of rRNA in tissues other than skeletal muscle. 
Surprisingly, in this study a significant (p<0.05) decrease in UBF Ser637 
phosphorylation to 0.7 of control was noted (figures 5.3 & 5.4), which does not 
explain the reported increased rRNA synthesis following CMNS (Williams ci aL, 
1987). Phosphorylation of UBF was not measured in response to in vitro stimulation, 
although it may have been interesting in order to see if the HFS protocol could 
specifically induce phosphorylation of UBF. This may have provided insights into the 
capacity for protein synthesis following HFS. 
5.3.3 Mitochondrial biogenesis signalling - activated through CMNS, 
and selectively following LFS 
The observed 4-fold increase in AMPK Thu 72 and 4.5-fold increase in 
p38a1J3 Thrl8OfT'yr182 phosphorylation can partially explain the increase in 
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mitochondrial content and oxidative and fat catabolism enzyme activities that occurs 
in response to CMNS (1-Ienriksson et aL, 1986). AMPK has been shown to stimulate 
mitochondrial biogenesis via increasing the expression of the co-activator peroxisome 
proliferator activated receptor y coactivator-1 (PGC-lct) (Terada et at, 2002; Zong et 
aL, 2002). In addition, activated AMPIC will increase glucose uptake into the 
contsacting muscle (Hayashi et aL, 1998), increase the expression of GLUT4 
transporters (Ojuka et aL, 2002) and regulate fat metabolism (1-lardie & Pan, 2001). 
Mitochondrial biogenesis is also likely to be affected by the increased 
phosphorylation of p38a/13 noticed following CMNS. p380t/13 was shown to increase 
phosphorylation of PGC-lct and this is known to also promote mitochondrial 
biogenesis (Knutti et at, 2001). 
In the in vitro experiments, whilst PGC-la was induced with LFS and AMPK was 
activated (figure 5.7), surprisingly, pMot/p was not activated by the LFS protocol. 
This was in agreement with Wretman et aL, (2001) who showed that only high 
mechanical stress could activate p38 signalling, which would not be elicited by 
isometric contractions specific to LFS. The activity of Ca 2 fcalmodulin-dependent 
kinase (CamK) isoforms were not measured but it would be expected that the [Ca 211 
rise induced by stimulation was sufficient to increase Ca 2 fcalmodulin-activation of 
skeletal muscle CamK isoforms. If this was the case, then CamK was also likely to 
contribute to the stimulation of PGC-lcz induction and eventual mitochondrial 
biogenesis (Wu et at, 2002). This, however, remains speculative since the isoform 
reputed to be controlling this process (CAMKIV) is reportedly not expressed in 
skeletal muscle as discussed in chapter 1 of this thesis. Thus, AMPK, p38 and CainK 
were likely to affect the expression and phosphorylation of the transcriptional co- 
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activator PGC-la, which in turn together with other mitochondrial transcription 
factors such as NRFI,2 (Scarpulla, 2002) and TFAM (Larsson et aL, 1997) will have 
affected the expression of mitochondrial genes encoded in both nuclear and 
mitochondrial DNA. 
Only the LFS protocol increased AMPK Thr172 phosphorylation, whereas the HFS 
protocol had no effect. A possible explanation for the lack of AMPK activation by 
HFS is that AMP does not sufficiently change during the HFS protocol. For example, 
contractions at high intensity cause a steady decrease of phosphocreatine (PCr) 
(Miller et aL, 1987). PCr is linked to ADP via the creatine kinase reaction and ADP to 
AMP via the myokinase. It is likely that the 3 s stimulation bursts were probably too 
short to markedly increase AMP which could recover during the 10 s rests (or 1 mm 
between sets that followed) in between. The fact that AMPIC has been reportedly 
activated in response to high-intensity exercise does not disagree with the present 
study and can be explained since longer stimulations at 100 Hz will eventually deplete 
PCr and markedly increase AMP which explains the increase of AMPK activity after 
longer, more sustained 100 Hz stimulations (Sakamoto et aL, 2004). 
Conversely, the continuous LFS was likely to have led to a steady-state with a 
constant, moderate decrease of PCr and increase of AMP which was sufficient for 
AMPK activation. Furthermore, AMPK has a glycogen binding domain (Hudson et 
aL, 2003) and AMPK is more activated when the concentration of muscle glycogen is 
low (Wojtaszewski et aL, 2002). Therefore, the glycogen depletion associated with 
LFS was likely to have activated AMPK further, especially since the protocol was 3 h 
long. The increase in AMPK phosphorylation by LFS is consistent with a transient 
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increase in the transcriptional co-factor PGC-1 a, which is known to be induced by 
AMPK (Terada et aL, 2002). An increased expression of PGC-la occurs after 
endurance training (Baar et aL, 2002) and can explain an increase in mitochondrial 
biogenesis and an upregulation of slow motor proteins (Wu et aL, 1999; Lin et aL, 
2002), which are other known adaptations to endurance training. The inhibition of 
PGC-la directly after 1-IFS can be explained by the finding that PKB suppresses 
PGC-la expression (Daitoku et aL, 2003). 
5.3.4 Mitogen activated protein kinases in response to CMNS and in 
vitro stimulation 
CMINS also led to an increase in ERKI/2 signalling of 6.3 and 2.7-fold, respectively 
(figures 5.1 & 5.2) which is expected since ERKI/2 is implicated in inducing a slower 
muscle phenotype (Higginson et aL, 2002). p54  INK Thri 83/Tyr 185 phosphorylation 
was also increased 2-fold in response to CMNS (figures 5.1 & 5.2). The precise 
reason for this is not known, and activation is perhaps surprising since INK is 
implicated in response to increases in stretch, but the CMNS model elicits isometric 
contractions. In the in vitro model, the results are in agreement with some studies 
(Nader & Esser, 2001) and in contrast to others (Wretman et aL, 2001; Martineau & 
Gardiner, 2001) as no stimulation pattern-specific effects on ERIC I, p38  and iNK 
phosphorylation at the activity-related Thr/Tyr sites were found (figure 5.11). A 
stimulation-specific effect was found for ERK2 which increased more, up to 17.75 ± 
5.77-fold of control 3 h after 1-IFS whereas the maximal response after LFS was a 4.81 
± 1.69-fold increase directly after LFS. However, phosphorylation did not change in 
opposite directions. Moreover, this study did not detect any increase in p38 
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phosphorylation in response to either LFS or HFS. As previously mentioned, the 
ERK1/2 pathway has been shown to promote the formation of slow fibres and to 
induce slow and inhibit expression of fast motor proteins (Murgia ci aL, 2000; 
Higginson et aL, 2002), suggesting that ERKI/2 is involved in the fast-to-slow 
exchange of MHC isoforms in response to exercise and electrical stimulation. This 
does not contradict the finding that ERK1/2 phosphorylation also increases in 
response to HFS. Limited fast-to-slow changes in the expression of myosin heavy 
chain isofonns from IN to ha have been reported in response to resistance training 
(Williamson ci aL, 2001). The JNK response to HFS was small and not significantly 
different from the LFS response at any point contrary to the finding that iNK 
Thri 83ITyrl 85 phosphorylation is quantitatively related to the tension (Martineau & 
Gardiner, 2001). 
5.3.5 Selective activation of the PKJI-mTOR signalling cascade by 
HFS 
HFS specifically increased the phosphorylation of the anabolic PKB-TSC2-mTOR, 
GSK-33 and significantly activated the translation initiation regulators p70 S6K, 4E-
BPI, eIF2B and the translation elongation factor eEF2 (figures 5.8-5.10). This was 
reflected in the increased protein synthesis in response to HFS. In stark contrast to 
this, LFS stimulated the opposite response by inhibiting this signalling network from 
TSC2 downstream and also not increasing MPS. It should be mentioned here, that 
whilst MPS was not inhibited by LFS, this was due to the physiological amino acid 
mix which was used in the sarcoplasmic and myofibrillar MPS assays, stimulating 
mTOR in the fasted state post-LFS state. 
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The activation of the PKB-TSC2-mTOR signalling cascade specifically by HFS 
appears to be related to the high intensity of the HFS protocol. It has been recently 
hypothesised that high intensity contractions activate currently unknown 'upstream' 
signal transduction events which regulate the activation of specific muscle growth 
factors such as IGF-1, MGF and myostatin (Rennie et at, 2004), although the HFS-
related signal, its sensor and the upstream signalling events that activate PKB, mTOR, 
translational regulators and protein synthesis are as yet unknown. Passive stretch 
which is known to activate protein synthesis (Vandenburgh & Kaufhian, 1979), PKB 
(Sakamoto ci at, 2003) and p70 S6K (Baar ci at, 2000) is unlikely to be the signal 
because all contractions were isometric in this in vitro model. The unknown signal 
must therefore be related to the higher stimulation frequency, higher intermittent 
[Ca2 11, >2-fold higher tension generated or another unknown factor related to the 
specific nature of the HFS protocol. The hypothesis that high intensity is necessary for 
PKB activation is supported by Sakamoto et al who reported PKB activation in 
response to 100 Hz stimulation in situ (Sakamoto ci al., 2002). 
5.3.6 HFS, but not LFS activates translational regulators PKB, TSC2 
and mTOR 
HFS, but not LFS, increased TSC2 Thr1462 and mTOR Ser 2448 phosphorylation. 
PKB is known to phosphorylate TSC2 at Thr1462 resulting in TSC2 inactivation 
(Inoki et at, 2002). The results of this study have also found that PKB phosphorylated 
TSC2 was more highly ubiquitinated, suggesting that PKB-phosphorylation of TSC2 
at Thr1462 leads to its degradation by ubiquitin-dependent proteolysis (Inoki ci aL, 
2002). The current study identified a significant 3.13 ± 0.23-fold increase in TSC2 
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Thr1462 phosphorylation (normalised to total TSC2) and a significant decrease to 
0.82 ± 0.02 of control total TSC2 directly after HFS (p<005). These data further 
support the hypothesis that TSC2 is subsequently degraded after phosphorylation by 
PKB. In contrast, LFS significantly decreased phosphorylation of TSC2 at Thr1462 to 
0.24 ± 0.02 and 0.55 ± 0.06 directly and 3 h after LFS, respectively. LFS also 
significantly increased the TSC2 concentration to 1.27 ± 0.02 of control directly after 
LFS, suggesting that TSC2 Thr1462 phosphorylation and TSC2 concentration are 
linked. Taken together, these findings suggest that TSC2 mediates the anabolic 
response to HFS and inhibits protein synthesis during LFS-induced catabolism. TSC2 
partially controls activity of mTOR via the GTPase Rheb (Inoki et aL, 2002; Inoki et 
aL, 2003a) which is likely to regulate mTOR phosphorylation via a yet unknown 
Rheb-dependent kinase. PKB can also directly phosphorylate mTOR at Ser2448 
which is the site investigated in the present study (Nave et aL, 1999). It was found 
there was a 1.75 ± 0.08-fold increase in mTOR Ser2448 phosphorylation directly after 
HFS but no effect of LFS confirming that this site is not dependent on TSC2-Rheb 
signalling which was affected by LFS. 
5.3.7 HFS, but not LFS activates translational regulators p70 S6K, 
4E-BP1, eIF2B, GSK3fl and eEF2 
HFS significantly activated and LFS significantly inhibited the translational regulators 
p70 S6K, 4E-BPI, eIF2B and eEF2. In contrast to their upstream regulators, 
translational regulators were activated also 3 h after HFS with the exception of 4E-
BP1. These data suggest that HFS can activate a prolonged translation initiation and 
elongation signalling response even in fasted muscles. The origin of this long-term 
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translation activation effect is unknown and cannot be related to the short term 
upstream signalling not present 3 h post HFS 
The significant 6.85 ± 0.94-fold and 9.76 ± 0.60-fold (pc0.05) increases of p70 S6K 
phosphorylation directly and 3 h after HFS can explain the increased protein synthesis 
3 h after HFS. The long-term increase in p70 S6K phosphorylation is consistent with 
the observation that the phosphorylation of p70 S6K and protein synthesis in skeletal 
are activated long-term after resistance exercise (Baar & Esser, 1999; Hernandez et 
aL, 2000). It is unclear why p70 S6K Thr389 phosphorylation is elevated 3 h after 
I-IFS since phosphorylation of PKB at Ser473, TSC2 at Thr1462 and mTOR at 
Ser2448 are back to normal. Therefore, the prolonged p70 S6K activation must be 
related to some yet unknown upstream factor. An increase in 4E-BPI phosphorylation 
was observed in response to resistance exercise in rats (Bolster et aL, 2003) which is 
in line with these observations of a significant 3.20 ± 0.13-fold (p<0.05) increase in 
4E-BPI phosphorylation directly after FIFS. However, unlike the p70 56K response, 3 
h after HFS 4E-BP1 phosphorylation at Thr37/46 was not significantly different from 
control. In contrast to this, LFS caused a significant (p<0.05) decrease in 4E-BP1 
phosphorylation suggesting reduced protein synthesis. 
Another regulatory pathway affecting translation initiation is the PKB-GSK-313-eIF2B 
cascade. Activated PKB phosphorylates GSK3P at Ser9 which inhibits the activity of 
GSK-313 (Cross et aL, 1995). An inhibition of phosphorylated GSK-313 leads to a 
reduced phosphorylation of eIF2BE at Ser535 which promotes translation initiation 
(Welsh et aL, 1998) and inhibition of GSK-30 by phosphorylation promoted 
hypertrophy in cultured muscle cells (Vyas et aL, 2002). The 3.08 ± 0.12 fold increase 
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in GSK-30 Ser9 phosphorylation directly after HFS and decrease of eIF2Bs Ser535 
phosphorylation to 0.51 ± 0.05 and 0.78±0.06 of control directly and 3 h after HFS 
supports the hypothesis that this pathway is involved in stimulating an increase in 
protein synthesis in response to HFS. It is unclear why GSK-30 Ser9 phosphorylation 
only changed acutely whereas eIF2B Ser535 was decreased directly and 3 h after 
I-IFS. eEF2 catalyses the translocation of peptidyl-tRNA during translation elongation 
and is regulated by mTOR via p70 S6K and p90 RSKI (Wang et aL, 2001). 
Phosphorylation of eEF2 at Thr56 by its upstream kinase inactivates eEF2 (Proud, 
2004b). These data show a significant, prolonged decrease of eEF2 Thr56 to 0.76 ± 
0.02 and 0.38 ± 0.03 directly and 3 h after I-IFS, respectively, suggesting an activation 
and increased stimulus for peptide elongation. 
In direct contrast to the I-IFS response, LFS affected the phosphorylation of p70 S6K, 
4E-BP1, GSK3, eIF2B and eEF2 at various sites suggesting a pronounced inhibition 
of translation initiation and elongation that was still present 3 h after LFS (aside from 
GSK3I3). Recent studies have shown that AMPK can directly phosphorylate TSC2 at 
ThrI 227 and Sen 345 leading to an inhibition of mTOR and regulators of translation 
initiation (Bolster el aL, 2002; Cheng et aL, 2004; Dubbelhuis & Meijer, 2002). 
Therefore it appears that TSC2 is capable of being modified by both PKB and AMPK 
to have contrasting effects on Rheb, and thus a 'tug of war' between these proteins 
could exist when both are activated together. In addition, the translation elongation 
regulator eEF2 is also inhibited by AMPK via its upstream eEF2 kinase (Norman et 
aL, 2002b; Browne et aL, 2004). These results suggest that LFS inhibits energy-
consuming protein synthesis as long as the muscle is kept in a fasted state. An 
inhibition of translational regulators by stimuli similar to LFS was noted by one group 
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who reported a decrease of 4E-BPI phosphorylation after endurance exercise which 
was reversed by subsequent feeding (Gautsch et aL, 1998). Activation of mTOR via a 
nutrient-sensitive pathway by the amino acid mix necessary for the measurement of 
protein synthesis can explain why myofibrillar and sarcoplasmic protein synthesis 3 It 
after LFS were not significantly lower compared to control as the signalling responses 
would suggest. 
5.3.8 Conclusion 
The results of these studies are extremely novel and comprise the largest amount of 
data culminating our understanding of both how exercise leads to the appropriate 
adaptations depending upon the nature of contractile activity, and how contrasting 
training types produce such very different physiological characteristics even though 
the gross stimulus - muscle contraction - is the same. Furthermore the AMPK-PKB 
switch, for the first time, provides an explanation for the specificity in activation of 
each signalling protein depending upon its known genetic or translational effects. 
The results show that a signal transduction network rather than one or two pathways 
regulate adaptive responses to CMNS (Wackerhage & Woods, 2002), and that chronic 
signalling is maintained even following 6 weeks of CMNS. This is also extremely 
likely to be the case with chronic endurance acitivity. The CMNS model also shows 
that 'rest' is surely not as important as is thought in adaptative processes. Furthermore 
the data provide an explanation for how distinct signalling states are induced by LFS 
and HFS to explain the critical question of why there is a growth response to 
resistance-like exercise and a phenotype shift in response to endurance activity. 
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Chapter 6 
The effect of essential amino acids 
upon anabolic responses in both healthy 
the elderly and elderly with Type II 
Diabetes Mellitus: an explanation for 
the development of Sarcopenia? 
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6.1 Introduction 
Previous chapters of this thesis have been dedicated to many aspects of muscle 
phenotype and mass regulation with the primary focus being on physical activity and 
contraction. Therefore, in order to widen the scope of this study, this chapter was 
included to examine how muscle is affected by ageing (sarcopenia) and disease (type 
11 DM) thus gaining a view of muscle regulation from both exercise induced-
phenotype change and hypertrophy; to the contrasting atrophy noticed in sarcopenia 
and some disease states. 
Sarcopenia is the gradual loss of muscle mass associated with ageing, which begins 
around the fourth decade of life and accelerates after the age of 75 years 
(Baumgartner ci aL, 1993). Sarcopenia is caused by both a loss of fibres (Lexell ci aL, 
1988) and atrophy of fibres, the latter of which must be mediated by net protein 
breakdown. Over time as sarcopenia progresses, the elderly become more frail since 
progressive loss of muscle mass leads to a reduction in strength (Roth ci aL, 2000). 
The precise aetiologies of sarcopenia appear to be multi-factorial as discussed in 
chapter 1 (see 1.8.3). Sarcopenia is not restricted to those with disease conditions 
since it is noticeable in otherwise healthy ageing. At the same time, age-related 
sarcopenia is also linked to an increase in the risk of metabolic disorders such as adult 
onset type II DM (Beaufrere & Mono, 2000). Therefore, there remains the question as 
to whether additional complications in the muscles, such as type 11 DM, may lead to 
an increased susceptibility to the progression and severity of sarcopenia. 
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As discussed in chapter I, it is unlikely that changes in muscle protein synthesis 
(MPS) or breakdown (MPB) are the primary cause of sarcopenia as other factors 
identified do not appear to be able to explain the very gradual loss of muscle mass 
in the healthy elderly. Therefore, if a decline in MPS or an increase in MPB is not 
in evidence then there must be another key mechanism of sarcopenia yet to be 
identified. Since amino acids are powerful stimulators of muscle anabolism (even 
in the absence of exercise) and are readily available from foodstuffs, it is possible 
that dysregulation of this process with ageing (and elderly with Type II DM) 
could affect NIPS responses to essential amino acids (EAA) and thus an 
explanation could lie therein. Therefore the aim of this study was to determine the 
anabolic responses to EAA in both healthy elderly and those with type II DM. 
This was done by measuring MPS in response to various EAA doses. Molecular 
signalling responses were also determined through measuring total protein and 
phosphorylation of elements of the translational mediating pathways. The specific 
hypotheses of this study were: 
The elderly possess a blunted MPS response to EAA, characterised by reduced 
mTOR signalling and capacity, when compared with young individuals. 
2) Elderly individuals with chronic type II DM possess a blunted anabolic 
response to EAA when compared with otherwise healthy elderly using the 
same parameters. 
Methods 
As described in Chapter 2. 
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6.2 Results 
6.2.1 Basal MPS responses elderly/young 
In the young and the elderly, basal post-absorptive fractional synthesis rates (FSR) 
values for myofibrillar and sarcoplasmic proteins were similar (means, 0.04 ± 0.15 
and 0.06 ± 0.01 %.h', respectively young n=20, elderly n=24). tThe protein synthesis 
data were obtained by members of Professor Michael J Rennie's laboratory, 
University of Nottingham/University of Dundee, and included within this thesis in 
order to put the signalling data into context. 
6.2.2 MPS response to EAA doses in the healthy elderly and young 
In the young, EAA between 2-10 g stimulated myofibrillar protein synthesis in a 
dose-dependant fashion but 20 g EAA failed to elicit any additional stimulation 
(figure 6.1a); sarcoplasmic protein synthesis showed a similar but less responsive 
pattern of stimulation (figure 6.1 b). The elderly also showed dose-dependant increases 
in rates of myofibrillar and sarcoplasmic protein synthesis but, compared to the values 
in the young, the curves were shifted to the right and depressed. These results indicate 
both a decreased sensitivity (relative myofibrillar increase, A 13.8 % per g EAA vs. A 
3.6 %; sarcoplasmic: A 10.7 % vs. A 4.4 % per g EAA; both Pc 0.001) and also a 
decreased responsiveness to EAA (maximal rate, Vmax, myofibrillar: 0.11 vs. 0.07 
%.h'; sarcoplasmic, Vmax 0.13 vs. 0.11 %.h', both Pc 0.001). A higher dose of EAA 
(40 g) given to the elderly failed to restore rates of myofibrillar or sarcoplasmic 
protein synthesis to those seen in the young with 10 g of EAA. However, 10 g of 
EAA in the elderly promoted the rates of MPS to those seen with 5 g in the young. 
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Figure 6.1. Graphs showing the fractional synthesis rate (FSR) dose response of (a) 
myofibrillar and (b) sarcoplasmic muscle protein fractions in response to 10, 20, 30 or 
40 g EAA. Elderly subjects exhibit a reduced muscle protein synthesis (MPS) rate in 
response to EAA when compared with younger controls for both 10 g and 20 g EAA. 
Data are means ±SEM, young n=20, elderly n=24 p<0.05. 
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6.2.3 Characterisation of signalling responses in healthy elderly and 
young 
The phosphorylation of mTOR at Ser2448 and p70 S6K at Thr389 increased 
significantly (p<0.05) in both the young and elderly subjects in response to 10 g of 
EAA but less so in the elderly (-.30 % of the response in the young) (figure 6.2a). In 
the young, mTOR and p70 S6K phosphorylation increased by 5.2 and 8.1-fold, 
respectively, whereas, in the elderly, mTOR and p70 S6K phosphorylation only 
increased 2.7 and 3.5-fold, respectively (p<0.05) (figure 6.2 a,b). Increased EAA 
availability also led to increased phosphorylation of 4E-BP1 at Ser 37/46 in both the 
young 5.9-fold and the elderly 3.2-fold (p<0.05) (figure 6.2c). The phosphorylation of 
eI17213s at Ser 544 (eIF2Bc is activated by dephosphorylation; downstream of GSK3[3 
but not of mTOR) fell to —0.6 of fasted values in response to 10 g EAA in both the 
young and elderly, so that the actual extent of activation was less in the elderly 
(p<0.05) (figure 6.2d). 
180 
15 
LI 
IOgEAA 
5 
0 
* 	 LI OgEAA 
I0 I0gEAA 
(a) Phospho-mTOR (Ser2448) 	 (b) Phospho-p70 S6K (Thr 389) 
Young 	 Old 
(c) Phospho-4E-BP1 (Thr37/46) 
LIII  
Young 	 Old 
(c) Phospho-eIF2B (Ser535) 
OgEAA 
lOg EAA 30 
20 
10 
0 
 
Young 	 Old 
2.0 
1.5 
l.0 
0.5 
0.0 
Young 	 Old 
Figure. 6.2. Bar charts showing the phosphorylation of p70 S6K, mTOR, 4E-BP1 and 
eIF2B. In response to EAA, phosphorylation of each protein was increased 
significantly more in the young subjects, than in healthy elderly. Data are means ±SE 
arbitrary densitometric units (n8) p<0.05. 
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6.2.4 Changes in relative signalling protein levels in healthy elderly 
individuals compared to young 
Levels of total proteins also were different between young and old skeletal muscle. 
Total levels of mTOR, (-50%) and p70 S6K (-50%) were reduced in the elderly 
whereas NFiB (-400%) protein were increased in elderly (p<0.05; figure 6.3). eIF2B 
protein concentrations were not significantly different between young and elderly. 
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Figure 6.3. Bar chart showing total levels of mTOR, eIF2B, p70 S6K and NFiB 
relative protein levels in young and old subjects. Data are means ±SE arbitrary 
densitometric units (A.U), (n=8) p<O.OS. 
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6.2.5 Basal MPS responses in Type H DM subjects/healthy elderly 
Basal FSR were similar between groups (myofibrillar, 0.027 ± 0.003 %.h', 
sarcoplasmic, 0.051 ± 0.002 %.h 4 , grand means ± SD) but the patients with Type II 
DM showed reduced responsiveness of FSR of both myofibrillar and sarcoplasmic 
proteins to 20 g EAA (figure 6.4). 
6.2.6 MPS response to EAA doses in Type It DM subjects/healthy 
elderly 
0.15 
U) 
U) 
C 
= 
Co 
€5 
01 
LL 
Sc, 
o — 
— (5 
0. 	 0.05 
L. 
€5 
I. 
.0 
.0 
0 
0 
U Control Subjects 0.15 
U) 
C 
C 
C 
U) 
It 
C 
o 	 0.1 
4- - 
o 0 
IL 	 0.05 
E 
U) 
It 
a. 
0 
U 
I- (5 
0 
• Control Subjects 
09 	 20g 	 Og 	 20g 
Dose of Oral Essential Amino Acids 	 Dose of Oral Essential Amino Acids 
Figure 6.4. Myofibrillar and sarcoplasmic fractional synthesis rates (FSR) in response 
to 0 g and 20 g EAA. Note that whilst protein synthesis rate are similar with no EAA 
feeding, an influx of 20 g has a greater effect increasing protein synthesis than in 
control elderly subjects. Data are means ±SEM, n=8 p<0.05. 
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6.2.7 Characterisation of signalling responses in Type H DM 
subjects/healthy elderly 
Phosphorylation of mTOR at Ser2448, p70 S6K at Thr389 and 4E-BPI at Thr37/46 
only increased significantly (pc0.05) in the control but not the diabetic subjects in 
response to feeding 10 g EAA (figure 6.5). 
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Figure 6.5. Bar charts showing the phosphorylation of mTOR at Ser2448 (a), p70 S6K 
at Thr389 (b) and 4E-BPI at Thr37/46 (c) indicating control elderly and elderly with 
type 11 DM molecular responses to 20 g EAA. Data are means ±SE arbitrary 
densitometric units (n8), *pcOOS 
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6.2.8 Changes in relative protein levels in Type II DM 
subjects/healthy elderly 
There were no differences in either mTOR or 4E-BP1 levels between groups (n8), 
whilst there was a significantly (p<0.05) lower level of p70 S6K in the subjects with 
type II DM. This illustrates that reduced p70 S6K levels could be responsible for 
some of the blunted response in MPS following EAA. 
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Figure 6.6. Bar chart showing total protein concentrations of mTOR, p70 S6K and 
4E-BP1 in the healthy elderly and those with type II DM. Data are means ±SE 
arbitrary densitometric units (n=8), *pc0•05• 
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6.3 Discussion 
These studies highlight perhaps the most likely cause of sarcopenia to date in showing 
that the elderly have a diminished anabolic response to EAA compared to the young, 
which might explain the gradual loss of muscle mass with advancing age. 
Furthermore, those elderly individuals with type II DM are likely to be more 
susceptible to sarcopenia mediated by blunted EAA responses than the otherwise 
healthy elderly. There was no difference between young and elderly nor diabetic and 
aged matched controls in the components of myofibrillar or sarcoplasmic protein 
synthesis in muscle in the post-absorptive state. Therefore, it can be concluded that 
the inability of the elderly to respond to the availability of blood EAA should limit 
their ability to maintain muscle mass and this effect may be magnified in those with 
muscle disease, and specifically the metabolic state, type II DM. 
6.3.1 Molecular responses to EAA - Total protein levels are often at 
decreased levels in the elderly and those elderly with type II DM 
These results have demonstrated that there are marked decrements in the elderly and 
type II diabetics in the sensitivity and capacity of the muscle protein synthetic 
apparatus in response to FAA. This leads to a diminished anabolic (protein synthesis) 
response to EAA. The reduced sensitivity of the system may be caused by the 
reduction in the amounts of proteins in the mTOR anabolic amino acid sensing and 
signalling pathway. For example, in the healthy elderly there was significantly 
diminished mTOR and p70 S6K (-50 %) suggesting this could be true. Interestingly, 
when compared to the healthy elderly, those with type II DM had a further reduced 
186 
level of p70 S6K which is responsible for synthesis of ribosomal proteins and eEF2 
phosphorylation. This provides a mechanism by which the capacity of elderly 
individuals with type II DM to increase MPS in response to EAA is further 
diminished. Therefore, given that the output of a signalling pathway is in part 
dependent upon the total amount of a signalling protein (see chapter 3, metabolic 
control analysis) then the reduced mTOR pathway protein levels may be part 
explanation for a reduction in the capacity of the elderly system to mount full anabolic 
responses to protein intake. The protein level of eIF2B was not significantly altered in 
suggesting that the most important contribution to blunted MPS responses to EAA 
comes through mTOR. 
There was also a marked 4-fold increase in the protein concentration of NFiB in 
elderly, which may add support to the hypothesis that ageing is associated with a 
chronic sub-inflammatory process (Chung ci aL, 2001). The regulatory events 
responsible for the marked increase in the total NFiB concentration in aged muscles 
are unclear. NFiB has been shown to mediate TNFa-induced muscle wasting (Li & 
Reid, 2000) partially by decreasing the expression of myogenic regulatory factor 
MyoD (Guttridge ci aL, 2000). The observed higher NFiCB levels are likely to amplify 
the effect of the catabolic cytokines such as TNFa that are often found at higher 
concentrations in the elderly (Greiwe ci aL, 2001). It remains to be shown that higher 
concentrations of NFiB actually have an inhibitory effect on the protein synthetic 
process. However, evindence for this comes from the fact that direct chronic NFiB 
activation leads to muscle wasting (Guttridge, 2004) and NFicB targets many genes of 
the ubiquitin-proteasome pathway (Whitehouse & Tisdale, 2003) and the muscle 
metalloproteases (Yoo ci aL, 2002); and so this remains a likely hypothesis. 
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6.3.2 Molecular responses to FAA - Phosphorylation of translation 
proteins are often lower in elderly and those elderly with type LI DM 
There was a significant (p<0.05) decrease in the extent of phosphorylation of key 
elements of protein synthesis pathways in response to EAA, particularly mTOR 
Ser2448, p70 56K Thr389 and 4E-BPI Thr37/46 which might explain the decreased 
sensitivity to EAA induced MPS (figure 6.2). Since particularly, the cellular amino 
acid sensor, mTOR 5er2448 phosphorylation (Nave et aL, 1999) was reduced in the 
elderly, there appears some reduction in sensitivity to amino acid stimulation of 
mTOR activity which therefore blunts translational responses though 4E-BP1 and p70 
S6K. eIF2Bc phosphorylation was also activated to a greater extent in the young 
suggesting that either this protein or upstream kinases, such as GSK30 might also be 
sensitive to changes in cellular EAA, and that this mechanism is also impaired in 
ageing independent of mTOR. Further to this, in the diabetic individuals, both MPS, 
mTOR, p70 S6K and 4E-BPI phosphorylation were even more suppressed in 
response to EAA when compared with healthy age-matched elderly (figure 6.5). This 
suggests that there are additional complications within type II diabetic elderly muscles 
affecting the ability to mount anabolic signalling responses to EAA. It is very difficult 
to provide an explanation for this reduced phosphorylation of these proteins, 
especially since the mechanisms by which amino acids activate mTOR are not 
established. However, since intracellular amino acid levels within the cells were 
equivalent to those of the young (Cuthbertson et aL, 2004), the blunted effect of MPS 
by EAA may not be mediated through decreased amino acid import. Therefore, there 
must be an intracellular mechanism via which amino acids fail to stimulate muscle 
protein synthesis, and this warrants further attention. 
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6.3.3 Conclusion 
Taken together, these results suggest a process of the blunting of translation mediating 
signalling and MPS in response to EAA. This indicates impaired capacity for 
translation of mRNA in response to EAA for the development of sarcopenia. This will 
be fbrther blunted in elderly with type II DM, and shows that they become 'amino 
acid resistant' (at least on an intracellular level) as well as insulin resistant which 
potentially has importance for progress of sarcopenia mediated by reduced EAA-
induced anabolism. Furthermore the decreased protein levels of the mTOR pathway 
suggest that there is a reduced capacity to 'amplify' the EAA-induced anabolic 
response. 
Thus, it appears that it is the defects in the ability of the elderly to make use of the 
protein in their diet, which would be more consistent with the gradual losses of 
muscle mass and quality observed. Therefore, given that exercise (particularly 
resistive type training) reduces the rate of sarcopenia and since there is little 
decrement in the ability of elderly subjects to respond to resistance exercise (Jozsi et 
aL, 2001); coupled with the fact that EAA stimulates net protein synthesis following 
exercise even in elderly (Yarasheski et aL, 1993) the elderly should eat their main 
protein-containing meal close to a bout of resistance exercise to maximise 
maintenance of muscle protein mass. This intervention should allow the elderly to 
maintain muscle strength, since muscle mass is somewhat proportional to the ability 
to produce force. Therefore maintenance of muscle mass with protein/exercise 
combinatorial strategies should reduce frailty, a major cause of morbidity in the 
elderly. 
189 
Chapter 7 
General biscussion 
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7.1 Discussion 
The results presented in this thesis provide insights into the molecular control of 
muscle mass and phenotype in response to both growth stimulating activity and 
phenotype altering stimuli. Moreover, they identif' potential signalling explanations 
for the decreased EAA-stimulated MPS as a contributory factor to development of 
sarcopenia, and atrophy in type II diabetics. Overall this makes a substantial 
contribution to a more thorough understanding of regulation of skeletal muscle mass 
and phenotype on a molecular level. Below, each chapter of work will be summarised 
before a detailed summary in order to bring together these findings. 
7.2 Myostatin signalling 
Myostatin is a major regulator of skeletal muscle size, in that it has the ability to 
control muscle mass during embryogenesis through cell cycle regulation and also 
through adult-hood by affecting transcription and translation (Taylor et aL, 2001), 
(figure 7.1). The gene array data presented in chapter 3 provide fascinating insights 
into the transcriptional regulation under which myostatin exerts its negative effects 
upon muscle mass, apparently through inhibition of transcription. Although a 
selection of genes have been identified that were downregulated and the potential 
effects of this have been discussed, these data have not been verified using RT-PCR 
or Northern blotting. Furthermore, there are much data that warrant further attention 
although time restraints of the Ph.D means that the follow-up work will have to be 
completed following submission of this thesis. Nevertheless, these data open exciting 
new avenues to further examine the role of myostatin and gene expression. 
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The current data also provide information on protein synthesis in showing that the 
reduction in protein synthesis when myostatin is present in cells, could be due to the 
inhibition of the cellular signalling components controlling initiation of protein 
synthesis, such as p70 S6K. These data offer potential for targets to curb the negative 
effects of myostatin on MPS in disease states, where myostatin is elevated. Myostatin 
would serve to be a much better target for the treatment of muscle wasting diseases 
and atrophy than IGF-1, and such growth factors, since GeneCards indicate that it is 
almost uniquely expressed in skeletal muscle. 
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Figure 7.1. Myostatin signalling in adult skeletal muscle as identified by the studies in 
chapter 3. Myostatin binds to activin type 11 receptors (I), which leads to the 
phosphorylation of SMAD2/3 (2). Myostatin will negatively regulate satellite cell 
proliferation and differentiation through its effects on the cell cycle, and thus inhibit 
hypertrophy (3). SMAD2 phosphorylation leads to an inhibition of many elements of 
the insulinllGF-1 pathway including PKB, mTOR, p70 S6K and possibly 4E-BP1 
thus negatively regulating translation and MPS (4). Finally, increased myostatin 
expression leads to a down-regulation in transcription of many genes which probably 
promote cell growth such as eIF4A2 and Syndecan-4 (5). 
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7.3 Concentrations of signalling proteins 
Signalling proteins are the cellular mediators that turn a stimulus into either a genetic 
response, or one that controls translational regulation. Therefore, the regulation of 
these proteins are of critical importance, especially since varying their levels by 
genetic knock-out causes a variety of phenotypic effects. The present study identified 
differences in signalling protein levels between typically fast and slow rat muscle, and 
then further determined how a phenotypic altering stimuli such as CMNS can render 
these protein concentrations subject to change. The levels of signalling proteins do 
differ between muscles and this variation is likely to have an effect upon transmission 
of a given signal (Atherton et al., 2004) (figure 7.2a). This could mean that if the the 
levels of signalling proteins also differ between human individuals then this could 
provide evidence of trainability. For example, if one individual possessed a higher 
concentration of elements of the P1-3K pathway, such as p70 S6K, then perhaps they 
would respond more strongly to a growth stimulus such as resistance training; whilst 
conversely one with higher AMPK levels might respond to endurance type training 
more effectively. It was further identified that these proteins were subject to change, 
although not always in a direction one would expect. For example, calcineurin levels 
(fast-to-slow phenotype) were actually reduced following 6 weeks of chronic 
electrical stimulation. This may be an example of a negative feedback mechanism 
where the muscle has adapted to the stimulus and no longer requires the same 
amplification through this protein, and thus expression is suppressed. Conversely, 
other proteins were changed in the 'expected' direction thus perhaps the muscle was 
still adapting. This study showed that signalling proteins are regulable and a change in 
concentration could change its ability to adapt to future signals (figure 7.2b.) 
193 
Stimulus 	 rjaj transduction protein1 	 Cell response 
concentration J 
Stimulus 
Signal transduction protein 
concentration 
Cell response = 
Figure 7.2.a. Diagram showing how the concentration of a signalling protein could 
affect cellular responses to stimuli. Predominantly fast and slow skeletal muscles 
contained different concentrations implying that they would display varying levels of 
cellular responses to exercise and disease stimuli. 
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Figure 7.2.b. Diagram showing that signal transduction proteins are under regulation 
by chronic contractile activity (and may also be by disease), and their concentrations 
can move in either direction. Any change in signal protein concentrations could have 
marked effects upon cellular responses to exercise, insulin and/or disease stimuli. 
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7.4 The AMPK-PKB switch 
The data comprising chapter 5 of this thesis are from over 300 experiments and 
comprise the most novel study to date to contributing to our understanding of the 
molecular governance of physiological adaptation exercise training. Moreover, they 
provide fresh information on how critical signals activate pathways to achieve the 
contrasting responses to resistance and endurance training (figure 7.3). 
The ability of skeletal muscles to specifically adapt to variations in physical activity is 
a phenomenon that had not been previously understood. Shown in chapter 5, there is 
evidence that this could be controlled by a selective activation of signalling pathways 
in response to variations in stimuli produced by different modes of contractile 
activity. This is evident from the selective activation of the AMPK in response to 
activity which specifically increases AMP and inhibits the P1-3K pathway in response 
to low frequency chronic exercise stimulation. This leads to an effect of increased 
signalling producing mitochondrial biogenesis and slow fibre characteristics. 
Furthermore, whilst under prolonged stress when AMPK is active protein synthesis is 
inhibited, which limits energy turnover that is not immediately necessary. Conversely, 
with high frequency intermittent stimulation, metabolic sources and specifically the 
phosphagen system are allowed to resynthesise ATP before AMP levels are allowed 
to rise, thus not activating AMPK. At the same time, the PKB pathway is activated by 
IGF-1 or some other yet unknown factor. Therefore, the net effect is increased protein 
synthesis. This behaviour has been termed the AMPK-PKB switch and provides a 
specific mechanism for the selective activation of signalling pathways which lead to 
the contrasting physiological adaptations to strength and endurance exercise. 
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These data are not purely for 'molecular satisfaction' but also provide several possible 
benefits to our knowledge of maximisation of training response. For example, when 
resistance training and attempting to maximise protein synthesis, individuals should 
avoid endurance training (even an extended cool down) for the same muscle group 
afterwards in order to maximise muscle growth. This is evidently important because 
the activation of AMPK by endurance training is likely to inhibit translation initiation 
and elongation and thus protein synthesis (Inoki et aL, 2003b; Browne et aL, 2004). 
Furthermore, glycogen depletion should be avoided for maximal protein synthesis 
since AMPK is more activated when glycogen levels are low (Wojtaszewski et aL, 
2003) as AMPK has a glycogen-binding domain (Hudson et aL, 2003), and is 
therefore presumably incapable of activation when glycogen-bound. Thus, it seems 
likely that protein synthesis after resistance training is higher in glycogen loaded 
muscles. Protein synthesis and the signalling in the lower half of the PKB-TSC2-
mTOR pathway are activated for up to 48 h after resistance training (Rennie & 
Tipton, 2000; Hernandez et aL, 2000). Therefore, in order to train at a high level, split 
routine training programmes should be used in order to produce a larger growth 
stimulus and allow a prolonged protein synthesis response. In addition, knowledge of 
these mechanisms shows consumption of protein shortly before or after training will 
maximise positive protein balance. This study may also benefit endurance athletes. 
Since AMPK activation is maximal when glycogen levels are low, then it could be 
recommended for people to perform endurance exercise when at some level of 
glycogen depletion, possibly before breakfast. However, whilst potentially 
maximising adaptive responses this could of course prove counterproductive given the 
fact that glycogen depletion correlates with metabolic fatigue and glycogen provides a 
major substrate during exercise (Hargreaves, 2004). 
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Figure 7.3. An overview of the proposed 'AMPK-PKB switch'. (I) LFS produces 
increases in AMP and a decline in glycogen which activates AMPK. (2) AMPK 
induces PGC-la promoting transcription of slow genes and mitochondrial biogenesis. 
(3) Some signal, perhaps tension could induce IGF-1 which would activate PKB 
through P1-3K. (4) PKB will then activate mTOR either directly or though 
phosphorylation of TSC2 which will activate mTOR through decreasing the intrinsic 
GTPase activity of Rheb. (5) Nutrients affect mTOR directly, with increased amino 
acid availability stimulating activity. (6) Combined mTOR activation will direct 
increases phosphorylation of p70 S6K and 4E-BP I to promote translational initiation. 
(7) PKB phosphorylation leads to the inhibition of GSK30 of which a downstream 
substrate is eIF2B. Once GSK3 inhibitory effect on eIF2B has been removed, the 
protein becomes more active and its GAP activity increases thus promoting 
translational initiation. (8) On a different phosphorylation site than PKB, AMPK can 
also phosphorylate and inhibit TSC2, which will decrease mTOR activity through 
increasing Rheb GTPase activity (Atherton et aL, 2005). 
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7.5 Sarcopenia in healthy elderly and those with Type II DM 
Sarcopenia is a major cause of frailty in the elderly population and it has been 
identified that the aetiologies of muscle wasting in ageing are both complex and 
multifactorial. The results presented in chapter 6 provide novel evidence for a reduced 
anabolic effect to exogenous essential amino acids in the elderly and this is even more 
clearly pronounced in elderly with type II DM (see schematic model in 7.4). This 
provides a major mechanism by which a gradual loss of muscle mass may be 
explained with advancing age and in type II DM, and provides a cogent explanation 
for the gradual atrophy. Molecular studies showed further evidence of reduced 
mTOR-downstream signalling suggesting that there is some way in which ageing and 
type II DM affect cellular components of protein synthesis to reduce the response to 
EAA through diminished phosphorylation and translational protein concentrations. 
This in itself is likely to have an effect upon cellular capacity to respond to EAA 
(figure 7.3). Furthermore, since those elderly with type II DM showed further MPS 
and cellular diminution of response to EAA, they should be aware that another factor 
in morbidity of type II DM is likely to be advanced sarcopenia brought about by the 
EAA resistance, in addition to the characterised insulin resistance. 
Therefore, these data have important consequences for the maximisation of the 
anabolic effects of resistance training and feeding EAA in elderly. Since EAA feeding 
has an effect upon signalling (Karlsson et aL, 2004) and muscle growth (Levenhagen 
et aL, 2001; Esmarck et aL, 2001) as does resistance training (even in the elderly), an 
additive and a timed co-ordination of resistance training and feeding is important in 
the elderly to make the most of the reduced EAA sensitivity. 
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Figure 7.5. Muscle protein synthesis (MPS) responses in the young (left) and elderly 
(right). In the young an infused dose of EAA leads to a robust stimulation of MPS. 
However, in the elderly there is a diminished MPS anabolic response to EAA. This 
could be due to the reduced concentration of components of the IGF- 1 pathway, 
mTOR and p70 S6K as shown in this study (indicated in blue). Furthermore, a 
blunting in the phosphorylation of mTOR, p70 S6K and 4E-BPI following EAA 
administration, shows the blunted response on a molecular level and explains the 
diminished MPS response (indicated in red). Individuals with type 11 DM were 
characterised by an even more striking reduction in concentration of p70 S6K, and 
phosphorylation of mTOR, p70 S6K and 4E-BP 1. 
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7.6 Thesis summary 
The results presented in this thesis are summarised below and have: 
1) Identified new insights into the transcriptional effects of myostatin upon 
muscle mass. Furthermore, they distinguish the mechanisms by which 
myostatin exerts its inhibitory effect upon skeletal muscle protein synthesis. 
2) Characterised differential concentrations of signalling proteins and 
highlighting potential importance of these upon adaptation and pre-
determination to adapt to activity. Furthermore, as muscle enzymes, signalling 
proteins are regulable and subject to change by CMNS. It is likely these 
changes are important mechanisms in adaptive responses, and performance. 
3) Identified the potential 'switch' that controls whether a muscle hypertrophies 
in response to resistance training or undergoes gross phenotype change in 
response to endurance activity, by selectively 'recognising' specific signals 
produced by disparate contractile activity. This behaviour has been termed the 
'AMPK-PKB' switch and provides a mechanism by which muscle knows how 
to adapt to variations in messages elicited by different contractile activity. 
4) Provided new evidence of the importance of EAA in the aetiology of 
sarcopenia and type II DM. Furthermore, the signalling controlling this 
diminished sensitivity is characterised and provides an explanation behind the 
reduced protein synthesis rates in response to exogenous EAA. 
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7.7 Scope for future studies 
1) The AMPK-PKB switch: Whilst the 'AMPK-PKB switch' appears to function in 
rats as shown in chapter 5 of this thesis at least with in vitro stimulation, these 
findings needs to be verified in human beings during exercise and not electrical 
stimulation. If in agreement with the present data, these studies could then 
comprehensively demonstrate the reasons for disparate physiological adaptations to 
different types of training in humans. 
2) Prolonged activation of translational regulators following i-IFS: PKB, TSC2 and 
mTOR are only transiently activated (<3 h) whereas some translational regulators, in 
particular p70 S6K are activated for longer (>6 h). This activation correlates with 
MPS in this study, but also in other studies which show p70 S6K phosphorylation and 
MPS activation for >24h (Hernandez et aL, 2000). Therefore, further dissection of 
these pathways is required in order to characterise the unknown upstream kinases that 
maintain the activity of these translational regulators, even in the absence of 
activation of known upstream kinases such as P1(8, TSC2 and mTOR. 
3) Ident(fying  the 'upstream 'growth signal: It is still unsure how the HFS model used 
in this study activates the PKB-TSC2-mTOR cascade. Studies examining 
mechanotransduction (mechanical stretch), IGF- 1 splice variants, and myostatin 
responses in this in vitro model may help to elucidate the unknown upstream signal. 
This also would need to be verified in the human study, in attempting to correlate a 
growth signal, such as increased IGF splice variant messages, with activation of the 
cascade. 
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4) Jdentj/}ing myostatin interactions to control MPS: Whilst it was clearly identified 
that myostatin inhibits the P1-3K pathway, the mechanism by which myostatin-
SMAD signalling affects MPS is not known. Therefore, immunoprecipitation might 
be useffil to examine PKB pathway-SMAD-FOXO complexes, as might yeast two 
hybrid screening. Interactions between these SMAD (Conery ci aL, 2004) and FOXO 
(Seone et aL, 2004) proteins might lead to alterations in kinase activity of these P1-3K 
pathway and therefore explain reduced phosphorylation of elements of this pathway 
when SMAD2/3 signalling is elicited by myostatin binding to activin type II 
receptors. Furthermore, there is evidence that SMAD2 activation induces SHIP-I to 
inhibit PPK signalling (Valderrama-Carvajal ci aL, 2002) 
5) Myostatin and contrasting exercise: It would be interesting to see the effect of HFS 
and LFS on myostatin expression in order to assess its role in adaptation to resistance 
and endurance exercise training. Furthermore, larger studies on myostatin expression 
in humans in response to different exercise types would aid in identifying whether 
myostatin has a role in adaptive processes to disparate exercise types. 
6) Signalling protein concentrations in human muscle: It would be interesting to see 
whether humans possess different concentrations of signalling proteins controlling 
transcription and translation of exercise-relevant responses. An endurance athlete for 
example might contain a higher concentration of AMPK which could potentially 
maximise the signal and thus exhibit heightened mitochondrial biogenesis, whereas 
those with higher concentrations of elements of the PI-3K-PKB pathway may exhibit 
larger increases in MPS in response to resistance exercise. If this were true then the 
concentrations of signalling proteins could prove good indicators of trainability. 
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7) Optimising exercise-nutrition strategies: Interactions between timing of nutritional 
intake and exercise need further attention. In order for athletes to gain maximum 
hypertrophy or optimum glycogen resynthesis for strength and endurance athletes 
respectively, nutritional timing may be able to give an extra edge. Studies should 
examine these strategies on a cellular level and understand the kinetics of the cellular 
signalling system controlled in synergy by exercise and nutrition. 
8) Adaptation of connective tissues to physical activity: Studies on adaptation to 
exercise should be extended to the muscle extracellular matrix, bone and tendons 
(Kjaer, 2004). It has been shown that these areas regulated by exercise and loading, 
and as skeletal muscle adapt. However, many of the physiological changes are not 
characterised. Moreover the cell signalling and genetics are completely unknown, and 
thus this is an area that will prove a 'hot –bed' of research in the near future. 
9) PKB and AMPK signalling to TSC2: It was hypothesised in this thesis that specific 
AMPK or PKB phosphorylation sites on TSC2 could opposingly affect proteins 
synthesis through Rheb (below). To substantiate this model one could activate AMPK 
by AICAR during HFS which should abolish mTOR Ser2448 phosphorylation. 
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